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Abstract 
Osteosarcoma (OS) is the most common bone malignancy often producing aggressive 
tumours in adolescents. OS aetiology is poorly understood, however, recent studies 
suggest OS cancers contain a small population of cancer stem cells (CSC) which initiate 
tumour growth. The cancer stem cell hypothesis describes cancers as a hierarchical 
population of heterogeneous cells. It has been proposed that CSC are at the base of this 
hierarchy and are responsible for the initiation, growth and spread of the tumour and 
pose a therapeutic challenge due to enhanced chemotherapy resistance. This project 
had three aims: identifying whether OS cell lines contain subpopulations of putative CSC, 
identifying if CSC contribute to chemotherapeutic resistance and to elucidate paracrine 
cell signals controlling OS tumour growth.  
 
Eight OS cell lines (143B, Cal72, G292, HOS, MG63, MNNG-HOS, U2OS and SaOS-2) along 
with the breast cancer cell line MCF7 have been analysed for the presence of sub-
population of cells expressing putative CSC markers (aldehyde dehydrogenase and 
CD117). The intracellular enzyme aldehyde dehydrogenase (ALDH) and tyrosine kinase 
receptor CD117 were found to be heterogeneously expressed amongst the cell lines. All 
cell lines when plated at low density could recapitulate the colony hierarchies based on 
variation in colony morphology (holoclones, meroclones and paraclones), this was 
originally observed in carcinoma cell lines and is further putative evidence a CSC 
hierarchy exists within these cell lines. ALDH expressing cells were found to be confined 
to the holoclones (in cell lines with ALDH populations comprising less than 10 % of the 
total population) indicating that putative CSCs reside within this population. All OS cell 
lines also expressed mesenchymal markers (high vimentin and CD44 expression and low 
e-cadherin expression) suggesting they are a progenitor of mesenchymal stem cells. The 
expression of CD117 was found to negatively correlate with cisplatin chemotherapy 
resistance whereas ALDH inhibition using the specific antagonist diethylaminobenzalde 
sensitised different cells lines to opposing chemotherapeutics, suggesting a 
heterogenous response of OS ALDH cells to cytotoxic compounds. 
 
All OS cells lines, except 143B and HOS, were found to secrete a paracine growth factor 
which was capable of significantly enhancing their own growth. U2OS conditioned 
media was also able to enhance the growth of the breast cancer cell line MCF7 and a 
fibrosarcoma cell line (HT1080).  Analysis of the cytokine expression profile of OS cell 
lines (HOS, MG63 and U2OS) demonstrated these cells secrete a broad range of 
cytokines associated with inflammation. The cytokine CCL-2 was identified as the 
putative OS paracrine growth factor as determined by the response to recombinant CCL-
2, receptor antagonism and CCL-2 RNA interference. Genes with altered expression in 
response to CCL-2 were associated with transcription, suggesting that CCL-2 enhances 
proliferation through its downstream effect on transcription.     
   
Overall this thesis has contributed to the field of oncology by further defining the 
populations of putative CSC within a panel of OS cell lines. In addition the identification 
of a novel OS growth factor provides a possible adjuvant therapeutic target, which could 
aid in the reduction of OS proliferation.
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1.1 Introduction to cancer 
Cancer is a broad range of diseases all with varying characteristics and prognoses, which 
are classified based upon the tissue of origin. There are the four cancer types; carcinomas 
of the epithelium, sarcomas of the connective tissue (Mackall et al., 2002), tumours of the 
nervous system (Louis et al., 2007)  and lymphomas and leukaemias which arise from the 
haematopoietic lineage (Vardiman et al., 2009, Harris et al., 1999). In order for a cell to 
become cancerous it must acquire six characteristics; chronic proliferation, evasion of 
contact inhibition, the ability to resist cell death, replicative immortality, sustained 
angiogenesis and the ability to invade surrounding tissues and metastasise to distant 
organs  (Hanahan and Weinberg, 2011). A cell which acquires these six characteristics will 
develop in to a malignant cancer, however, benign tumours can also develop if a cell 
acquires the same hallmarks excluding the ability to invade and metastasise (Lazebnik, 
2010). Benign tumours can still grow large in size but lack these most fatal aspects of 
cancer, which are often attributed to treatment complications and cancer related fatalities 
(Ford et al., 1994). 
Improvements in cancer therapy have been made since the first chemotherapeutic was 
discovered and used to induce a remission in 1947 (Farber and Diamond, 1948). The use of 
combined chemotherapy regimens in combination with surgery, has dramatically reduced 
tumour reoccurrence (Jaffe et al., 1974). However due to the toxic nature of these 
chemotherapeutics (Shapiro et al., 1998) and the enhanced risk of leukaemia following 
treatment (Curtis et al., 1992), this has led to the introduction of cancer treatments which 
have a reduced toxicity to non-cancerous cells. These targeted therapies are now able to 
distinguish cancer cells from healthy cells, using agents which inhibit the signaling networks 
required for maintenance of a malignant phenotype. These treatment strategies, even 
when used as single agents, have been found to induce high rates of tumour suppression 
and are associated with low rates of toxicity (Kantarjian et al., 2002). However, cancer is 
still a leading cause of death worldwide, predictions in 2012 estimate 14.1 million new 
cancer cases within that year and 8.2 million cancer related deaths (GLOBOCAN, 2014). This 
figure is only likely to rise with the increased proportion of elderly people within developed 
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countries (Croce, 2008), making improved cancer therapies a necessity to reduce mortality 
rates. 
1.1.1 Cancer associated mutations 
The evolution of a normal healthy cell in to an invasive tumour is often a gradual process 
which requires a number of genetic insults. Cancer driving mutations occur with either the 
loss of tumour suppressors; genes involved in regulating the cell cycle or a mutation which 
may enhance the expression of an oncogene, the result of which will force a cell to divide. 
These mutations are usually acquired somatically, however in some rare cases germline 
mutations can also predispose cells towards cancer (Gayther et al., 1997). One of the most 
common somatic mutations is the loss of the tumour suppressor P53 which occurs in up to 
50 % of head and neck, ovarian, oesophageal, colorectal and lung cancers (Jones and Baylin, 
2002). One of the first germline mutations associated with cancer to be identified was the 
tumour suppressor breast cancer 1, early onset gene (BRCA1) where individuals carrying a 
mutation causing the loss of one BRCA1 allele have an elevated risk of cancer with an 80 % 
chance of developing breast cancer and increased risk of ovarian and secondary cancers 
(Ford et al., 1994).  
The heterogenous nature of cancers is highlighted by the finding that the somatic mutation 
rate can vary from 0.001 to 400 mutations per megabase even in cancers of the same type 
(Stefanska et al., 2011).  Although mutations do play a significant role in tumour formation 
altering gene expression via epigenetic mechanisms has also been shown to be important.  
Gene silencing via methylation of CpG islands upsteam of gene promoters is commonly 
observed in the silencing of tumour suppressors such as BRCA1 (Jones and Baylin, 2002). 
Conversely regions of the genome containing oncogenes can become hypomethylated and 
this can lead to increased gene expression resulting in neoplasias (Feinberg and Tycko, 
2004). Analysis of gene methylation in liver cancer found that hypermethylated genes were 
involved in growth, angiogenesis and metastasis (Stefanska et al., 2011), which are crucial 
for cancer formation. In addition genome wide hypomethylation has been found to induce 
chromosome instability, which has been proposed as a mechanism by which cancer cells 
can gain mutations and lose heterozygosity in areas containing tumour suppressors  (Chen 
et al., 1998). 
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1.1.2 Classification of cancer 
Excluding embryonic tumours, cancers can be broadly classed in to either carcinomas, 
haematologic neoplasms, neuronal cancers and sarcomas. Carcinomas originate from 
epithelial cells, and are the most common cancer type. Lung cancer is an example of a 
carcinoma and alone is the most frequently diagnosed cancer worldwide, contributing to 
≥50 % of all cancer related deaths (Jemal et al., 2010). The high incidence of carcinomas is 
possibly a result of the large abundance of these cells as well as a consequence of their 
exposure to the external environment. Organs such as the lungs, skin and alimentary tract 
are in constant interaction with an environment frequently containing carcinogens, 
increasing the likelihood of tumour formation (Berman, 2004). Carcinomas can effect all 
organs containing epithelial or endothelial cells, therefore, comprise a diverse collection of 
cancers. In the breast for example a collection of neoplasias have been characterised which 
have distinct clinical outcomes (Vargo-Gogola and Rosen, 2007). Currently six different 
breast cancer subtypes have been identified using gene microarrays, these include normal 
breast like, basal like, epidermal growth factor 2 expressing (EGFR2 +), and the luminal 
types which are comprised of the A,B and C subtypes (Sorlie et al., 2006).  
The haematologic neoplasms more commonly called leukaemia, encompass any tumour 
arising from the haematopoietic stem cells which reside in the bone marrow. These stem 
cells give rise to all the blood cells of the body, therefore neoplasms can be either lymphoid, 
myeloid or histiocytic (Harris et al., 1999). All leukaemias can be divided in to acute and 
chronic diseases. Acute forms are charcterised by a high percentage of haematopoietic 
progenitor cells more commonly called blast cells, which have lost their ability to 
differentiate (Estey and Dohner, 2006). In contrast chronic forms contain more 
differentiated leukaemic cells, however these diseases can progress in to a blast phase, 
whereby differentiated leukaemic cells are replaced by blast cells (Sawyers, 1999). Myeloid 
leukaemias encompass neoplasias originating in either the granulocyte (neutrophils, 
basophils and eosinophils), monocytes/macrophages, megakaryocytes or mast lineage of 
cells (Vardiman et al., 2009). Although all age groups can be effected by chronic myeloid 
leukaemia on average people in their 50s are effected and the disease is usually diagnosed 
at a fairly benign phase, however this can progress to a fatal blast crisis (Calabretta and 
Perrotti, 2004, Sawyers, 1999). Acute myeloid leukaemias are characterised by the de novo 
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presentation of a blast count 20 % or greater (Vardiman et al., 2009). The build up of these 
immature myeloid cells can rapidly lead to fatal infection, internal bleeding or organ 
infiltration if left untreated (Estey and Dohner, 2006).  
Neuronal cancers include brain tumours which can be divided in to either 
medulloblastomas arising from a neuronal progenitor or astrocytoma and 
oligodendroglioma originating from a glioma precursor (Mischel et al., 2004). 
Medulloblastoma and glioblastomas (the most malignant form of astrocytoma) have an 
incidence in the US of around 10 % and are associated with poor prognosis.  Even with 
improved treatment strategies the long term (5 year) survival rate has not improved for 20 
years (Deorah et al., 2006) and in particular glioma survival rates are very poor with a 
median survival time post diagnosis of 12 – 15 months (Wen and Kesari, 2008). One issue 
that makes treating brain tumours a challenge is the effect of the blood brain barrier to 
inhibit anti-cancer drugs reaching the central nervous system. In order for treatment 
strategies to be improved it will be important to design drugs with enhanced lipophilicity 
or packaging in to liposomes (Huse and Holland, 2010).    
Sarcomas arise from the connective tissue (bone, cartilage, fat and muscle) and account for 
around 5 % of adult cancers and 20 % of paediatric cancers (Mackall et al., 2002). Classifying 
sarcomas can often be a challenge because tumours display little similarity to differentiated 
connective tissue (Henderson et al., 2005). As a consequence tumour location is often less 
important in sarcoma diagnosis, emphasis is instead placed on molecular pathology. This 
has led to sarcomas being broadly classified in to either a tumour with either a simple or 
complex karyotypic defects (Berman, 2004). Simple karyotypic sarcomas include tumours 
with a disease specific translocation giving rise to a fusion protein which plays an active 
role in tumour formation. In 85 % of Ewing’s sarcomas a fusion of chromosome 22 to either 
chromosome 2, 7, 11, 17 and 21 occurs leading to the expression of a fusion protein which 
enhances cellular proliferation (Riggi et al., 2005). In contrast, complex neoplasias contain 
extensive chromosomal rearrangements and are commonly associated with genetic 
abnormalities including the loss of tumour suppressors such as P53, murine double minute 
2 (MDM2) and especially retinoblastoma (Rb) which is commonly mutated (Wang et al., 
1995).  In some sarcomas mesenchymal precursor cells have been identified as the 
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initiating cell (Riggi et al., 2005), which is also hypothesised to be the case in other sarcomas 
such as osteosarcoma (Tang et al., 2008).  
 
1.1.3 Osteosarcoma 
Osteosarcoma (OS) describes malignancies characterised by direct formation of bone or 
osteoid tissue from tumour cells (Schajowicz et al., 1995). It primarily effects adolescents 
and has been found to have a bimodal age distribution with the highest incidence at 10 - 
19 years and a subsequent increase at >70 years (Jawad et al., 2010). In adolescents the 
peak incidence of OS has been linked to the ages of highest growth velocity (Hems, 1970). 
Although rare, OS is the most common malignant primary bone tumour with an estimated 
incidence of 1 case per 500,000 persons per year (Klein and Siegal, 2006). It has a poor 
clinical outcome, even with improved treatment strategies still only 40 - 50 % of patients 
achieve long term survival of 10 years (Bielack et al., 2002, Petrilli et al., 2006). 
OS is a collection of lesions which are classified according to their histological features and 
grade. Different tumour types produce variable quantities of cartilage matrix or fibrous 
tissue. This has given rise to three classical subdivisions: osteoblastic, chondroblastic and 
fibroblastic tumours. In reality all OS tumours contain a variety of cell types and matrices 
so classification is based on >50 % predominance of any histologic type (Klein and Siegal, 
2006). The cellular origin of OS is still unclear, the origin of an alternative sarcoma (Ewing’s 
sarcoma) has been identified as bone marrow derived mesenchymal cells (Riggi et al., 
2005). A similar cellular origin has been hypothesised in OS (Tang et al., 2008), however, 
further research is required to substantiate this theory.  To aid with the study of OS a variety 
of cell lines are available which mimic the different tumour morphologies. These cell lines 
include Saos-2 and U2OS which contain cells of an epithelial morphology, MG63 is a 
fibroblastic cell line and there are also mixed morphology cell lines such as 143B, HOS and 
MNNG-HOS (Table 1.1).    
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Table 1.1: Human OS cell lines. * indicates cell lines derived from HOS by Ki-ras 
transformation (*1) and by N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) treatment (*2). 
# indicates ATCC® bank line not available; cell line derived from Rochet et al 1999. 
OS Cell line Phenotype ATCC number® 
CAL 72 Epithelia # 
G-292 Fibroblastic CRL_1423 
HOS Mixed CRL_1543 
143B*1 Mixed CRL_8303 
MMNG HOS*2 Mixed CRL_1547 
U2OS Epithelia HTB_96 
MG63 Fibroblastic CRL_1427 
Saos-2 Epithelia HTB_85 
 
The aetiology of OS is poorly understood, the disease has no familial patterns and is classed 
as a complex karyotype sarcoma with a host of different genetic abnormalities observed 
within tumours (Hansen, 2002). Several common OS associated mutations include the loss 
of the tumour suppressors such as P53 and Rb (Diller et al., 1990, Miller et al., 1996). Loss 
of Rb leads to a significant increase in OS incidence (Lueder et al., 1986), with the protein 
product of Rb (pRb) promoting osteoblast cell cycle arrest and differentiation when 
dephosphorylated (Lipinski and Jacks, 1999, Thomas et al., 2001). In osteosarcoma ectopic 
expression of pRB in the OS cell line SaOS-2 was found to lead to cell senescence and 
apoptosis by inhibiting E2F transcription factors, which inhibits entry into S phase of the 
cell cycle (Tiemann and Hinds, 1998). p16ink4 is an inhibitor of cyclin dependant kinases 4 
and 6 which are involved in the deactivation of pRb via phosphorylation. OS U2OS cells 
transfected with p16ink4 become senescent (Dai and Enders, 2000) highlighting that pRb 
can be inactivated via alternative mechanisms rather than just loss of gene function. The 
activator protein 1 (AP-1) transcription factors c-fos and c-jun are commonly overexpressed 
in OS (Franchi et al., 1998) with c-fos playing an important role in osteoblast activity 
(Grigoriadis et al., 1993). When c-fos and c-jun are both overexpressed in transgenic mice 
this enhances OS formation (Wang et al., 1995), through the increased expression of genes 
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associated with proliferation and survival (Angel and Karin, 1991). When c-jun and c-fos 
form a heterodimeric protein they bind genes containing promoters with AP-1 transcription 
activation elements 25 times more efficiently than homodimeric proteins (Halazonetis et 
al., 1988), which indicates why overexpression of both these proteins can lead to 
osteosarcoma formation.  
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1.2 Stem cells and cancer 
Stem cells (SC) have the capability to undergo self-renewal and to produce progeny which 
can differentiate into separate cell lineages (Hall and Watt, 1989). The potency of a SC 
refers to how many cellular lineages it can give rise to. Totipotency describes cells with the 
greatest potency such as the zygote, with the ability to produce every cell in the body, 
whereas pluripotency refers to cells able to produce any adult or embryonic cell (Mitalipov 
and Wolf, 2009). Multipotency is a cell which can give rise to a limited number of cell 
lineages and these are found in the later stages of embryo development as well as 
throughout adult life which is why they are often referred to as adult stem cells. Adult SCs 
have been identified in a wide range of organs including the epidermis, intestine, liver, 
brain (Hall and Watt, 1989, Weissman, 2000) and two distinct populations (mesenchymal 
and haematopietic cells) found within the bone marrow (Delorme et al., 2008). Within 
these organs the SCs reside in specific niches which provide a suitable environment for a 
stem cell population and provide substrates to control their self-renewal and progeny 
production (Spradling et al., 2001). Control over SCs is vital in order for them to effectively 
fulfill their purpose of maintaining the number of differentiated cells and ensuring that any 
tissue damage can be repaired (Hall and Watt, 1989). Adult SCs use clonal succession in 
order to maintain cell populations. This is achieved by a small percentage of SCs dividing 
either asymmetrically to replenish differentiated progeny or symmetrically to produce 
daughter SCs. The remaining SCs population is dormant and acts like a reserve only dividing 
when a replacement or extra SCs are required (Abkowitz et al., 1990).  
Traditionally the stochastic model was used to describe cancer formation; this theory states 
that any cell within an organ can become tumourigenic, giving rise to a homogenous 
population of cells all with equal tumorigenicity (Odoux et al., 2008, Patel et al., 2010). 
Recent findings contradict this idea and indicate that many cancers are in fact composed 
of a hierarchical population of cells with a mutated progenitor cell driving the initiation and 
maintenance of neoplastic growth (Siclari and Qin, 2010). Mutated progenitor cells have 
been aptly named cancer stem cells (CSC), because like stem cells they have plasticity and 
divide to produce either a daughter CSC or progeny which will mature and recapitulate the 
original tumour heterogeneity (Mackenzie, 2008). Often tumours can be viewed as 
aberrant organs due to tumours containing a hierarchical organisation which reflects a 
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healthy organ (Reya et al., 2001). However it should be made clear that CSC do not 
necessarily have to arise from an adult stem cell, an alternative source of CSC could be 
differentiated cells acquiring mutations allowing them to regress and gain stem cell 
properties (Figure 1.1) (Valent et al., 2012). Therefore, a CSC does not have to originate 
from a  SC and has been defined as a cell within a cancer, which has the capacity to self-
renew and give rise to heterogenous lineages of cells that comprise a malignancy (Clarke 
et al., 2006). An important caveat of Clarke et al (2006) CSC definition proposes that a CSC 
may not be the original tumour initiating cell. A cell which initiates tumour formation may 
lack SC properties, which are acquired through additional mutations during cancer 
progression 
 
Figure 1.1: Cancer stem cell evolution model. As is found in normal stem cell populations within a 
healthy organ (top of figure) and cancer (middle and bottom of figure), stem cells can divide 
asymmetrically to produce transit amplifying cells, which will go through several rounds of division 
and differentiate to eventually become terminally differentiated cells, which can no longer divide. 
The evolution toward a malignant phenotype requires the acquisition of multiple mutations, in the 
middle of the figure either a stem cell or a de-differentiated transit amplifying cell has acquired a 
mutation which enhances its proliferation leading to clonal expansion of these cells and the 
formation of a premalignant lesion.  The accumulation of further mutations in the CSC population 
leads to the formation of multiple CSC phenotypes (bottom of figure) indicated by different CSC 
colours, these cells not only have enhanced proliferation rates but also the ability to invade the 
surrounding tissue and metastasise. Adapted from Valent et al. (2012). 
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1.2.1 Evidence supporting the cancer stem cell theory  
Observations that tumours contained a stem cell population date back to the 19th century 
when it was noted that cancers contain embryonic like cells (Askanazy, 1907). The first in 
vitro experiment proving the presence of CSC was achieved in murine myeloma cells (Park 
et al., 1971) and later in human cancers (Hamburger and Salmon, 1977). The experiments 
conducted from human myeloma patients found that only 0.001 – 0.1 % of myeloma cells 
had the ability to form colonies. Suggesting that not all cancer cells are capable of 
proliferating and only a small population of cells are responsible for myeloma growth 
(Hamburger and Salmon, 1977). An assay which was originally found to select multi-potent 
neuronal cells (Reynolds et al., 1992),  allows the formation of spherical colonies in low 
attachment serum starved conditions. This assay is now commonly used to identify 
putative CSC and has been shown to harbour cells with increased murine tumourigenicity 
in breast cancer (Zhang et al., 2008), glioblastoma (Yuan et al., 2004) and osteosarcoma 
(Rainusso et al., 2011).   
The assay now used to identify CSC is the serial transplantation of suspected CSC cells in to 
immunocompromised mice (Clarke et al., 2006), the ability of CSC to form tumours within 
a mouse model is now considered the gold standard. The first use of this in vivo technique 
was work carried out in leukaemia, separating cells according to the surface expression of 
CD34 and CD38. It was found that only cells expressing CD34 and lacking CD38 could 
recapitulate the original tumour heterogeneity in a xenotransplantation model (Lapidot et 
al., 1996, Bonnet and Dick, 1997).  
Recent studies have used lineage tracing in mouse models to study tumour formation and 
the role CSC play in tumour maintenance. This model induces tumour formation through 
either the exposure to carcinogens or using a tumour susceptible mouse. The mouse model 
is also genetically modified with a cre-lox system (Sauer, 1987) which can be used to induce 
fluorescence in specific cells, allowing cells and their progeny to be monitored. Using this 
system benign papillomas and malignant carcinomas of the squamous tissue were 
compared. Interestingly the population of benign SC mirrored the SC hierarchy in healthy 
tissue and contained a population with limited proliferative potential and another with a 
longer lifespan and increased proliferation. In contrast the malignant counterpart was 
found to contain only one population of CSC which was solely responsible for tumour 
Chapter 1. General Introduction 
29 
 
formation and had a limited potential for terminal differentiation (Driessens et al., 2012). 
A study using a similar methodology in glioblastoma identified a quiescent population of 
CSC capable of recapitulating tumour heterogeneity after chemotherapy. Interestingly 
inhibiting the growth of these quiescent CSC eradicated tumour formation after 
chemotherapy treatment (Chen et al., 2012).  
 
1.2.2 Markers of CSCs  
Cancer therapy is often hindered because CSC have a reduced sensitivity to chemotherapy, 
making relapses possible even when the vast majority of the tumour mass is removed 
(Gong et al., 2010). The ability to identify and therapeutically target CSC is crucial for 
cancers to be effectively treated. Current research has focused on the identification of stem 
cell markers in healthy tissue with the expectation that these markers will also be found in 
CSC (McDonald et al., 2009). There is no consensus on the most suitable CSC marker, 
however, varying markers have been identified for each tissue type. The markers carry out 
a range of cellular functions including cell adhesion, cryoprotection and drug effluxing 
pumps (Alison et al., 2010b). 
Xenotransplantation has also been used to prove the existence of CSC in solid tumours. 
Breast CSCs were the first to be identified based on the extracellular expression of CD44 
(Al-Hajj et al., 2003). CD44 is a member of the cartilage link protein family (Stamenkovic et 
al., 1989), which is the principal extracellular receptor for hyaluronate (Aruffo et al., 1990). 
Hyaluronan is the most abundant component of the extracellular matrix and is vital for cell-
cell and cell-matrix interactions (Almond, 2007). CD44 expression from CSC has so far been 
implicated in two roles; the activation of the transcription factor nanog which is important 
for self-renewal, pluripotency and chemo-resistance through increased expression of both 
apoptosis inhibitors and multi drug resistance proteins (Bourguignon et al., 2009).  CD44 
has been used as a CSC marker in a range of cancers (Table 1.2) and now in vivo studies 
suggest that it could also be used as a therapeutic target (Zoller, 2011). However, in somatic 
cells CD44 plays a role in maintaining homeostasis especially in the innate immune system. 
It has been found to be integral for leukocyte migration in early inflammation to non 
lymphoidal tissues (Veselska et al., 2008) and macrophage recognition and phagocytosis 
Chapter 1. General Introduction 
30 
 
(Vachon et al., 2006). This highlights the challenge of designing therapeutics that have the 
ability to differentiate between CD44 expression on healthy cells and CSC. One method 
which may provide some promise is the use of bispecific antibodies which bind CD44 in 
conjunction with a tumour specific surface protein.  This method has been used in a murine 
model using an antibody able to bind both CD44 and a lymphoma specific marker. This 
antibody was found to reduce lymphoma metastasis and had no effect on immune 
responses unlike an antibody targeting only CD44 (Avin et al., 2004). 
 
Table 1.2: CSC identified using a CD44 phenotype 
Tumour Antigenic phenotype Reference 
Breast carcinoma CD44, CD24- Al-Hajj et al., 2003 
Squamous cell carcinoma CD44, ESA Biddle et al., 2011 
Head and neck, prostate 
and breast carcinomas 
CD44 Harper et al., 2010 
 
Head and neck carcinomas CD44 Prince et al., 2007 
 
The intracellular enzyme aldehdye dehydrogenase (ALDH) has been used to identify SC in 
a number of cancers including liver (Ma et al., 2008), colon (Huang et al., 2009), acute 
myeloid leukaemia (Pearce et al., 2005) and OS (Wang et al., 2011). ALDH comprises a 
family of enzymes which catalyse the pyridine-dependant oxidation of aldehydes to weak 
carboxylic acids (Sladek, 2003). In humans there are 19 ALDH genes which are organised 
into 11 groups, the largest is  group 1 which comprises 6 members (Alison et al., 2010a). 
The cytosoloic enzyme ALDH1 is found in higher quantities in stem cells because it enables 
the production of retinoids which are required for early differentiation (Chute et al., 2006). 
The presence of an elevated ALDH1 activity also provides resistance to chemotherapeutic 
agents such as cyclophosphamide (Magni et al., 1996), this resistance is achieved through 
the catalytic ability of ALDH to reduce the DNA cross-linking of alkylating agents (Bunting 
and Townsend, 1996). Inhibition of ALDH has been shown in vitro to sensitise breast CSC to 
chemotherapy (Croker and Allan, 2012), however, inhibition of ALDH in human 
haematopoietic stem cells and breast cancer cell lines suggest that this not a suitable 
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therapeutic strategy. The ALDH inhibitor diethylaminobenzalde (DEAB) has been found to 
increase the spherical colony forming ability of breast cancer cell lines (Ginestier et al., 
2009) and  of the presence haematopoietic stem cells based on the phenotype CD34+CD38-
Lin-  (Chute et al., 2006). DEAB was proposed to increase the stem cell population through 
the inhibition of retinoic acid production which is required for stem cell differentiation. 
The proto-oncogene c-kit expresses the transmembrane tyrosine kinase receptor CD117, 
which binds to the ligand stem cell factor (SCF). This signaling system plays a central role in 
normal cell differentiation, proliferation and maturation (Entz-Werle et al., 2005). The 
expression of CD117 has been identified in a number of solid cancers including melanoma 
(Berdel et al., 1992), testicular cancer (Strohmeyer et al., 1991), OS (Adhikari et al., 2010, 
Entz-Werle et al., 2005) and breast cancer (Hines et al., 1995). In breast cancer CD117 was 
found to increase the growth of the breast cancer cell line MCF7 (Hines et al., 1995), 
whereas in OS CD117 expression correlates with poor chemotherapy response (Miiji et al., 
2011). Work carried out by Adhikari et al. (2010) demonstrated that OS cells expressing 
both CD117 and the mesenchymal marker Stro-1, were found to produce 
xenotransplantable tumours which had elevated chemo-resistance properties. CD117 
could provide a possible therapeutic mechanism for targeting CSC. The tyrosine kinase 
inhibitor imatinib mesylate is an antagonist of CD117 signaling and has been shown to 
decrease OS proliferation (Miiji et al., 2011), an alternative approach is the use of CD117 
blocking antibodies, which has been shown to reduce breast carcinoma growth (Hines et 
al., 1995).   
The expression of specific surface proteins and enzymes from CSC provide us with a means 
of isolating these highly tumourigenic cells. However, even cells lacking the expression of 
these markers can also produce tumours, suggesting a separate population of CSC exists 
(Adhikari et al., 2010). It has been suggested that these results are caused by differentiated 
cancer cells reverting to a CSC phenotype (Zapperi and La Porta, 2012). If true this would 
contradict the CSC hierarchy, so an alternative explanation could be the presence of 
multiple CSC phenotypes within a single tumour. An interesting study in squamous cell 
carcinoma identified two distinct CSC populations. The populations were identified via the 
expression of CD44 with either the presence or absence of epithelial specific antigen (ESA). 
Cells lacking ESA- had a migratory phenotype, whilst ESA+ cells had proliferative phenotype, 
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it was found that only ALDH expressing cells could switch between the two phenotypes 
(Biddle et al., 2011). This finding highlights the complexity of CSC identification and 
importance of fully understanding the CSC population dynamics. 
 
1.2.3 Cancer cell hierarchy 
SC have the ability to divide either symmetrically to produce a daughter SC or 
asymmetrically to produce a cell that will mature, it has been proposed that in a healthy 
state each division will produce one SC and an asymmetric progeny. The maturing progeny 
are highly proliferative and will go through several rounds of division before maturing and 
terminally differentiating (Tudor et al., 2004). This hierarchy is fundamental to the 
maintenance of healthy organs and cellular systems within the body. In cancer this 
hierarchy is also present albeit in a dysfunctional manner, tumours have been proposed to 
behave like aberrant organs with a population of stem like cells driving growth (Reya et al., 
2001).  
The hierarchy which exists within healthy tissues has been examined by seeding cells in 
vitro at clonogenic (low) densities. The initial experiments carried out by Barrandon and 
Green (1987), demonstrated that when primary epithelial cells were grown as single 
colonies three different colony types were present; holoclones, meroclones and 
paraclones. Holoclones formed very tight colonies and possessed the greatest reproductive 
capacity, paraclones were made of loosely associated cells and were able to divide very few 
times before aborting and differentiating. Meroclones had features of both colonies and 
were considered to be a transitional stage between holoclone and paraclone (Barrandon 
and Green, 1987) (Figure 1.2). CSC have also been shown to reside only within the 
holoclones, a study using the prostate cancer cell line PC3 demonstrated that only 
holoclone cells could form xenotransplantable tumours (Li et al., 2008). In addition an OS 
study has demonstrated that holoclone cells isolated from the cell line MG63 display 
enhanced tumourigenic and drug resistance properties (Lou et al., 2010).  
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Figure 1.2: Holoclone, meroclone and paraclone morphologies in the malignant cell line 
VB6 (Locke et al., 2005). 
The majority of studies examining the role of hierarchical organisation of cells within cancer 
utilise cell lines (Li et al., 2008, Wang et al., 2011), however, working with cells in an in vitro 
system has inherent limitations. Genomic comparison of over 50 breast cancer cell lines 
with primary breast cancer tissues has demonstrated that although the genomes were 
similar, the cell culture conditions were attributable for an increased number of high copy 
aberrations (Neve et al., 2006). Maintaining cells in an artificial environment alters cellular 
phenotypes but often the impracticalities of in vivo work make cell lines the most suitable 
option (Joseph and Morrison, 2005). Evidence suggests that cancer cell lines have the same 
hierarchical organisation (Locke et al., 2005) and include stem cells which express markers 
of stemness (Wang et al., 2009) as well as being able to induce tumour formation in 
NOD/SCID mice (Wang et al., 2011). In addition cell lines have been used to study CSC in a 
wide variety of cancers including breast (Hwang-Verslues et al., 2009), liver (Ma et al., 
2008), colon (Deng et al., 2010) and OS (Wang et al., 2010); making them a useful 
alternative to circumvent the impracticalities of working in vivo. 
 
1.2.4 Epithelial to mesenchymal transition 
The process of epithelial to mesenchymal transition (EMT) plays an integral role during 
embryo development with the most significant EMT event occurring when epithelial cells 
transition to mesenchyme and condense to become the mesoderm and endoderm (Hay, 
2005). EMT is initiated by the disaggregation of epithelial cells followed by a change in 
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cellular morphology. Epithelial cells are defined as polarised because they have a basal 
surface which is bound to the underlying basement membrane and an apical membrane 
surface which is unattached (Hay, 2005). Upon initiation of EMT the polarised cell releases 
matrix metalloproteases which degrade the attachments to the basement membrane. This 
allows detachment of the cell followed by multiple biochemical changes including the 
expression of transcription factors, cytoskeletal rearrangement and changes in surface 
protein expression to acquire a motile mesenchymal phenotype (Kalluri and Weinberg, 
2009).  
EMT and the associated reverse process of mesenchymal to epithelial transition (MET) have 
been identified in three distinct biological settings. The first outlines the formation of 
mesenchymal cells required for embryogenesis, the second is in response to tissue damage 
or inflammation. In order to repair tissue mesenchymal cells are recruited to regenerate 
the tissue and this process is halted once inflammation ceases. The third setting is found 
only in neoplastic cells which have acquired specific genetic and epigenetic changes which 
allow them to undergo EMT. Once tumour cells acquire this ability to migrate and survive 
outside their cellular niche, an EMT cancer cell can enter the lymphatic or blood vessels in 
order to disseminate throughout the body (Friedl and Wolf, 2003). The transcription factor 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) has been shown to be 
integral for EMT. NFκB plays an important role in apoptosis resistance (Webster and 
Perkins, 1999) and acquisition of mesenchymal properties in mammary epithelial cells 
(Huber et al., 2004). Huber et al (2004) also demonstrated that inhibition of NFκB in human 
mesenchymal cells reverted them to an epithelial morphology, highlighting the 
requirement of NFκB for maintaining a mesenchymal morphology. 
In order to protect somatic cells from neoplastic growth the aberrant activation of 
oncogenes results in senescence (Kalluri and Weinberg, 2009). Transcription factors over-
expressed in cancer cells undergoing EMT have been implicated in escape from senescence, 
allowing tumour progression to continue (Ansieau et al., 2008). EMT associated 
transcription factors include twist 1 and 2 (Ansieau et al., 2008), slug (Thiery, 2002), snail 
(Ren et al., 2011) and zeb1 and 2 (Ahmad et al., 2011). The mechanism by which these 
transcription factors are up regulated is unclear, however the acquisition of mutations and 
epigenetic modifications as a tumour progresses is a likely mechanism (Kalluri and 
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Weinberg, 2009). Tumour associated stroma may also promote EMT through the 
expression of transforming growth factor β (TGFβ) and epidermal growth factor (EGF). Both 
growth factors have been shown to increase the expression of EMT transcription factors 
and enhance tumour progression toward EMT (Thiery, 2002). Along with the up regulation 
of specific transcription factors there are several phenotypic changes which are indicative 
of EMT, with loss of e-cadherin arguably the most common marker of EMT. E-cadherin is a 
homophilic calcium dependent cell-cell adhesion protein (Takeichi, 1995), and loss of this 
protein allows cells to acquire a migratory phenotype (von Schlippe et al., 2000). Loss of e-
cadherin has also been correlated with an increase in tumour grade and worse prognosis 
(Umbas et al., 1994).  
An alternative marker which is gained as a result of a mesenchymal phenotype is the 
cytoskeletal protein vimentin. The presence of increased vimentin in cancer cell lines has 
been linked with enhanced invasiveness (Sommers et al., 1994, Salvatori et al., 2012).  In 
order for a tumour cell to metastasise it must also undergo the reverse process of 
mesenchymal to epithelial transition (MET). The reason for a cell undergoing MET at a 
specific site is attributed to the favourable local environment provided by this secondary 
organ (Thiery, 2002, Kalluri and Weinberg, 2009). The exact mechanism by which MET 
occurs is not fully understood, however, bladder cancer studies have demonstrated that 
fibroblast growth receptor 2IIc (FGFR2IIc) is up regulated on metastatic cells and crucial for 
the reacquisition of an epithelial phenotype (Chaffer et al., 2006). This finding highlights 
the chemotactic effect particular organs may have on metastasing cells, and the potential 
therapeutic application of targeting these cellular receptors. 
 
1.2.5 Cancer stem cells and epithelial mesenchymal transition 
In order for a cancer cell to metastasise to distant parts of the body it must not only acquire 
the ability to migrate but also to colonise and self-renew. Evidence now suggests that 
undergoing EMT may in fact transform a cell in to a stem cell. The transcription factors 
Twist and Snail have both been found to induce EMT (Yang et al., 2006, Cano et al., 2000). 
Mani et al (2008) has demonstrated that both the ectopic expression of both Twist and 
Snail in differentiated human mammary epithelial cells (HMEC) reverted epithelial cells to 
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a fibroblastic phenotype with enhanced self-renewal properties and increased expression 
of EMT markers. This effect was also observed in V12-HRas oncogene transformed HMECs 
and led to an increase in the presence of CSC and tumourigenic potential of the cells (Mani 
et al., 2008).   
The homebox transcription factors nanog and oct4 both play important roles in inducing 
pluripotency of differentiated cells (Okita et al., 2007) and have been shown to play a role 
in cancer EMT. Lung adenocarcinoma in vitro experiments demonstrated that expression 
of oct4 and nanog enhanced the migration and expression of EMT associated proteins 
(Chiou et al., 2010). The ability of CSC to switch between proliferative and migratory 
phenotypes has been studied in oral squamous cell carcinoma. ALDH+ CSC had the ability 
to switch from a migratory to a proliferative epithelial phenotype (Biddle et al., 2011). 
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1.3 Osteosarcoma chemotherapy treatment 
OS chemotherapy strategies comprise a range of different chemotherapeutic 
combinations. Common treatment regimes include a combination of doxorubicin and 
cisplatin with or without the following agents: high dose methotrexate, ifosfamide or 
etoposide (Anninga et al., 2011). Radiotherapy is only used for patients with inoperable OS 
tumours (Jawad et al., 2011). The use of these drugs in pre and post-operative 
chemotherapy has improved OS long term survival to 66%, however this figure has not 
improved for 20 years (Jawad et al., 2011).  The emergence of multi-drug resistant tumours 
is hindering improvement in long term survival (Bruland and Pihl, 1997) and highlights why 
tumour response to pre-operative chemotherapy is the most important prognostic factor 
(Bielack et al., 2002). Tumours often rapidly acquire resistance mechanisms to 
chemotherapeutics, which is highlighted by the majority of research focusing on resistance 
mechanisms following discovery of a new chemotherapeutic (Kelland, 2007). Recent OS 
research has identified a number of drug resistance mechanisms which vary depending 
upon the drug target. Understanding these mechanisms will be important in identifying the 
targets of future therapies as adjuvants which increase OS chemotherapy response will 
enable the toxicity of drugs regimes to be reduced and maximize the effectiveness of 
treatment strategies.         
 
1.3.1 Doxorubicn resistance 
The anthracycline antibiotic doxorubicin has been used to treat osteosarcoma for the last 
50 years (Singal and Iliskovic, 1998) and was first isolated from the bacteria Streptomyces 
peucetius. The cell killing action of anthracylines is debatable but the following mechanisms 
have been suggested; DNA intercalation, generation of free radicals leading to DNA 
damage, DNA binding and alkylation, DNA crosslinking, inhibition of DNA unwinding or 
strand separation, a direct cell membrane effect and inhibition of topoisomerase II 
mediated DNA damage (Minotti et al., 2004). 
When investigating doxorubicin resistance in OS, it has been found that seven genes were 
down regulated including P53 (Rajkumar and Yamuna, 2008). The loss of the tumour 
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suppressor P53 has previously been identified as a mechanism for OS doxorubicin 
resistance (Tsang et al., 2005). In response to DNA damage the wild type P53 induces 
apoptosis through the activation of Bax homodimers resulting in outer membrane 
mitochondrial pore formation and release of cytochrome C which leads to the caspase 
cascade and apoptosis (Fan et al., 2005, Li et al., 1999). In OS loss of P53 resulted in 
doxorubicin resistance due to an inability to activate caspase 3 in response to DNA damage 
(Tsang et al., 2005). Bcl-2 is commonly up-regulated in OS has been identified as a means 
of overcoming doxorubicin apoptosis by reducing the formation of Bax-Bax homodimers 
(Zhao et al., 2009). The nucleolar protein neuroguidin/CANu1 is also upregulated in tumour 
cells and provides OS cells (with a functional p53) a mechanism for doxorubicin resistance 
(Park et al., 2011a). Although the pathway through which neuroguidin/CANu1 signals is 
unclear it has been found to inhibit p21, which is activated by p53 in response to 
doxorubicin DNA damage and stabilize Bcl-2 (Figure 1.3). 
 
Figure 1.3: Doxorubcin (Dox) resistance mechanisms. Dox induces apoptosis through the action of 
p53 in response to DNA damage, however OS cells with mutated p53 are unable to activate the 
apoptotic caspase cascade or Bax homerdimersation which leads to outer mitochondrial membrane 
pore formation. OS cells with functional p53 have been found to resist dox DNA damage through 
the action of neuroguidin/CANu1 (CANu1). CANu1 inhibits p21 and stabilises Bcl2, inhibiting cell 
cycle arrest and Bax homodimerisation.   
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1.3.2 Platinum based by chemotherapy resistance 
The platinium based chemotherapeutics include cisplatin and the less toxic alternative 
carboplatin, which exert tumour cell apoptosis by becoming intracellularly activated 
allowing them to covalently bind to DNA and form adducts (Kelland, 2007). The resistance 
of both cisplatin and carboplatin is based on three mechanisms: impeding the influx of drug 
in to a cell, improved DNA adduct repair (Kelland, 2007) and detoxification of the activated 
intracellular drug (Meijer et al., 1990).  
In OS cell line research suggests tumour cells decrease the intracellular quantities of 
platinum based drugs not through efflux but by reducing membrane permeability (Martelli 
et al., 2007). The membrane changes in OS have yet to be identified, however 
rearrangements in membrane mobile lipids confer reduced permeability in breast cancer 
(Santini et al., 2001). Mutated P53 has also been suggested as a means of cisplatin 
resistance, tumours with a wild type P53 have increased sensitivity to cisplatin than 
mutated counterparts (Martelli et al., 2007). Tumour cells are able to overcome DNA 
adduct formation via mutations in genes involved with DNA mismatch repair. Loss of these 
proteins inhibits cells from identifying DNA damage and undergoing apoptosis (Aebi et al., 
1996), in OS loss of the mismatch repair protein PMS2 has been found to induce cisplatin 
resistance in the cell line U2OS (Perego et al., 1999). The antioxidant glutathione and has 
been linked with intracellular cisplatin detoxification (Siddik, 2003). Activation of 
intracellular cisplatin through aquation allows cytosolic glutathione to carry out cisplatin 
detoxification in a reaction facilitated by glutathione S transferases. Clinical data shows that 
OS tumours expressing a high glutathione S-transferase P1 (GSTP1), had a significantly 
higher relapse rates and worse clinical outcome (Pasello et al., 2008). 
 
1.3.3 Methotrexate resistance 
The de novo synthesis of DNA relies on the reduction of folic acid via the enzyme 
dihydrofolate reductase (DHFR) to synthesise purine, pyrimidine and methionine (Hagner 
and Joerger, 2010). DNA synthesis is crucial for cell survival therefore targeting this process 
through the use of structural analogs of folate is a useful strategy in cancer therapy. One 
of the earliest antifolate drugs and still in use today is methotrexate (MTX). It was first used 
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to treat acute leukaemia over 60 years ago (Farber and Diamond, 1948) and causes cell 
death through inhibition of DHFR (Assaraf, 2007). Resistance to antifolate drugs has 
become a common problem in cancer treatment (Assaraf, 2007) with different tumours 
using alternative mechanisms (Bertino et al., 1996). Two common mechanisms of OS MTX 
resistance is the down-regulation of the folate receptor (FR), present in 65% of tumours, 
and over expression of the enzyme DHFR (Guo et al., 1999). Over expression of DHFR has 
been attributed to the gene Rb which is frequently altered in OS (Section 1.1.4). pRb 
negatively regulates the expression of E2F transcription factors which increase the 
expression of cell cycle proteins such as DHFR (Li et al., 1997). However OS cell line evidence 
contradicts this observation, DHFR expression was actually found to be increased in the Rb 
negative cell line SaOS-2. This in vitro study found MTX resistance to be independent of 
DHFR expression and instead relied on down regulation of FR (Serra et al., 2004).       
The gene C-MYC is the only gene consistently gained in MTX resistant OS cell lines 
(Hattinger et al., 2003). Inhibition of C-MYC expression reduced resistance to MTX, (Scionti 
et al., 2008), the mechanism through which c-myc signals is unknown and appears to 
produce contradictory effects depending on the chemotherapeutic drug as elevated 
expression of C-MYC increased sensitivity to cisplatin (Xie et al., 2006).  
A novel approach to investigating MTX resistance is to study the mRNA translational 
properties of micro RNAs (miRNA). Song and colleagues (2010) studied colon and OS cell 
lines and identified miR-215 conferred reduced MTX sensitivity through G2 cell cycle arrest. 
MTX can only target cells in the S phase so G2 arrest provides complete MTX resistance. It 
was hypothesized that miR-215 exerts its action by targeting the G2/M checkpoint 
regulator denticleless protein homolog (DTL) with inactivation of DTL preventing the 
ubiquitination of p53 allowing increased activation of p21 and consequently G2 cell cycle 
arrest occurs (Song et al., 2010).  
 
1.3.4 Cancer stem cells and chemotherapy resistance 
CSC have been found to have a reduced sensitivity to chemotherapy and have been 
attributed to relapses even when the vast majority of the tumour mass is removed (Gong 
Chapter 1. General Introduction 
41 
 
et al., 2010). In OS chemotherapy exposure has been found to enrich for CSC highlighting 
their ability to withstand higher drug concentrations (Tang et al., 2011). Several 
mechanisms have been identified which confer OS CSC chemotherapy resistance and 
include the expression of the ATP-binding cassette transporter ABCG2 which has been 
found on 60 – 90% of OS CSC (Adhikari et al., 2010). It is hypothesized that this transporter 
allows cells to efflux drugs reducing the opportunity of chemotherapies to interact with 
their intracellular targets. The enzyme aldehyde dehydrogenase (ALDH) which carries out 
the detoxification of aldehydes to weak carboxylic acids (Sladek, 2003), has also been 
suggested as a mechanism through which CSC detoxify chemotherapeutic agents (Honoki 
et al., 2010). Although not observed in OS, increased DNA repair could also be used to 
overcome drug induced apoptosis. Upon cisplatin exposure head and neck carcinoma stem 
cells have been found to increase time spent in the G2 phase of the cell cycle allowing an 
increase of cell cycle checkpoint proteins to be expressed, which aid in the repair of DNA 
damage (Harper et al., 2010). MTX resistance in colon CSC is linked with their 3 fold higher 
expression of miR-215, which enabled cells to spend an increased amount of time in G2, 
protecting against MTX apoptosis (Song et al., 2010).   
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1.4 Cell signaling networks  
Cells within the body are tightly controlled by interaction with external stimuli during 
development and throughout the lifespan of an organism. This control is mediated via 
signaling molecules (ligands), which interact with extracellular receptors allowing 
intracellular signal transduction to proceed to the nucleus or cytoskeleton. The spatial 
location of a ligand releasing cell to the affected cell will determine the type of signaling, 
therefore there are four types of signaling; autocrine (acts on cell of origin), paracrine 
(secretion acts upon cells in close proximity) endocrine (ligand is released systemically), or 
juxtacrine, (ligand remains membrane bound and can interact with the receptor on an 
adjacent cell) (Singh and Harris, 2005) (Figure 1.4). The range of responses one receptor 
can activate is often diverse, for example the epidermal growth factor receptor has been 
found in vitro to play a role in cell proliferation, differentiation, de-differentiation and 
apoptosis depending upon the which signal transduction pathway is utilised (Fischer et al., 
2003, Singh and Harris, 2005).  
 
Figure 1.4: Autocrine, paracrine, endocrine and juxtacrine signalling mechanisms. A 
signaling molecule (orange oval) is produced from a cell and interact with a receptor in four 
possible mechanisms. Either autocrinally whereby it is released from a cell and binds to a 
receptor upon the same cell, alternatively it may bind paracrinally to a cell in the local 
environment. Endocrine signaling involves the signaling molecule being released 
systemically allowing it to reach a distant site in the body. Juxtacrine signaling does not 
involve the release of a growth factor, instead the molecule remains attached to the cell 
which presents it to a neighbouring cell.     
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1.4.1 Signalling networks in healthy bone 
Bone is a rigid organ which is dynamic in terms of its ability to remodel and is required to 
do so during development, maintenance and repair (Boyle et al., 2003). The cells 
responsible for bone formation are the mesenchymal stem cells (MSC), these multipotent 
cells have the ability to differentiate in to the bone forming cells, osteoblasts which can 
secrete osteoid before fully differentiating to become osteocytes (Pittenger et al., 1999). 
MSCs reside within the bone marrow endosteal region (Mendez-Ferrer et al., 2010) and 
also the bone marrow perivasculature (Shi and Gronthos, 2003). Bone resorption is critical 
for maintaining bone mass and the osteoclast (a tissue specific macrophage) is able to 
degrade bone. To ensure that bone resorption is balanced with bone formation tight 
signaling controls are required (Friedenstein et al., 1966). 
One signaling molecule which has been identified in the control of bone development and 
acts via an autocrine/paracrine signaling pathway is Wnt. Wnt ligands bind to the 
transmembrane domain frizzled receptor family and require LRP5/6 co-receptors for 
intracellular signal transduction (Guo et al., 2007, Tamai et al., 2000). Signals can lead to 
several different intracellular cascades: the canonical pathway leading to stabilization of β-
catenin and activation of target gene genes; Wnt/Ca2 pathway activates Ca2 dependent 
enzymes (calmodulin-dependent protein kinase II and protein kinase C) (Kühl et al., 2000); 
and the JNK pathway (Thorpe et al., 2000). MSCs have been shown to differentiate in to 
osteoblasts after activation of Wnt10b and signal transduction via the canonical pathway 
(Bennett et al., 2007). Osteoblasts are reliant on Wnt signaling for proliferation, mice 
lacking LRP5 have been shown to have decreased bone mass due to a reduced proliferation 
of osteoblast precursors (Kato et al., 2002), which is mirrored in humans lacking a 
functional LRP5 gene (Gong et al., 2001). Control over Wnt signaling has also been shown 
to effect osteoblast apoptosis and differentiation. Loss of secreted Wnt inhibitor frizzled 
related protein 1 has been shown to increase bone mass, which was attributed to a 
decrease in osteoblast apoptosis and increase osteoblast differentiation to osteocytes. 
Interestingly this was only observed in mice after they had acquired a peak bone mass, 
suggesting that this control mechanism is activated to limit bone density in only 
differentiated bone forming cells (Bodine et al., 2004).  
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Osteoclast bone resorption is an essential process for bone remodeling during 
development and also for the release of important minerals during starvation. RANK 
(receptor activator of nuclear factor κ B) is an important receptor crucial for 
osteoclastogenesis and responds to the ligand RANKL which is secreted by osteoblasts 
(Yasuda et al., 1998b). Activation of osteoclast RANK leads to rapid actin cytoskeletal 
rearrangements and enhanced bone resorption (Burgess et al., 1999). In order to control 
osteoclast activity the receptor osteoprotegrin (OSP) inhibits osteoclastogenesis. 
Interestingly it is expressed by both osteoblasts and thyroid cells suggesting it acts via 
paracrine and endocrine pathways (Yasuda et al., 1998a). OSP mechanism of 
osteoclastogenesis inhibition is directly related to RANKL, OPG is a soluble decoy receptor 
which binds RANKL and competes with RANK. Therefore, reducing RANK ability to activate 
osteoclasts (Schoppet et al., 2002), which is highlighted by overexpression of OSP leading 
to decreased osteoclast differentiation and osteopetrosis (Simonet et al., 1997)    
 
1.4.2 Influence of the microenvironment upon cancer 
Tumours are unable to self-sustain and require external signals to maintain their malignant 
properties (Spaeth et al., 2009). The tumour microenvironment has been identified as the 
source of these stimuli and therefore plays an important role in tumour progression. A 
seminal study carried out in breast cancer identified that, when grown in 3D culture, 
reducing β1 integrin activation was sufficient to revert malignant cells to a normal 
phenotype (Weaver et al., 1997). Cancer progression has also been found to heavily rely on 
a complex cytokine signaling network between both neighbouring tumour cells and 
supporting tissues (Mueller and Fusenig, 2004). Cytokine signaling in breast cancer has 
been observed to originate from distant sites in the body such as the bone marrow. One 
such pathway identified in breast cancer found tumour release of IL-6 recruited bone 
marrow derived MSCs to the tumour site. MSCs were found to enhance the growth of the 
breast cancer in response to IL-6 through the release of CXCL7, which created a positive 
feedback loop perpetuating tumour progression (Liu et al., 2011). Cytokines have also been 
secreted autocrinally to enhance tumour progression, one such factor secreted factor is 
the glycolytic enzyme phosphoglucose isomerase (PGI). In response to hypoxia tumour cells 
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secrete PGI which autocrinally acted upon breast cancer cells to increase cell motility 
(Funasaka et al., 2007). 
 
1.4.3 Osteosarcoma signaling networks 
Work carried out by Fawdar (2010) identified that holoclonal cells from the OS cell line HOS 
secrete paracrine factors which supports holoclone formation and the growth and 
migration of paraclonal cells. In the absence of media conditioned by HOS holoclones the 
paraclone cells undergo several rounds of division before undergoing cell death. 
Conversely, in the presence of holoclone conditioned media the paraclonal cells proliferate 
and in the parental cell line an increase in holoclone formation was observed. In addition 
to these observations HOS paraclone cells were also found to migrate towards holoclonal 
colonies, indicating that HOS holoclones secrete paracrine factors which are required for 
HOS paraclone growth, migration and also holoclone formation in the parental cell line. 
Although the paracrine factor responsible for these findings was never established OS cell 
lines have been found to secrete PGI which promotes migration. PGI is only released by 
cancer cells (Niinaka et al., 2010, Ahmad et al., 2011) and has been found to up regulate 
the expression of TGF-β which has been implicated in the acquisition of a mesenchymal 
phenotype. Interestingly silencing of PGI in OS caused the cell line MG63 to differentiate 
and lose its malignant properties (Niinaka et al., 2010), highlighting a potential novel target 
for OS treatment.  
 
1.4.4 CCL2 expression in cancer 
The chemokine CCL2 (also known as monocyte chemotractant protein MCP-1) is a 13 kDa 
protein, the gene maps to chromosome  17q11.2 and it has been found to signal via the G-
protein coupled receptor CCR2  (Deshmane et al., 2009).  It was initially of interest because 
of its potent monocyte chemotractant properties (Matsushima et al., 1989) and has also 
been found to play an important role in bone development and in particular osseus 
metabolism (Graves et al., 1999). Osteolysis was found to occur through osteoblast 
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secretion of CCL2 which recruits monocytes, however, normal osteoblasts do not express 
CCL2 unless stimulated with IL-1 (Williams et al., 1992).  
CCL2 expression has been implicated in cancer growth and progression. Breast cancer 
studies have demonstrated CCL2 expression from cancer associated fibroblasts, enhances 
the presence of breast cancer stem cells (CSC) (Tsuyada et al., 2012) and potential to 
metastasis (Nam et al., 2006, Youngs et al., 1997). Prostate cancer research has also 
demonstrated that tumour cells may migrate to the bone due to enhanced expression of 
CCL2, however in this case the CCL2 originates from bone marrow endothelial cells (Loberg 
et al., 2006). In vivo CCL2 neutralisation significantly reduces prostate tumour proliferation, 
and expression of the CCL2 receptor correlates with cancer progression and metastasis 
(Loberg et al., 2007). An autocrine response to CCL2 has also been observed, multiple 
myeloma cells were found to have an enhanced CCL2 expression in response to TNFα. This 
enhanced expression of CCL2 was proposed to increase metastasis to the bone via 
transendothelial migration (Johrer et al., 2004). Osteosarcoma studies have found that the 
cells do secrete CCL2 (Grigolo et al., 1999) and this expression was attributed to aid tumour 
progression through the recruitment of cancer associated macrophages (Graves et al., 
1989).  
CCR2 signal transduction is not fully understood, however, one pathway which seems to be 
indispensable for signaling is via phosphatidyl-inositiol-3-kinase (PI3K). This pathway was 
found to be indispensable for both monocyte chemotaxis and prostate cancer proliferation 
(Terashima et al., 2005, Loberg et al., 2006). A downstream response of CCR2 signaling in 
breast cancer is up-regulation of notch, which has been found to play a pivotal role in 
renewing CSC (Tsuyada et al., 2012). 
 
1.4.5 IL-8 expression in cancer 
IL-8 is a member of the CXC chemokine family and was originally identified as a monocyte 
derived neutrophil chemotactic factor (Yoshimura et al., 1987). In humans IL-8 binds with 
high affinity to the G-protein coupled receptors CXCR1 an CXCR2 (Park et al., 2011b), and 
has been found to induce angiogenesis in endothelial cells by activation of the Rho and Rac 
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signaling pathways (Li et al., 2003). Due to IL-8 having a potent chemotractive effect on 
neutrophils it plays an important role in the initiation of acute inflammatory responses. 
Therefore its overexpression has been attributed as a causative agent in pathologies such 
as dermatitis, arthritis and immune complex type glomerulonephritis (Harada et al., 1994).  
Aberrant IL-8 expression has been documented in tumours. Melanoma cells were the first 
neoplastic cells identified to express IL-8 and it was hypothesised to enhance tumour 
growth and progression (Zachariae et al., 1991). IL-8 has now been found to be expressed 
by a range of cancers including breast, colon, gastric, melanoma, pancreatic and B-cell 
chronic lymphocytic leukaemia (Lippitz, 2013). The expression of IL-8 from such a variety 
of cancers indicates it has profound role to play in tumour progression, colon cancer cells 
have been observed to increase proliferation in response to IL-8 (Lee et al., 2012), in breast 
cancer it has been found to not only enhance invasiveness (Freund et al., 2003) but also 
the presence of ALDH+ CSC (Ginestier et al., 2010). CSC in breast cancer were found to have 
a significantly enhanced expression of CXCR1, when these cell lines were treated with 
recombinant IL-8 this was found to enhance the ALDH+ population of cells and increase 
mammosphere formation (Charafe-Jauffret et al., 2009). This finding has been investigated 
further by Singh  et al (2013) using patient derived tumours ex vivo, IL-8 concentration of 
metastatic fluid and pleural effusions correlated directly with mammosphere forming 
ability of tumours. IL-8 was found not to act in an autocrine loop, suggesting that 
surrounding stroma are responsible for the IL-8 secretion. IL-8 was found to signal via a 
pathway also utilized by human epidermal growth receptor 2 (HER2) (Singh et al., 2013). 
HER2 has been successfully targeted to treat breast cancers overexpressing HER2 using the 
humanised antibody trastumuzumab (Piccart-Gebhart et al., 2005), therefore CXCR1/2 
inhibitors (e.g. Repertaxin) may provide useful treatments in trastumuzumab resistant 
tumours. 
 
1.4.6 Targeted cancer therapeutics 
The reliance of cancer cells upon particular growth factors and signaling pathways enables 
tumour cells to be specifically targeted with therapeutics. Many of these overactive 
pathways and signaling molecules are also present in healthy tissues often making some 
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treatments impractical due to high toxicity levels, however, this has not stopped the 
development of effective adjuvant therapies. One endocrine pathway which has been 
effectively targeted is the reliance of breast cancer cells on estrogen receptor activation 
(Howell et al., 1997). The pro-drug tamoxifen is an antagonist of the estrogen receptor. In 
patients with a high risk of breast cancer the long term administration of tamoxifen was 
found to reduce breast cancer incidence by 50 % (Fisher et al., 1998). Another receptor 
which is commonly targeted in breast cancer treatment is the epidermal growth receptor 
2 (HER2). This receptor has been implicated in the evolution of breast and gastric cancers 
(Baselga and Swain, 2009), with 20 % of breast cancer patients over expressing the receptor 
(Owens et al., 2004). Treatment with trastuzumab inhibits signal transduction via HER2 and 
post chemotherapy was found to significantly enhance disease free survival (Piccart-
Gebhart et al., 2005). 
One of the most successful targeted therapies is imatinib mesylate which is a potent 
inhibitor of the tryrosine kinase ABL, platelet derived growth factor receptor and cKIT 
(CD117) (Ren, 2005). Imatinib has been successfully used to treat both chronic myeloid 
leukaemia (CML) and gastrointestinal stromal tumours (GIST) due to the presence of 
constitutively active mutant tyrosine kinases. The presence of the tyrosine kinase fusion 
protein BCR-ABL in CML and constitutively active CD117 in GIST allows imatinib to target 
these tumours and inhibit growth (Corless et al., 2011, Deininger et al., 1997). Currently no 
adjuvant therapies targeting OS signaling pathways exist, however, potential growth 
factors have been identified.  Existing anticancer drugs may also provide some benefit for 
OS treatment, the expression of CD117 has been correlated with a poor chemotherapy 
response. In addition it was found that the use of imatinib could reduce the growth of the 
OS cell line MG63 and at high doses reduce migration (Miiji et al., 2011). Suggesting 
imatinib may provide some benefit in OS treatment, however further clinical trials will be 
required to prove this.  
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1.5 Thesis aims 
OS CSC were recently described in OS cell lines (Adhikari et al., 2010, Wang et al., 2011).  
The main aim of this project is to extend their work by characterising the population of CSC 
which reside within a heterogeneous panel of OS cell lines. A more complete understanding 
of the OS CSC will enable the hierarchical organisation of OS cells to be further understood. 
The observation that OS CSC are more resistant to chemotherapeutics (Tang et al., 2011), 
will be utilised in an attempt to enrich CSC. Gaining an understanding of the phenotypic 
properties of these chemotherapy resistant cells could provide a mechanism for accurately 
determining an OS response to therapy. OS cell lines have been observed to secrete a factor 
which promoted growth of paraclonal colonies (Fawdar, 2010). An additional aim of this 
project will be to characterise this factor which will provide a significant insight in to the 
paracrine cell communication which occurs in OS. The ability to target this factor will also 
be investigated as possible means to inhibit OS growth. 
 
In order to investigate these aims, the main objectives will be to: 
 
 
1) Characterise putative CSC populations present within OS cell lines. Using a panel of 
seven OS cell lines and one breast cancer cell line to act as a comparison to carcinoma, 
cell lines will be screened for a range of CSC markers. Cell lines will also be tested for 
the presence of the colony hierarchies identified by Locke et al (2005), and the ability 
of the cell lines to form sarcospheres will also be assessed.  
 
2) Identify if CSC contribute to osteosarcoma chemotherapeutic drug resistance. LD50 
for three chemotherapeutics (cisplatin, doxorubicin and methotrexate) will be 
determined for the panel of cell lines. Through exposure to a sub-lethal concentration 
of chemotherapy, CSC will be enriched due to their enhanced resistance to 
chemotherapeutics. These CSC enriched cell lines can then be tested for the presence 
of CSC markers and tumuorigenic properties.  
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3) Characterise paracrine cell signalling used to control osteosarcoma growth. The 
presence of secreted growth factors will be identified for the panel of cell lines. Cell 
lines can then be profiled for cytokine expression to identify candidate factors, which 
can then be further analysed via supplementation of the paracrine factor, gene 
expression knockdown and receptor inhibition.
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2.1 Materials 
Unless otherwise, stated all reagents, chemicals and stains were obtained from Sigma 
Aldrich® (Dorset, UK). Tissue culture reagents were obtained from Lonza® (Slough, UK) 
unless stated otherwise. Antibodies used for CSC marker expression assessment, 
identifying EMT status and analysing the receptors CXCR1, CXCR2 and CCR2 are listed in 
table 2.4. Primers used in the assessment of CCL-2 gene knockdown were purchased from 
Invitrogen (Paisley, UK).  
 
2.2 Cell lines 
The OS cell lines used within in this study include 143B, Cal72, G292, HOS, MG63, MNNG-
HOS, OSS9-1, U2OS and SaOS-2 (Table 2.1). All these cell lines were derived from bone 
tumours and banked by ATCC (American Type culture collection); Cal72 (Rochet et al., 1999) 
and OS99-1 (Gillette et al., 2008) were the only exceptions which were generous gifts. Cal72 
was obtained from Professor Adrienne Flanagan and Dr Nadege Presneau (The Cancer 
Institute, University College London). OS99-1 was obtained from Dr Sheila M. Nielsen-Preiss 
(Montana State University, US). The OS cell lines 143B and MNNG-HOS are derivatives of 
HOS via Ki-ras transformation for 143B (Hensler et al., 1994) and N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG) exposure (Rhim et al., 1977) (Table 2.1). The sarcoma cell lines 
HT1080 (Fibrosarcoma), SKLNS1 (Leiomyosarcoma) and RDES-1 were a kind gift from Dr 
Nadege Presneau (Cancer institute, UCL) and the adenocarcinoma cell line MCF7 was a kind 
gift for Dr Miriam Dwek (University of Westminster). HEK293T cells were used for lentivirus 
packaging and were a generous gift from Dr Alastair Barr (University of Westminster). 
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Table 2.1: Osteosarcoma cell lines utilised within study. * Indicates cell line derived from 
HOS by either Ki-ras (*1) or MNNG (*2). # Indicates cell line not banked by ATCC®, cell line 
instead derived by #1 (Rochet et al., 1999) or #2 (Gillette et al., 2008). 
Cell lines Source ATCC® number 
143B*1 13 year old, female CRL-8303 
Cal72 10 year old, male #1 
G292 9 year old, female CRL-1423 
HOS 13 year old, female CRL-1543 
MG63 14 year old, male CRL-1427 
MNNG-HOS*2 13 year old, female CRL-1547 
OSS9-1 11 year old, female #2 
U2OS 15 year old, female HTB-96 
SaOS-2 11 year old, female HTB-85 
  
 
 2.2.1 Cell culture  
All cell lines were cultured in Dulbecco’s modified eagles media (DMEM) (4.5 g/L glucose 
with ultraglutamine® and phenol red) supplemented with 10 % foetal bovine serum (FBS) 
(Biosera®, Sussex, UK) (Complete media). When thawing cells from liquid nitrogen, vials 
were quickly defrosted in a 37 °C water bath, washed in 5 ml of complete media and seeded 
in to suitable culture flask. Cells were maintained in a 37°C incubator (Binder APT.line™ 
C150) and media changes were made every 3 days. Antibiotics were used when specified 
using antibiotic-antimycotic (Invitrogen®: 100 x stock, 10000 units/ml penicillin G sodium. 
10000 µg/ml streptomycin sulphate and 25 µg/ml amphotericin). 
 
2.2.2 Passaging cell lines 
Upon reaching the required confluency (70-90 %) cells were passaged or frozen for storage. 
When passaging, cells were washed once with Dulbecco’s phosphate buffered saline (DPBS) 
(free from calcium and magnesium), detached by exposure to 0.25 % trypsin and 0.038 % 
EDTA (Invitrogen®) for 3 mins at 37 ºC and the trypsin-EDTA neutralised with complete 
media. Cells were centrifuged at 1000 rpm for 3 mins (IEC CL30 centrifuge, Thermo 
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scientific®), cell pellet re-suspended in complete media and seeded into a fresh tissue 
culture flask. Depending upon the cell line, cells were passaged at a ratio of either at 1:3, 
1:6 or 1:9. When freezing cells were re-suspended in FBS containing 10 % DMSO and kept 
at -80 °C for 24 hours prior to storage in liquid nitrogen.  
 
2.2.3 Cell line trypsinisation and counting  
In order to prepare cells for seeding at specific densities cells were grown to 70 – 90 % 
confluency, complete media was removed and cells were washed once with DPBS (free 
from calcium and magnesium). Cells were detached from the culture vessel by exposure to 
0.25 % trypsin and 0.038 % EDTA (Invitrogen®) for 3 mins at 37 ºC and the enzyme 
neutralised with complete media. Cells were centrifuged at 1000 rpm for 3 mins (IEC CL30 
Centrifuge, Thermo scientific®), cell pellet re-suspended in complete media and cell 
concentration was assessed using a minimum of four haemocytometer cell counts in 
duplicate.        
 
2.2.4 Spherical colony assay 
OS cell lines and MCF7 were assessed for their ability to form primary and secondary 
spherical colonies in ultra-low attachment plates (Corning, Birmingham, UK). Growth media 
used was comprised of 2 ml serum free DMEM containing antibiotics/antimycotics, 20 
ng/ml epidermal growth factor (EGF), 20 ng/ml basic fibroblast growth factor (bFGF) 
(PreproTech®, London, UK) and B27 supplement (Invitrogen®). In order to test the effect of 
recombinant IL-8 (BioLegend®, London, UK) and CCL-2 (BioLegend®) on sarcosphere 
formation 9 ng/ml of IL-8 or 36.4 mg/ml CCL-2 was supplemented in to the media and 
freshly added every 3 days throughout the experiment.   
In order to assess colony formation, cell lines were trypsinised, counted (Section 2.2.3) and 
seeded at 1052 cells/cm2 ultra low attachment plate. Fresh 20 ng/ml bFGF, EGF and B27 
were added to cells every 3 days throughout the assay. After 7 days primary spherical 
colony images were captured and spherical colonies were collected and centrifuged at 
1000 rpm for 3 mins. Washed with 2 ml DPBS and centrifuged (1000 rpm for 3 mins) and 
exposed to trypsin-EDTA for 5 mins at 37 °C. Prior to neutralising trypsin-EDTA with 
complete media trypsinised cells were aspirated and ejected 10 times with a 1000 µl 
pipette to dissociate cells, then centrifuged (1000 rpm for 3 mins). Media was removed and 
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in a volume of 200 µl cells were re-suspended and counted using a haemocytometer. To 
ensure the majority of cells seeded were single cells, cells were only used if single cells 
comprised ≥ 95 %.  210 cells/cm2 were seeded in to a low attachment plate and grown for 
7 days to form secondary sarcospheres. Colony size was assessed using an eyepiece 
graticule and colonies ≥ 40 µM were counted. Colony size of primary sarcospheres was 
estimated using Imagej. Sarcosphere forming efficiency (SFE), was calculated using the 
following equation: 
 
𝑆𝐹𝐸 (%) =  (
𝑁𝑜.  𝑜𝑓 𝑠𝑒𝑐𝑜𝑛𝑑𝑎𝑟𝑦 𝑠𝑎𝑟𝑐𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠
𝑁𝑜. 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑
 )  𝑋 100 
 
 
2.2.5 Soft agarose assay 
OS cell line anchorage-independent growth has been previously assessed using the soft 
agarose assay (Fawdar, 2010), using the same methodology as Fawdar (2010) anchorage- 
independent growth has been assessed. A 2 % agarose solution was prepared by diluting 
6 % autoclaved low melting point agarose (dissolved in DPBS) in complete media 
(containing antibiotic/antimycotic) and maintained as a liquid by incubating at 55 ºC. The 
2 % agarose was further diluted in complete media to make 0.6 % of which 2 ml was used 
as the base layer and set for 30 mins at 4 ºC. Cells were trypsinised, counted (Section 2.2.3) 
and 10000 cells were seeded in 2 ml of 0.35 % agarose. This formed the middle layer of the 
assay, which was set for 30 mins at 4 ºC and then incubated at 37 ºC. The following day 2 
ml of complete media (containing antibiotic/antimycotic) was added to wells and changed 
every 3 days for up to 15 days. Colony formation was monitored throughout the 
experiment and assessed after 12 or 15 days using an eye piece graticule. Due to the larger 
size of MG63 colonies, U2OS colonies ≥ 85 µM and MG63 colonies ≥ 170 µm were counted. 
For the assessment of CCL-2 and IL-8 upon soft agarose colony formation CCL-2 (36.4 ng/ml) 
or IL-8 (9 ng/ml) were added to the middle 0.6 % agarose layer and top media layer of the 
assay. 
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2.3 Chemotoxicity analysis 
2.3.1 Assessment of median lethal doses in response to chemotherapeutics and DEAB 
Cells were trypsinsied and counted (Section 2.2.3), seeded at 15625 cells/cm2 in a 96 well 
plate (BD falcon, Oxford, UK) and allowed to attach for 24 hours. After which media was 
removed and replaced with media containing either cisplatin (0 - 100 µM), doxorubicin (0 
- 3 µM) or DEAB (0 - 800 µMol) for 48 hours. For methotrexate (0 - 3 µM) cells were exposed 
for 5 days. Cells were quantified by adding 100 µl of 1 mg/mL thiazolyl blue tetrazolium 
bromide (MTT) (dissolved in complete media) which was added directly to cells and 
incubated for 1 hour (except SaOS-2, where a 2 hour MTT incubation was used) at 37 °C. 
MTT containing media was removed and replaced with 50 µl of dimethyl sulfoxide (DMSO), 
absorbance was measured at 530 nm on a microplate reader (Sunrise, TECAN™) using 
softmax® pro. MTT reduction (% of control) was calculated using the following equation: 
(
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (530 𝑛𝑚)
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑏𝑙𝑎𝑛𝑘 (0µ𝑀)𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒(530 𝑛𝑚)
) × 100 
LD50 values were calculated using a linear regression of drug concentration against cell 
viability. 
 
2.3.2 Clonogenicity of chemotherapy treated cells 
 
Cell lines were seeded at 15625 cells/cm2 and allowed to attach and grow for 24 hours after 
which media was removed and replaced with media containing either cisplatin (0 - 100 µM) 
or doxorubicin (0 - 3 µM) for 48 hours. The incubation period was extended to 5 days for 
methotrexate (0 - 3 µM). After drug exposure cells were trypsinised and counted (Section 
2.2.3) and re-seeded at low density (2 - 4 cells/cm2). Cells seeded at low density were grown 
for 14 days then washed with 5 ml DPBS, stained for 10 mins in 0.5 % crystal violet 
(dissolved in 100 % methanol) and washed 3 times with water. Prior to staining the first 30 
colony hierarchies were randomly observed using an inverted microscope (Inverso 3650) 
and recorded. Colony size and number was assessed using the image processing software 
ImageJ, all colonies were measured.  
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2.3.3 Combined DEAB and chemotherapy exposure 
 
Cells were trypsinsied and counted (Section 2.2.3), seeded at 15625 cells/cm2 in a 96 well 
plate (BD falcon, Oxford, UK) and allowed to attach for 24 hours with the cell line specific 
DEAB LD50 concentration. DEAB media was removed and replaced with complete media 
containing a DEAB LD50 and either cisplatin, doxorubicin or methotrexate LD50. Cisplatin 
and doxorubicin exposed cells were exposed for 48 hours and methotrexate for 5 days. 
Cells were quantified by adding 100 µl of 1 mg/mL thiazolyl blue tetrazolium bromide (MTT) 
(dissolved in complete media) which was added directly to cells and incubated for 1 hour 
at 37 °C. MTT containing media was removed and replaced with 50 µl of dimethyl sulfoxide 
(DMSO), absorbance was measured at 530 nm on a microplate reader (Sunrise, TECAN™)   
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2.4 Paracrine growth experiments 
2.4.1 Conditioned media collection 
For the collection of conditioned media each cell line was allowed to reach confluency in a 
cell culture dish (55 cm2). The media was replaced with 10 ml complete media which was 
harvested after either 24, 48 or 72 hours. Conditioned media was filtered using 0.2 µM 
filter (Millipore, Abingdon, UK) and stored at -20 °C. All conditioned media was diluted 1:1 
in complete media when used as a growth media.  
  
2.4.2 Conditioned media effect on colony formation 
In order to establish whether conditioned media effects cell growth each cell line was 
seeded in triplicate in 55 cm2 growth area dishes at a cell density which produced 
approximately 100 colonies (2 - 4 cells/cm2) after 8 - 15 days. Cells were grown in either 
the presence of conditioned media or non-conditioned media (complete media). Media 
was changed every 3 days and growth examined by staining after 8 - 15 days depending 
upon the cell line. Cells were stained for 10 mins in 0.5 % crystal violet (dissolved in 100 % 
methanol) and washed 3 times with water. Prior to staining the first 30 colony hierarchies 
were randomly observed using an inverted microscope (Inverso 3650) and recorded. 
Colony size and number was assessed using the image processing software ImageJ, all 
colonies were measured.  
 
2.4.3 96 well growth assay 
In order to assess the enhanced growth rates from exposure to conditioned media HOS and 
U2OS. Cells were seeded at either 125 cell/cm2 (HOS) or 156 cell/cm2 (U2OS) in to a 96 well 
plate in a volume of 100 µl, different cell densities were used to produce the same 
confluency of 80 % for both HOS and U2OS. After 8 – 9 days, 100 µl of 1 mg/ml MTT was 
added directly on to cells and incubated at 37 ºC for 1 hour, after which, media was 
removed and replaced with 50 µl DMSO and plate absorbance was read at 530 nm on a 
microplate reader (Sunrise, TECAN™) using softmax® pro.  Absorbances of a cell line tested 
in conditioned media or cytokine supplemented media was compared to the MCF7 
conditioned media absorbances to assess statistically significanct growth enhancement.        
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2.4.4 CXCR1, CXCR2 and CCR2 receptor antagonist experiment 
Antagonising Antibodies for CXCR1 (Clone 42705) (R&D systems®, Abingdon, UK) CXCR2 
(Clone 48311) (R&D systems®) and a small molecule CCR2 antagonist (RS 504393) (R&D 
systems®) were diluted in either complete media, U2OS or MG63 72 hour conditioned 
media. U2OS and HOS cells were trypsinised (Section 2.2.2) and seeded at either 125 
cell/cm2 (HOS) or 156 cell/cm2 (U2OS) in to a 96 well plate and grown for 9 days. To assess 
cell growth 1 mg/ml MTT was added directly to cells and incubated at 37 ºC for 1 hour, after 
which, media was removed and replaced with 50 µl DMSO, plate absorbance was read at 
530 nm on a microplate reader (Sunrise, TECAN™) using the software softmax® pro.         
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2.5 Cytokine expression 
2.5.1 Cytokine array 
Assessment of the cytokine profile of 72 hour conditioned media was achieved using a 
cytokine array (R&D systems, Abingdon, UK). The array was tested according to the 
manufacturers instructions. To summarise, membranes were blocked with kit buffer for 1 
hour whilst 700 µl of conditioned media was incubated with a cocktail of detection 
antibodies. Blocking buffer was removed from membranes and replaced with sample-
antibody cocktail and incubated overnight on a rocking shaker. Membranes were washed 
with wash buffer 3 times for 10 mins each, incubated with streptavidin-HRP for 30 mins 
and washed with kit wash buffer. Chemiluminescence was analysed using an EZ-ECL kit 
(Geneflow, Lichfield, UK). Membranes were exposed for 10 mins before developing X-ray 
film (Kodak®, Hemel Hempstead, UK).  
 
2.5.2 CCL-2 and IL-8 ELISA 
To determine the IL-8 and CCL-2 concentration of conditioned media, samples were 
analysed by antibody sandwich ELISAs (BioLegend®) following manufactures instructions. 
To briefly summarise the samples were diluted either 1:2, 1:10 or 1:40 in the provided assay 
buffer and 50 µl added to plates along with an equal volume of assay buffer. For all 
incubation periods plates were incubated shaking (185 rpm) at room temperature. Plates 
were washed using 300 µl wash solution per well 4 times and blotted dry on absorbent 
paper. To develop the assay 100 µl substrate solution was added to each well and incubated 
in the dark for 15 mins before the addition of 100 µl stop solution (1 M sulphuric acid). 
Once reaction was stopped plate absorbance was read at 450 nm and 570 nm on a 
microplate reader (Sunrise, TECAN™) using softmax® pro. Data analysed by subtracting 
absorbances at 570 nm from absorbances at 450 nm, all samples and standards were tested 
in triplicate and concentrations were calculated from the linear regression analysis of the 
standard curve. 
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2.6 CCL-2 RNA gene interference 
In order to achieve stable CCL-2 knockdown the pLKO.1 vector was used which is a 
derivative of the third generation self-inactivating lentiviral vector 
pRRLSIN.cPPT.PGK/GFP/WPRE (Dull et al., 1998). This vector contains a human U6 
promoter to drive expression of shRNA and human phosphoglycerate kinase promoter 
(hPGK promoter) for puromycin resistance (PurR) gene expression for selection of 
transduced cells (Moffat et al., 2006) (Figure 2.1). Three separate plasmids were used for 
lentiviral packaging in HE293T cells which contained the packaging genes Gag, Pol, Rev and 
protein coat gene Vsv-G to minimise potential plasmid recombination and creation of 
replication competent viruses (Root et al., 2006). The RNAi consortium (TRC) was 
established to create shRNA libraries with multiple constructs for over 15,000 genes 
(Moffat et al., 2006). Using the TRC library five CCL-2 shRNA constructs were selected to 
identify potential shRNA with effective gene knockdown upon U2OS cells (Table 2.2) 
 
 
 
Figure 2.1: Diagram of pLKO.1 vector map used for the RNA interference of CCL-2. Image 
was taken from Thermo scientific TRC shRNA user manual (Dharmacon, 2014). 
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Table 2.2: shRNA lentiviral sequences used to assess stable knockdown of CCL-2 in U2OS 
cells. shRNA sequences were established by the RNAi consortium (TRC) and distributed by 
Thermoscientific®. 
 
Thermo scientific® clone ID Antisense sequence 
RHS3979-201738552 TAAGGCATAATGTTTCACATC 
RHS3979-201738553 TATTGGTGAAGTTATAACAGC 
RHS3979-201738554 ATTCTTCTATAGCTCGCGAGC 
RHS3979-201738555 AATGGTCTTGAAGATCACAGC 
RHS3979-201738556 TTATAACAGCAGGTGACTGGG 
 
 
2.6.1 Transforming bacterial competent cells 
Packaging vectors were transformed into competent cells (XL1-blue competent cells) 
(Invitrogen®) by mixing 1 µl of plasmid DNA (packaging plasmids PL1, PL2 and pVSVG 
(Invitrogen®) with a vial of competent cells and incubated on ice for 5 mins. Competent 
cells were heat shocked at 42 ºC for 1 min, incubated on ice for 5 mins followed by addition 
of 250 µl SOC buffer (2 % tryptone, 0.5 % yeast extract, 8.6 mM NaCl, 2.5 mM KCl and 10 
mM MgCL2) and 1 hour shaking at 37 ºC (200 rpm) to transform cells. 
 
2.6.2 Plasmid preparation 
TRC lentiviral shRNA (Thermo scientific®) constructs were received as bacterial stocks. 
Bacterial frozen stocks were streaked on to an agar plate containing 100 µg/ml carbenicillin, 
incubated overnight at 37 ºC. 3 - 5 colonies were picked in to 6 ml of 2 x LB broth (LB-Lennox 
broth 20 g/L, peptone 10 g/L and yeast extract 5 g/L all from fisher) and incubated at 37 ºC 
for 16 hours with shaking (200 rpm).  Cultures were centrifuged at 3000 rpm for 10 mins, 
supernatant was discarded then plasmid extracted from the pellet using PureLink® quick 
plasmid miniprep kit (Invitrogen) according to the kit instructions. DNA was quantified 
using the nanodrop 1000 spectrophotometer (Thermo scientific) and stored at - 20 ºC.    
 
2.6.3 CCL-2 stable knockdown 
U2OS CCL-2 knocked-down was achieved using lentiviral transduction, packaging of 
lentiviruses and U2OS transduction was carried out at St George’s University (London, UK) 
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under their GM licence. HEK293T cells were used to package the vectors when grown to 
80 % - 90 % confluency in a T25 flask. In a DNA free eppendorf 1.5 µg of pL1, pL3 and 
lentiviral construct were mixed with 1.09 µg pL2 and 23 µl polyethylenimine (PEI) along 
with 341 µl of 0.15 M NaCl. This mixture was vortexed and incubated at room temperature 
for 10 mins.  The mixture was added to HEK293T cells at 80 - 90 % confluent in complete 
media and the media changed after 24 hours. After 48 hours of transfection the media 
contained packaged lentiviral particles at which point the media was collected, centrifuged 
at 4000 rpm for 10 mins and supernatant added to U2OS cells at 70 - 80 % confluency in a 
T25 flask. After 24 hours exposure the virus containing media was removed and cells were 
allowed to recover for 48 hours in fresh complete media. Transduced cells were 
transported back to the University of Westminster and exposed to 1.25 µg/ml puromycin 
(Fisher), to select for cells stably expressing the plasmid. Plasmids which conferred 
knockdown included the following the antisense sequence TTATAACAGCAGGTGACTGGG 
(RHS3979-201775815) and TAAGGCATAATGTTTCACATC (RHS3979-201738552) (Table 2.2).    
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2.7 Gene expression analysis 
2.7.1 RNA extraction 
Total RNA was extracted from cell lines using purelink RNA kit (Life technologies, Paisley, 
UK) following the manufacturers protocol. To summarise the procedure, 1 x 106 cells were 
harvested from a 70 – 90 % confluent T25 flask (except for RNA extracted Illuimina micro 
array gene analysis, U2OS cells were seeded at 36 cells/cm2 in a 55cm2 growth area and 
grown for 7 days before collecting RNA) and re-suspended in 600 µl kit lysis buffer 
containing 1 % 2-mercaptoethanol. Cells were homogenised by passing 10 times through a 
21 gauge needle. The homogenate was then centrifuged at 2600 x g for 5 mins, supernatant 
mixed with an equal volume of 70 % ethanol and transferred to a spin cartridge and 
centrifuged at 12000 x g for 15 seconds. Flow-through was discarded and the spin cartridge 
washed 3 times with kit washing buffers and membrane allowed to dry by centrifugation 
at 12000 x g for 15 seconds. RNA was eluted using 30 µl RNAase free water which was 
incubated (on the column) at room temperature for 1 min, and eluted by centrifuging at 
12000 x g to collect in an RNAase free eppendorf tube.  RNA was quantified using a 
Nanodrop 1000 spectrophotometer (Thermo scientific) and stored at -80 ºC.      
 
2.7.2 Reverse transcription 
Reverse transcription (RT) was performed using the QuantiTect reverse transcription kit 
(Qiagen®, Crawley, UK). 1 µg of the collected RNA was used in each reaction, which involved 
a 2 min incubation at 42 ºC with the genomic DNA wipeout buffer. The RNA was then mixed 
with the kit buffers containing the reverse transcriptase and primers, incubated at 42 ºC for 
15 mins followed by 3 mins at 95 ºC.  DNA concentration was quantified using a Nanodrop 
1000 spectrophotometer (Thermo scientific) and stored at -20 ºC 
 
2.7.3 Quantitative real time PCR 
Quantitative real time PCR was performed on the Qiagen rotor geneQ™ using the rotor 
gene kit SYBR green (Qiagen®). A typical 25 µl reaction was set up using the following 
reagents: 100 ng of template DNA, 1 µM of forward and reverse primers and 1x Qiagen 
rotor gene master mix containg DNA polymerase, dNTPs and MgCl2. The PCR conditions 
used were an initial activation of 95 ºC for 5 mins followed by 35 cycles of 95 ºC for 5 seconds 
and 60 ºC for 10 seconds. A melt curve was also used to assess the primer annealing 
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temperatures. Reverse transcribed cDNA was tested in triplicate and normalised using 18s 
rRNA. Primer sets used: CCL2, 5’ AAGATCTCAGTGCAGAGGCTCG 3’ (forward primer) and 5′-
TTGCTTGTCCAGGTGGTCCAT-3′ (reverse primer); and 18S rRNA, 5′-
CGCGGTTCTATTTTGTTGGT-3′ (forward primer) and 5′-CCCTCTTAATCATGGCCTCA-3′ 
(reverse primer).  
 
2.7.4 Gene microarray 
U2OS cells were seeded at 36 cells/cm2 in a 55cm2 growth area and grown for 7 days before 
collecting RNA (Section 2.7.1). RNA was prepared for microarray analysis using the Illumina 
Total prep-RNA amplification kit (Invitrogen®). To summarise briefly 500 ng mRNA was 
added to master mix (dNTPs, T7 oligo(dT) primer, RNase inhibitor and Array Script) and 
incubated at 42 ºC for 2 hours for reverse transcription. Second strand cDNA was 
synthesised by incubating the reverse transcribed RNA with DNA polymerase, dNTPS and 
RNAase for 2 hours at 16 ºC. Biotinylated cRNA was then produced by incubating with 
Biotin-NTP, T7 RNA polymerase and reaction buffer for 4 – 14 hours at 37ºC. cRNA was then 
eluted and hybridised to the Illumina Sentrix array for analysis.  
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2.8 Flow cytometry 
2.8.1 Extracellular antibody staining 
Cells were trypsinsed upon reaching 70 - 90 % confluency and stained using antibodies for 
the surface markers CD44-phycoerythrin (PE) (Miltenyl biotech®, Surrey, UK) or e-cadherin-
fluroescein isothiocyanate (FITC) (BioLegend®, Cambridge, UK). Prior to staining cells were 
counted using a haemocytometer and diluted in ice cold DPBS and 1 % FBS to 5 x 105 cells 
per sample. Centrifuged at 2000 rpm for 5 mins and re-suspended in 100 μl 1% FBS and 
incubated with the appropriate concentration of primary antibody (1:100) on ice for 15 
mins in the dark. Following antibody incubation cells were centrifuged at 1000 rpm for 3 
mins and washed with 1 % FBS 3 times and re-suspended in 0.5 ml 1% FBS. For all antibodies 
tested a corresponding isotype control conjugated to the same fluorescent detector was 
used to assess non-specific binding with all cell lines tested in triplicate (Table 2.3). 
 
Table 2.3: Comparison of primary antibodies used for assessment of cell marker 
expression in flow cytometry. Staining antibodies had specificity for protein marker and all 
control antibodies had no specificity to human proteins. All antibodies were either raised 
in mouse or rabbit. (Miltenyl biotech®, Surrey, UK), Santa cruz (Heidelberg, Germany), 
Abcam, R&D systems (Abingdon, UK), BioLegend (London, UK). 
 
Protein marker Staining 
antibody origin, 
isotype 
conjugate 
Antibody 
supplier 
Control 
antibody origin, 
isotype 
conjugate 
Control 
antibody 
supplier 
CD44 Mouse IgG2b 
(PE) 
Miltenyl Mouse IgG2bκ 
(PE) 
BioLegend 
CD117 Mouse, IgG1κ 
(APC) 
BioLegend Mouse, IgG1κ 
(APC) 
BioLegend 
E-cadherin Mouse, IgG1κ 
(Alexa fluor® 
488) 
BioLegend Mouse, IgG1κ 
(Alexa fluor® 
488) 
BioLegend 
Vimentin Rabbit, IgG 
polyclonal 
(unconjugated) 
Santa cruz Rabbit, IgG 
polyclonal 
(unconjugated) 
Santa cruz 
CXCR1 Mouse, IgG2A 
(unconjugated) 
R&D systems Mouse, IgG2a 
(unconjugated) 
BioLegend 
CXCr2 Mouse, IgG2a 
(unconjugated) 
R&D systems Mouse, IgG2a 
(unconjugated) 
BioLegend 
CCR2 Mouse, IgG2a 
(unconjugated) 
BioLegend Mouse, IgG2a 
(unconjugated) 
BioLegend 
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2.8.2 Intracellular antibody staining 
Cells were trypsinsed upon reaching 70 - 90 % confluency, then 1 x 106 cells fixed in 100 µl 
BD cell fix (BD Biosciences ®, Oxford, UK) and incubated for 15 mins. 500 µl of 1% BSA 
(diluted in DPBS) was added directly on to fixed cells then centrifuged at 2000 rpm for 5 
mins and washed with a further 500 µl of 1% BSA. Cell membranes were then permeabilised 
with 200 µl 0.1% triton (diluted in DPBS) incubated in the dark for 10 mins followed by 
centrifugation (2000 rpm for 5 mins) and washed once with  500 µl 1% BSA. Cells were re-
suspended in 100 µl 1% BSA FC blocker (Miltenyi Biotec, Surrey, UK) with appropriate 
antibody and incubated for 15 mins in the dark. Three 1 ml 1% BSA washes were used to 
remove any unbound antibody, followed by re-suspension in 100 µl 1% BSA and incubation 
with secondary antibody (1:200) for 15 mins (Table 2.4). Finally cells were washed twice 
and re-suspended in 1 ml 1% FBS for flow cytometry analysis. 
 
Table 2.4: Antibodies used to stain for CSC markers, epithelial or mesenchymal status and 
expression of cytokine receptors. *Indicates co-incubation of antibody with Fc receptor 
blocker. All primary antibodies monoclonal and raised in mouse, except for the vimentin 
antibody which was polyclonal and raised in rabbit. Secondary antibodies were polyclonal 
and raised in goat. Dako (Cambridge, UK).  
 
 
Antibody 
Antibody 
conjugation 
Dilution Source 
1º 2º 1º 2º 1º 2º 
CD44 PE  1:100  Miltenyl  
CD117 APC  1:100  BioLegend  
E-
cadherin 
FITC  1:100  BioLegend  
Vimentin*  FITC 1:100 1:200 Santa 
Cruz 
Dako 
CXCR1*  FITC 1:100 1:200 R&D 
systems 
Abcam 
CXCr2*  FITC 1:100 1:200 R&D 
systems 
Abcam 
CCR2  FITC 1:100 1:200 BioLegend Abcam 
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2.8.3 Aldehyde dehydrogenase staining (ALDH) 
ALDH reconstitution was carried out according to manufacturer’s instructions. Cells were 
stained for ALDH using the ALDEFLUOR kit (Stem cell technologies®, Genoble, France), after 
trypsinisation and counting (Section 2.2.3), cells were diluted in kit buffer to 5 x 105 cells 
per 500 μl sample.  Next 2.5 μl of the ALDH activated reagent was mixed with the sample 
and 250 μl was immediately removed and mixed in a separate tube with 2.5 μl of the ALDH 
inhibitor diethylaminobenzaldehyde (DEAB) to act as a negative control. Samples were 
incubated at 37 °C for 50 mins, centrifuged at 2000 rpm for 5 mins and re-suspended in 0.5 
ml ALDH buffer and analysed using the flow cytometer.  
 
2.8.4 Living cell discrimination 
In order to distinguish between live and dead cells, propidium iodide (PI) or Live/dead 
staining kit (Invitrogen®) was used when PI conflicted with the emission spectra of the 
fluorescent detector.  PI was used at 1 μg/μl and incubated with a sample after antibody 
staining and 15 mins prior to flow cytometric analysis. PI can only interact with dead cell 
DNA producing an emission spectra detected by the PE channel, allowing cells positive for 
PE to be removed during data analysis. 
The reconstitution of the live dead kit was carried out according to manufacturer’s 
instructions. Briefly, live dead staining was undertaken either before fixation or after 
antibody staining of non-fixed, cells were centrifuged at 2000 rpm and re-suspended in 0.5 
ml DPBS and stained with the activated reagent (1:1000) on ice in the dark for 30 mins. 
After staining cells were washed once in 0.5 ml DPBS and re-suspended in 1 % FBS (diluted 
in DPBS). The near IR channel live dead kit binds only to dead cell amines producing an 
emission spectra detected by the APC-cy7 channel, allowing these cells to be removed 
during analysis. 
 
2.8.5 Flow cytometric analysis 
For each sample a total of 10,000 cells were counted on a CyAn™ ADP flow cytometer 
(DakoCytomation) and data was analysed using the summit v4.3 software. Cell lines were 
gated according to an unstained sample and lasers were adjusted accordingly. Unstained 
cells were used to set gates for cell size and internal complexity, dead cells were removed 
along with doublets (two cells passing past the laser at once).  
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2.8.6 CSC marker expression of chemotherapy treated cells 
Cell lines were seeded at 15625 cells/cm2 and allowed to attach and grow for 24 hours. 
After which media was removed and replaced with media containing either cisplatin (0 - 
100 µM) or doxorubicin (0 - 3 µM) for 48 hours. Methotrexate (0 – 3 µM) was exposed to 
cells for 5 days, cells were then trypsinised and stained for either CD117 (Section 2.8.1) or 
ALDH (Section 2.8.3). 
 
 
2.8.7 ALDH cell density expression 
Cell lines were seeded at 15625 cells/cm2 and allowed to attach for 24 hours, after which, 
media was removed and replaced with complete media for 5 days, cells were then 
trypsinised and stained for ALDH (Section 2.8.3). 
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2.9 Confocal microscopy 
Cells were seeded at 1050 cells/cm2 on to 10 mm diameter circular cover slips (Fisher®) for 
3 – 5 days. Upon colonies reaching a suitable size cover slips were washed once with 500 
µl DPBS and for ALDH stained simultaneously using To-pro-3 (1:800) (Invitrogen), Aldefluor 
kit stain (1:400), and CD44 antibody (1:80) (BD sciences) diluted in ALDEFLUOR kit buffer. 
Coverslips were stained for 37 ºC for 50 mins, then washed 3 times in ALDEFLUOR buffer 
and mounted with 50 % glycerol (diluted in ALDEFLUOR buffer) and analysed immediately. 
For the ALDH control sample DEAB (1:50) was added in to the staining buffer to inhibit 
ALDH fluorescence. 
CD117 and e-cadherin antibodies were used to stain colonies grown upon coverslips, prior 
to antibody staining cells were fixed in 400 µl 4 % paraformaldehyde. After fixation 
coverslips were washed with 400 µl DPBS, blocked in 7 % casein (diluted in DPBS) with 
RNAase (1:100) for 30 mins at 37 ºC. Washed 3 times in DPBS and stained for 1 hour in the 
dark (antibodies diluted 1:50 in 7 % casein), then washed with 3 times with DPBS and 
stained with To-pro-3 (1:1000) for 30 mins at room temperature in the dark. Cells were 
washed 3 times with DPBS and mounted in 70 % glycerol (diluted in DPBS) and analysed 
using the confocal microscope (Leica).  
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3.1 Introduction 
Osteosarcoma is defined as a cancer of the connective tissue origin which is characterised 
by the production of the bone matrix osteoid (Schajowicz et al., 1995). In most cases OS 
arises within the medullary cavity of the metaphysis of a growing long tubular bone, 
however rarer cases occur upon the bone surface, within the cortex or even in an 
extraskeletal site. High grade OS cancers are most commonly found within the meduallary 
region of the bone, whilst surface OS lesions are often lower grade and occur in patients at 
least a decade later than common OS lesions (Klein and Siegal, 2006). OS primarily affects 
adolescents (Jawad et al., 2011) and it has been found that patients with OS are significantly 
taller, it was suggested that this observation may be linked to rapid growth of bones during 
puberty (Cotterill et al., 2004) (section 1.1.3).  
Stem cells are responsible for the growth and maintenance of organs within the body 
(section 1.2). A similar hierarchical formation of cells has now been identified within many 
cancers including leukaemias (Bonnet and Dick, 1997) and solid tumours (Al-Hajj et al., 
2003), through the identification of CSC which are attributable for the initiation and growth 
of tumours. Based on the expression of mesenchymal stem cells marker Stro-1 and the 
transmembrane tyrosine kinase receptor CD117, OS CSC have been identified using the 
gold standard technique of xenotransplantation (Section 1.2.2). Stro-1+ CD117+ positive 
cells sorted from cell lines (KHOS-NP and MNNG-HOS) and primary cells (BCOS) were able 
to serially form tumours and had an elevated resistance to chemotherapeutics (Adhikari et 
al., 2010). Based on the use of one OS cell line (OS99-1) CSC have also been identified using 
xenotransplantation of cells expressing the intracellular enzyme ALDH (Wang et al., 2011). 
These findings suggest that potentially even within one cancer type multiple CSC markers 
may exist, however, the studies undertaken by Adhikari et al 2010 and Wang et al 2011 
utilised different procedures to assess the tumourigenicity of potential CSC. Therefore, the 
different markers of OS CSC identified by the groups may reflect differences in the 
methodologies used and not phenotypic differences, which highlight the need to utilise 
consistent protocols on a wide range of cell lines.  
An alternative method to identify CSC, which is not based on the expression of surface 
proteins, is the identification of the colony hierarchies (Locke et al., 2005, Li et al., 2008) 
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(Section 1.2.3). In the OS cell line MG63 holoclonal cells have been found to have enhanced 
drug resistance and sarcosphere forming efficiency (Lou et al., 2010). Identifying the 
presence of holoclonal cells in a range of OS cell lines would provide further evidence that 
CSC reside within sarcomas. The ability to identify the expression of CSC markers within 
these colonies would provide further evidence of the proteins which distinguish OS CSC. 
OS has a very poor prognosis which is often attributed to the presence of secondary 
tumours (Yen, 2009), 90 % of OS metastasic tumours occur in the lungs (Jeffree et al., 1975). 
Pulmonary secondary lesions pose a significant risk to patient health, halving long term 
survival (5 years) from 80 % to 40 % (Wu et al., 2009). In order for a cancer cell to colonise 
a distant site and form a secondary tumour it must first detach itself from surrounding cells, 
surivive anoikis and transition through the circulatory system (Simpson et al., 2008). The 
role of the microenvironment has been found to play a crucial role in providing cells with 
suitable cues to evolve in to a metastatic cell (Glinskii et al., 2003). The acquisition of 
migratory properties is based upon epithelial to mesenchymal transition EMT which is 
integral in embryo development (Hay, 2005) and cancer progression (Thiery, 2002) (Section 
1.2.4). The ability of a metastatic cell to colonise a new site and form a secondary tumour 
indicates this cell must have stem cell properties. Evidence now suggests that expression 
of EMT transcription factors converts cells to a CSC phenotype (Mani et al., 2008) (section 
1.2.5). In OS the phenotype of metastatic cells is not well defined, understanding the EMT 
status of commonly used OS cell lines will help to further characterise this cancer. 
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Aims 
CSC from different cancer types often have unique markers which are specific to that 
cancer type, in OS ALDH and CD117 have been utilised to identify CSC, in contrast, in 
carcinoma CSC research CD44 is a commonly used marker. Published research using 
commercially available OS cell lines often focus on only a single CSC marker. Characterising  
a panel of 8 OS cell lines for a range of CSC markers will provide more robust evidence that 
putative CSC are present within these cell lines. In addition understanding whether these 
cell lines contain cells which have a mesenchymal or epithelial phenotype, will help to build 
up a picture of the nature of OS. The specific objectives of this study which will be tested 
using a panel of 8 OS cell lines (Table 1.1) and the breast cancer cell line MCF7 as a control, 
are as follows: 
 
 Comparison of the CSC marker profiles of ALDH, CD44 and CD117. 
 Analyse the expression of the epithelial marker e-cadherin and mesenchymal 
marker vimentin. 
 Identification of the colony hierarchies based on the presence of holoclones, 
meroclones and paraclones. 
 Use fluorescent microscopy to identify what colony hierarchies (holoclones, 
meroclones and paraclones) contain cells expressing CSC markers; ALDH, CD44 and 
CD117.  
 Analyse the ability of cell lines to form spherical colonies in non-attachment 
conditions. 
 Through immunostaining of spherical colonies formed in non-attachment 
conditions the presence of cells expressing CSC markers (ALDH, CD44 and CD117) 
will be assessed. 
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3.2 Expression of cancer stem cell markers 
3.2.1 ALDH staining optimisation 
The cancer stem cell marker ALDH was previously used to identify cancer stem cells in OS 
(Wang et al., 2011) using the ALDEFLUOR kit (Stem cell technologies®, Genoble, France) 
(section 1.2.2). To determine if ALDH activity varied in OS the enzyme activity was 
measured in seven OS cell lines and MCF7. In order to obtain accurate measurements of 
ALDH the flow cytometry assay (Section 2.8.3) was used along with the following analysis.  
Firstly data was collected from only single cells by gating the pulse width parameter (Figure 
3.1), any cells above or below this were removed to exclude any doublets (two cells passing 
through the lasers at the same time) or debris. Cells were stained with propidum iodide (PI) 
so only living cells were analysed based on PE-texas red fluorescence. Due to the FITC 
fluorescence of ALDH stained cells interfering with the PE-texas channel of PI stained cells. 
A gate was used to include all the low expressing PE-Texas red cells and FITC expressing 
cells for both control (figure 3.2.A) and ALDH stained (Figure 3.2.B), this was used to identify 
all living and highly expressing ALDH cells. Finally, in order to identify the percentage of 
cells expressing ALDH the stained cells were compared to cells to which the ALDH inhibitor 
diethylaminobenzaldehyde (DEAB) was added (Figure 3.3). ALDH stained cells exceeding 
the FITC fluorescence of the DEAB inhibited cells were calculated as the ALDH positive 
population.  
 
 
 
 
Figure 3.1: Removal of two cells (duplets) passing through the flow cytometer laser at 
once. A gate (R1) was placed over the majority of cells with the same pulse width (cell 
width), to ensure only cells of a similar size were included in the analysis. Image is an 
example of HOS pulse width analysis. 
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(A)      (B) 
Figure 3.2: Optimisation of live/dead cells in ALDH staining. Propidium iodide was used to 
stain dead cells which could be detected using the PE channel. Due to FITC fluorescent cells 
(ALDH expressing cells) interfering with PE fluorescence detection, dead cells were 
removed by using a gate (R2) which would include all the cells expressing low levels of PE 
texas red for both DEAB control (A) and ALDH positive (B). Cells with a PE fluorescence 
corresponding to living cells were included in the gate (R2). Any cells outside this gate were 
considered dead and not included in the analysis. Image is an example of dead cell removal 
of HOS cells and is representative of 3 images. 
 
 
 
 
Figure 3.3: Analysis of ALDH positive population. The DEAB inhibited cells (green) were 
compared to the ALDH stained cells (red) (the example shows HOS stained cells (n=1). 
Comparison of stained cells to non-stained cells was used to calculate the percentage of 
ALDH positive cells. Representative of 3 images. 
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3.2.2 Analysis of ALDH expression in OS cell lines and MCF7  
The OS cell lines along with MCF7 were stained for ALDH to assess the percentage of cells 
expressing this putative CSC marker. The expression was heterogeneous ranging from 0.90 % 
in SaOS-2 to 60.60 % in HOS. The cell lines 143B and G292 also contained relatively large 
populations of 12.20 % and 9.60 % ALDH positive cells respectively. 143B contained a 
significantly larger (p <0.05) ALDH population than Cal72, MG63, MNNG-HOS and U2OS.  
The remaining cell lines all contained a similar sized population ranging from 2.13 % to 
3.30 %, the epithelial breast cancer cell line containing 3.26 %. 
 
 
 
Figure 3.4: Evaluation of the percentage of ALDH positive cells (ALDH+) in OS and MCF7 
cell lines. The HOS cell line contains a significantly larger population than all cell lines and 
143B was significantly larger than Cal72, G292, MG63, MNNG-HOS and U2OS, and G292 
(*p <0.05, **p <0.01Tukey’s post hoc analysis) of ALDH positive cells, when compared to 
all other cell lines. Each cell line was tested in triplicate and data presented as mean and 
standard deviation. 
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3.2.3 CD117 staining optimisation 
The CD117 tyrosine kinase receptor has been used to identify CSC in OS (Adhikari et al., 
2010) and has been associated with poor chemotherapy response (Miiji et al., 2011). In 
order to accurately identify CD117 expression, the flow cytometry assay outlined in the 
methods section (Section 2.8.5) was used along with the following analysis. Duplets were 
removed from analysis as in the ALDH staining procedure (Figure 3.1), PI was used to stain 
for dead cells. Data from living cells was captured by gating the PE low stained cells to 
include only living cells (Figure 3.5). Evaluation of CD117 expressing cells was calculated by 
comparing the isotype control stained antibody fluorescence with the CD117 antibody 
stained cells (Figure 3.6). Stained cells exceeding the control cell fluorescence were 
calculated as the CD117 positive population.  
 
Figure 3.5: Gating of dead cells using PE channel. Cells were stained with PI, a gate (R2) 
was created to include only cells which had a low PE fluorescence and any cells outside of 
this gate were considered dead and excluded. Image is an example of dead cell removal in 
143B cells.  
 
Figure 3.6: Evaluation of the percentage of CD117 positive cells in the cell line 143B. Cells 
stained for CD117 using a CD117 specific monoclonal antibody (IgG1,κ) conjugated to the 
fluorophore APC, isotype control IgG1,κ APC conjugated antibody with no  affinity for 
human cells. The isotype control stained cells (red), were compared to the CD117 stained 
cells (blue). Comparison of stained cells to isotype control cells was used to calculate the 
percentage of CD117 positive cells. Example shown is a representative of three images. 
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3.2.4 Analysis of CD117 expression in OS cell lines and MCF7 
 
The presence of CD117 has only been tested in one commonly used OS cell line, U2OS 
which was found to contain 0.6 % CD117 positive cells (Tang et al., 2011). The majority 
(65 %) of clinical tumour samples are positive for CD117 (Entz-Werle et al., 2005) so 
identifying if this marker is also expressed in a panel of OS cell lines is of interest. Using the 
method outlined in 3.2.3 all cell lines except 143B (6.40 %) contained less than 1 % of cells 
expressing CD117, Cal72 and HOS contained populations of 0.93 % and 0.77 % respectively 
and the remaining low expressing cell lines contained negligible populations less than 0.1 %. 
U2OS contained 0.008 % CD117 expressing cells, which was smaller than population 
reported by Tang et al., (2011). MG63 and MCF7 contained no CD117 positive cells and 
143B contained a significantly larger population than all other cells lines of 6.40 % (Figure 
3.7). 
 
Figure 3.7: Evaluation of the percentage of cells expressing CD117 in OS and MCF7 cell lines.  143B 
contains a significantly larger population (**p <0.01 Tukey’s post hoc analysis) of ALDH positive 
cells, when compared to all other cell lines. Results presented as mean and standard deviation. Each 
cell line tested in tripicate. 
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3.2.5 Analysis of CD44 expression in OS cell lines and MCF7 
Carcinoma cells with increased expression of the adhesion protein CD44 have been shown 
to comprise putative CSC with enhanced tumourigenicity (Harper et al., 2010). Cells 
expressing CD44 and lacking CD24 have been identified as CSC in breast cancer using a 
xenotransplantation model (Al-Hajj et al., 2003). All cell lines were screened for CD44 using 
a PE labelled antibody and dead cells identified using live dead stain (Invitrogen). An isotype 
and fluorophore (PE) matched antibody was used as a control and used to identify the 
percentage of cells expressing CD44, using the same analysis approach as CD117 expression 
(Figure 3.5 and 3.6). OS cell lines tested express CD44, HOS cell lines contained the smallest 
population of 69 % whilst G292, MG63, MNNG-HOS and SaOS-2 all contained over 99% of 
cells CD44 positive. The epithelial breast cancer cell line MCF7 contained only 4.9 % of cells 
expressing CD44. 
 
 
Figure 3.8: Evaluation of the percentage of cells expressing CD44 in OS and MCF7 cell lines. All 
cell OS cell lines contained a high proportion of CD44 positive cells in contrast MCF7 contained a 
significantly smaller population than all cell line and HOS was significantly smaller than 143B, 
G292, MG63, MNNG-HOS and SaOS-2 (**P <0.01 Tukey’s post hoc analysis). All results tested in 
triplicate. Results presented as mean and standard deviation. 
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3.3 Analysis of expression of mesenchymal and epithelial markers in OS cell lines and 
MCF7 
The process of EMT has been found to play an integral role in cancer progression, once a 
cancer cell has acquired the ability to migrate and invade surrounding tissues this can lead 
to metastasis. The calcium dependant cell-cell adhesion protein e-cadherin (e-cad) is a 
marker of an epithelial phenotype. Loss of e-cad is characteristic of a cell adopting a 
migratory mesenchymal phenotype  (von Schlippe et al., 2000), loss of e-cad is often 
associated with increased expression of the protein vimentin (vim), which is a type III 
intermediate filament protein highly expressed in mesenchymal cells (Steinert and Roop, 
1988). In carcinoma the de novo expression of vimentin is associated with the acquisition 
of a mesenchymal phenotype and enhanced invasiveness (Sommers et al., 1994). 
All cell lines were screened for both e-cad and vim using either a fluorescently labelled e-
cad antibody or a primary vim antibody followed by a fluorescently labelled secondary 
antibody. Flow cytometry was used to detect cell fluorescence and analysis was carried out 
on 1 x 104 cells, dead cells were removed by counter staining with PI for e-cad stained cells 
or live dead stain (Invitrogen®) for vim staining. Each labelled population was compared to 
an isotype control and where appropriate fluorescent label matched antibody. Overlay 
histograms were produced and the increase in fluorescence was determined using the 
same analysis approach as CD117 expression (Figure 3.5 and 3.6). 
All OS cell lines contained low levels of e-cad expression (≤ 0.22%), U2OS was the only cell 
which contained no e-cad positive cells. 143B had the largest population of 0.22 %, whilst 
the remaining cell lines all contained negligible populations below 0.06%. MCF7 contained 
a significantly larger population of 66.9 % which reflects the epithelial phenotype of this 
cell line (Figure 3.9).  
In the OS cell lines vim was highly expressed ranging from 90 % – 98 % of cells vim positive. 
MG63 and U2OS had the lowest average expression at 90 and 92 % respectively.  SaOS-2 
expressed it to the highest level at 98 %, whilst the remaining cell lines varied between 94 
– 97 %. In accordance with the epithelial nature of MCF7 it contained a very low level of 
vim expression with only 0.15 % expressing the protein (Figure 3.10). 
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Figure 3.9: Evaluation of cell lines expressing e-cadherin in OS and MCF7 cell lines. All OS 
cell lines contained only a small population (< 0.22 %) of e-cadherin positive cells, in 
particular U2OS contained no e-cadherin expression. MCF7 contained a significantly larger 
population of e-cadherin expressing cells (**p <0.01 Tukey’s post hoc analysis). Results 
tested in triplicate and presented as mean and standard deviation. 
 
Figure 3.10: Evaluation of cell lines expressing vimentin in OS and MCF7 cell lines. All OS 
cell lines contained large populations vimentin positive cells, MG63 contained the smallest 
population of 90 % and SaOS-2 the highest at 98 %. MCF7 cells had a significantly smaller 
population of cells expressing vimentin. (**p <0.01 Tukey’s post hoc analysis). Results 
tested in triplicate and presented as mean and standard deviation. 
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3.4 CD44 and epithelial and mesenchymal marker co-expression analysis 
 
3.4.1 Optimisation of method used to assess CD44 and e-cadherin expression  
 
Using a system to detect both CD44 and either e-cad or vimentin allows the presence of a 
double positive population to be analysed according to their epithelial status. Further tests 
will be required to identify whether these double positive cells represent a CSC population. 
In order to identify cells positive for CD44 along with an epithelial marker, a PE labelled 
CD44 antibody was used simultaneously with either a FITC labelled e-cad antibody or 
primary vimentin antibody followed by a secondary FITC antibody. All cell lines were gated 
for live cells using live dead stain (Invitrogen®) and pulse width to remove doublets as 
stated in the ALDH analysis procedure (Figure 3.1). In order to identify the populations of 
cells expressing CD44 and e-cad control antibodies were used which matched according to 
antibody isotype and fluorescent label but have no specificity to human cells. Accurate 
measurement of CD44 and e-cad analysis was achieved by using quadrants to identify the 
population sizes. In order to have a consistent placement of the quadrant it was firstly 
placed on the control cells so the top two quadrants (R4 and R5) included between 0.5 % - 
0.14 % (Figure 3.11 A) control cells. Once the quadrant placement had been fixed it was 
then overlaid on to the CD44 and epithelial marker stained cells and the populations 
quantified (Figure 3.11 B).  
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A             B 
Figure 3.11: Evaluation of CD44 and e-cadherin populations in OS and MCF7 cell lines. A) 
U2OS control cells (stained with isotype control), quadrant placed so regions R4 and R5 
include between 0.5 - 0.14 % of cells. The quandrant position obtained from A was then 
overlayed on to CD44 and e-cadherin U2OS stained cells (B). Y axis represent CD44 
expression and x axis represents e-cadherin expression. Each quandrant is used to assess 
the frequency of the following populations; R4 = CD44+ e-cad- stained cells; R5 = CD44+ e-
cad+ stained cells; R7 = CD44- e-cad+ stained cells and R6 CD44- e-cad-. Image representative 
of 3 images of HOS cells. 
 
 
 
3.4.2 Characterisation of CD44/e-cadherin phenotypes in OS cell lines and MCF7 
Four CD44/e-cad phenotypes were present based on cells either being double positive for 
both markers, single positive for a marker or double negative. In OS the CD44+/e-cad+ 
double positive populations were relatively small and varied from 0.1 % (143B) to 1.2 % 
(G292) (Figure 3.12.A). In contrast the CD44+/e-cad- single positive cells comprised the 
largest populations ranging from 99 % (SaOS-2) to 68 % (HOS) (Figure 3.12.B). The CD44-/e-
cad+ single positive phenotype was the least common and present in only Cal72 (0.005 %), 
HOS (0.003 %) and MNNG-HOS (0.26 %) (Figure 3.12.C). Due to the small size of the Cal72 
and HOS populations, these could in fact be an artefact caused by non-specific binding of 
antibodies to the cells. The presence of cells lacking both CD44 and e-cad (CD44-/e-cad-) 
forms the most variable population ranging from 0 % (MNNG-HOS) to 31 % (HOS) (Figure 
3.12.D). As a consequence  of MCF7 epithelial phenotype it has a large population of 
CD44+  
e-cad- 
CD44+  
e-cad+ 
 
CD44- 
e-cad- 
 
CD44- 
e-cad+ 
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CD44/ecad+ single positive cells which comprise 31 % (Figure 3.12.C) and also the largest 
population of CD44+/e-cad+ double positive cells (3.8 %) found in all cell lines tested (Figure 
3.12.A). In contrast to the OS cell lines, the smallest population of MCF7 was found within 
the CD44+/e-cad- population (1.1 %) (Figure 3.12.B) and largest within the double negative 
cells (CD44-/e-cad-) (63.7 %) (Figure 3.12.D). In order to clarify the markers expressed by 
each cell line, the CD44/e-cad phenotypes have been summarised within table 3.1.  
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(A) CD44+/e-cad+     (B) CD44+/e-cad-   
  
(C) CD44-/e-cad+     (D) CD44-/e-cad-  
  
Figure 3.12: Evaluation of CD44 and e-cadherin expression in OS and MCF7 cell lines. A) frequency 
of cells positive for both CD44 and e-cad expression (CD44+/e-cad+ cells) MCF7 contains a 
significantly smaller population than all cell lines. B) frequency of cells positive for CD44 expression 
and negative for e-cad (CD44+/e-cad-), MCF7 contains a significantly smaller population than all cell 
lines, HOS contains less than all OS cell lines, Cal72 and U2OS contain a smaller population than 
143B, G292, MG63, MNNG-HOS and SaOS-2. C) frequency of cells negative for CD44 expression and 
positive for e-cad (CD44-/e-cad+), MCF7 contains a significantly larger population than all cell lines. 
D) frequency of cells negative for CD44 expression and negative for e-cad (CD44- /e-cad-), MCF7 
contains a larger population than all cell lines, HOS contains a larger population than 143B, G292, 
MG63, MNNG-HOS and SaOS-2, U2OS contains a larger population tha SaOS-2. All results tested in 
triplicate and presented as mean and standard deviation. *p = <0.05, **p = <0.01 (Tukey’s post hoc 
analysis). 
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Table 3.1. CD44/e-cadherin phenotypes in OS cell lines and MCF7. Cell line CD44/e-cad 
populations presented tested in triplicate and presented as mean percentage values and 
standard deviation (S.D). 
 
Cell line 
CD44/e-cadherin populations (S.D) 
% of cells 
expressing 
CD44+/e-cad+ 
±S.D 
% of cells 
expressing 
CD44+/e-cad- 
±S.D 
% of cells 
expressing 
CD44-/e-cad+ 
±S.D 
% of cells 
expressing 
CD44-/e-cad-
±S.D 
143B 0.10 ± 0.09  98.30 ± 2.10 0.00 ± 0.00 1.60 ± 2.01 
Cal72 0.21 ± 0.07 83.41 ± 4.40 0.005 ± 0.005 16.38 ± 4.41 
G292 1.15 ± 0.61 98.30 ± 1.20 0.00 ± 0.00 0.55 ± 0.75 
HOS 0.36 ± 0.31 68.26 ± 6.81 0.003 ± 0.005 31.38 ± 7.20 
MG63 0.50 ± 0.42 96.43 ± 5.00 0.00 ± 0.00 3.06 ± 5.23 
MNNG-HOS 0.18 ± 0.12 99.43 ± 0.21 0.26 ± 0.11 0.00 ± 0.00 
U2OS 0.21 ± 0.08 83.14 ± 5.74 0.00 ± 0.00 16.66 ± 5.75 
SaOS-2 0.50 ± 0.09 99.46 ± 0.13 0.00 ± 0.00 0.04 ± 0.03 
MCF7 3.81 ± 2.37 3.81 ± 0.47 31.34 ± 12.46 63.72 ± 15.24 
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3.4.3 Characterisation of CD44/vimentin phenotypes in OS cell lines and MCF7  
Four CD44/vim phenotypes were present based on cells either being double positive for 
both markers, single positive for a marker or double negative. In the OS cell lines tested the 
majority of cells were present within the CD44+/vim+ double positive population with little 
very little variation present, population sizes ranged from 91 % (HOS) to 99 % (SaOS-2) 
(Figure 3.13.A). In contrast greater variability was observed in CD44+/vim- populations 
which ranged from 0.5 % (MNNG-HOS) to 4.7 % (143B) (Figure 3.13.B). Except for Cal72 
which contained a population of 2.5 % of  CD44-/vim+ cells, the remaining OS cells lines 
contained a small percentage of CD44-/vim+ cells ranging from 0.01 % (SaOS-2) to 0.9 % 
(U2OS) (Figure 3.13.C). The double negative CD44-/vim- phenotype was variable between 
OS cell lines. Ranging from 5.6 % (U2OS) to 0.09 % (SaOS-2) and making up a relatively small 
percentage of OS cells. In contrast MCF7 contained a large proportion (95.8 %) of these 
cells (Figure 3.14.D). The remaining MCF7 cells were mostly composed of CD44+ vim-/cells 
(3.5 %) (Figure 3.14.B) and to a lesser extent CD44-/vim+ (0.39 %) (Figure 3.13.C) and 
CD44+/vim+ cells (0.27 %) (Figure 3.13.A). In order to clarify the markers expressed by each 
cell line, the CD44/vim phenotypes have been summarised within table 3.2. 
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(A) CD44+/vim+     (B) CD44+/vim-  
 
(C) CD44-/vim+     (D) CD44-/vim-  
 
Figure 3.13: Evaluation of CD44 and vimentin expression of OS cell lines and MCF7. A) frequency 
of cells positive for both CD44 and vimentin expression (CD44+ vim+ cells), MCF7 contains a 
population smaller than all cell lines, SaOS-2 contains a larger population than 143B, Cal72, HOS 
and U2OS. B) frequency of cells positive for CD44 expression and negative for vimentin (CD44+ vim-
), 143B contains a significantly larger population than Cal72, MNNG-HOS and SaOS-2. C) frequency 
of cells negative for CD44 expression and positive for vimentin (CD44- vim+), Cal72 contains a 
significantly larger population than all cell lines. D) frequency of cells negative for CD44 expression 
and negative for vimentin (CD44- vim-), MCF7 contains a significantly larger population than all cell 
lines, HOS and U2OS contain larger populations than 143B, G292, MG63, MNNG-HOS and SaOS-2. 
All results tested in triplicate and presented as mean and standard deviation, *p = <0.05, **p = 
<0.01 (Tukey’s post hoc analysis). 
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Table 3.2: CD44/e-cadherin phenotypes in OS cell lines and MCF7. Cell line CD44/e-cad 
populations presented tested in triplicate and presented as mean percentage values and 
standard deviation (S.D). 
 
Cell line 
CD44/vimentin populations (%) 
% of cells 
expressing 
CD44+/vim+  
±S.D 
% of cells 
expressing 
CD44+/vim- 
±S.D 
% of cells 
expressing 
CD44-/vim+ 
±S.D 
% of cells 
expressing 
CD44-/vim- 
±S.D 
143B 92.60 ± 4.02 4.66 ± 3.86 0.96 ± 0.60 1.71 ± 0.26 
Cal72 92.38 ± 1.40 0.26 ± 0.37 2.54 ± 1.15 4.83 ± 0.27 
G292 96.16 ± 1.03 1.79 ± 1.29 0.24 ± 0.14 1.82 ± 0.99 
HOS 91.14 ± 1.85 1.76 ± 0.56 0.54 ± 0.20 6.56 ± 1.98 
MG63 97.04 ± 1.54 1.09 ± 0.56 0.15 ± 0.15 1.72 ± 1.88 
MNNG-HOS 98.03 ± 1.39 0.51 ± 0.49 0.18 ± 0.10 1.28 ± 0.72 
U2OS 92.75 ± 3.43 0.81 ± 0.73 0.89 ± 0.70 5.55 ± 2.53 
SaOS-2 99.45 ± 0.29 0.44 ± 0.34 0.01 ± 0.01 0.09 ± 0.09 
MCF7 0.27 ± 0.12 3.50 ± 0.87 0.39 ± 0.17 95.84 ± 0.97 
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3.5 Identification of the colony hierarchies within OS cell lines and MCF7 
 
The colony hierarchies identified by Locke et al (2005) represent the cellular heterogeneity 
present within both healthy tissues and tumours (Section 1.2.3). The identification of the 
tightly packed holoclonal colonies indicates the presence of putative CSC, meroclonal 
colonies (colonies containing features of both holoclones and paraclones) encompass a 
more mature population which will transiently divide before giving rise to the terminally 
differentiated paraclones (loose irregular colonies). All OS cell lines and MCF7 included in 
this study were able to recapitulate the three colony phenotypes (Figure 3.14) when 
seeded at low density (2 – 4 cells cm2) and cultured for 7 – 14 days. The appearance of the 
holoclones differed between each cell line, but all displayed tightly packed cells with a 
smooth boundary of cells encasing the colony. The holoclonal shape was predominantly 
round or oval shape and was observed in the majority of cell lines (143B, HOS, MNNG-HOS, 
G292, U2OS, SaOS-2 and MCF7). In contrast Cal72 and MG63 displayed holoclones with a 
more angular shape with Cal72 holoclones almost square in shape, whilst MG63 had 
angular projections. Meroclones were a mixture of the holoclone morphology with cells 
beginning to migrate from the colony, OS paraclonal colonies were composed of a 
dispersed population of cells; often cells would become totally detached from one another. 
The only exception was U2OS and Cal72 which tended to contain clusters of cells still bound 
together. MCF7 paraclones were not as dispersed as the OS colonies and were composed 
of clusters of cells which had migrated a short distance.    
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Cell line, 
(Phenotype, 
cancer type, 
days cultured) 
Holoclone Meroclone Paraclone 
143B, 
(Mixed, 
osteosarcoma, 
7 days) 
 
 
    
HOS, 
(mixed, 
osteosarcoma, 
8 days) 
 
  
 
 
MNNG-HOS 
(mixed, 
osteosarcoma, 
8 days) 
 
 
 
 
 
G292 
(Fibroblastic, 
osteosarcoma, 
9 days) 
 
 
 
 
 
  
Figure 3.14: Continued overleaf 
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Cell line 
(phenotype, 
cancer type) 
Holoclone Meroclone Paraclone 
MG63 
(Fibroblastic, 
osteosarcoma, 
9 days) 
 
 
    
Cal72 
(Epithelial, 
osteosarcoma, 
14 days) 
 
 
  
  
U2OS 
(Epithelial, 
osteosarcoma, 
9 days) 
 
 
 
 
 
 
 
 
 
 
SaOS-2 
(Epithelial, 
osteosarcoma, 
14 days) 
 
 
  
 
 
MCF7 
(Epithelial, 
breast 
adenocarcinoma, 
12 days) 
 
 
 
  
Figure 3.14: Colony hierarchies present within each cell line. Holoclone, meroclone and 
paraclone phenotypes from all cell lines when seeded at a density to produce 100 colonies 
per 55 cm² (seeding density varied from 2 - 4 cells per cm² depending upon the cell line) 
after 7 – 14 days of growth. Images representative of 4 images per hierarchy. Scale bar 
represents 100 µM.  
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3.6 Presence of cells expressing CSC markers within colony hierarchies 
Prostate cancer holoclones have been shown to contain CSC based on the expression of 
CSC markers (Li et al., 2008) providing a useful method of separating highly tumourigenic 
population of cells from their non tumourigenic counterparts. MG63 holoclones are 
reported to have enhanced clonogenicity and express elevated levels of CD133 (Lou et al., 
2010). A similar observation has been observed in head and neck carcinoma holoclones 
which have increased levels of the putative CSC marker CD44 (Harper et al., 2010). The 
analysis of OS colony hierarchies for expression of the putative OS CSC markers (CD117 and 
ALDH) has not been determined, therefore identifying whether these cells are restricted to 
one hierarchy will give an indication of whether these cells function as CSC.   
In order to investigate the location of CSC expressing cells within the colony hierarchies, 
cells were seeded at low density (26 cells/mm2) and grown on 12 mm circular coverslip for 
3 - 4 days, allowing the colony morphologies to form. Cells were fixed with 
paraformaldehyde when staining for CD117 or CD44 and e-cad, however, due to ALDH 
being an intracellular enzyme, only living cells could be used for analysis. In this case an 
antibody ALDEFLUOR staining mixture was prepared and stained in a short time (50 mins) 
at 37 ˚C to minimise cell disruption. Upon mounting coverslips in 50 % glycerol (diluted in 
ALDEFLUOR buffer) slides were kept on ice and analysed immediately. Due to the high 
expression of CD44 within all OS cell lines this antibody was used as membrane marker to 
identify the location of membranes within the images. To ensure fluroescently labeled cells 
were not the result of non-specific antibody interactions, isotype and fluroescent labelled 
matched antibodies were also used to stain cell to assess antibody specficity, ALDH was 
also inhibited with DEAB (Appendix I). 
 
3.6.1 Location of ALDH expressing cells within OS cell lines and MCF7 colony 
hierarchiesFig 
According to flow cytometry the OS cell lines 143B, G292 and HOS all contain populations 
of ALDH expressing cells > 10 %, whilst the remaining OS cell lines all contained populations 
< 10 % (section 3.2.2). It was found that  ALDH positive cells within the colony hierarchies 
are not restricted to holoclones in cell lines containing > 10 % ALDH+ cells (as determined 
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by flow cytometry).  The cells lines 143B, G292 and HOS all contained ALDH positive cells 
within the three colony morphologies.  143B  colony hierarchies (Figure 3.15.1) contain 
ALDH positive cells in meroclones and paraclones, however the holoclone situated in the 
centre of the image contains no ALDH positive cells, a similar finding was also observed in 
G292 (figure 3.15.2) and HOS (figure 3.15.3). Cell lines with low ALDH expression MG63 
(2.14 %) and SaOS-2 (3.4 %) contain ALDH positive cells which only reside within the 
holoclones, however, there are also holoclones present which lack any ALDH positive cells 
(figure 3.15.2 and figure 3.15.5). ALDH positive cells are present within MCF7 colonies but 
due to the low expression of CD44 it made identifying the colony morphologies difficult 
(figure 3.15.6), although, MCF7 ALDH cells appear restricted only to the densely packed 
holoclone like colonies.  
 
 
 
 
Figure 3.15: Continued overleaf 
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Figure 3.15: Colony morphologies containing ALDH positive cells OS cell lines and MCF7. 
Cell lines (143B (1), G292 (2), HOS (3), MG63 (4), SaOS-2 (5) and MCF7 (6) were seeded on 
coverslips (1050 cells/cm2) and grown for 3 - 5 days to form suitable sized colonies. ALDH 
expression was demonstrated by dual-colour fluoresence, coverslips were co-stained with 
To-pro-3 (blue nuclei), PE labelled CD44 antibody (red membrane) and ALDH using the 
ALDEFLUOR reagent (green putative CSC). (A) ALDH expressing cells, (B) CD44 expressing 
cells, (C) nuclei and (D) overlay of all 3 markers. ALDH positive colony circled. Image 
representative of at least 4 images. 
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3.6.2: Location of CD117 expressing cells within colony hierachy  of 143B 
According to the flow cyotmetry results 143B contained the largest population of CD117 
cells (6.4 %) (Figure 3.7), therefore would make the most suitable cell line to identify where 
these cells reside within the colony hierachies. When tested at a low density (1050 
cells/cm2) 143B contained very few cells expressing CD117, positive cells stained very 
weakly and were found around the outer the membranes of small holoclones (Figure 3.16). 
When 143B was allowed to reach a higher density (80 – 90 % confluency) the presence of 
CD117 increased. The high density meant colony hierachies were unidentifiable, however, 
CD117 expression was localised to very small sites on each cell and was present to the 
periphery of a colony, producing a speckled appearance around the colony edge (Figure 
3.17). 
 
Figure 3.16: Colony morphologies containing CD117 positive cells in 143B at low density. 
Demonstrated by dual-colour fluoresence, 143B cells (1050 cells/cm2) were grown for 3 days then 
stained with To-pro-3 (blue nuclei), PE labelled CD44 antibody (red membrane) and FITC labelled 
CD117 antibody (green putative CSC). (A) CD117 expressing cells, (B) CD44 expressing cells, (C) 
nuclei and (D) overlay of all 3 markers. CD117 positive colony circled. Image representative of at 
least 4 images. 
A B 
C D 
 
143B 
(Low density) 
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Figure 3.17: Colony morphologies containing CD117 positive cells in 143B at high density. 
Demonstrated by dual-colour fluoresence, 143B cells (2100 cells/cm2) were grown on 
coverslips for 3 days then stained with To-pro-3 (blue nuclei), PE labelled CD44 antibody 
(red membrane) and FITC labelled CD117 antibody (green putative CSC). (A) CD117 
expressing cells, (B) CD44 expressing cells, (C) nuclei and (D) overlay of all 3 markers. Image 
representative of at least 4 images. 
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3.6.3: Location of CD44 and e-cadherin expressing cells within colony hierachy 
The presence of cells co-expressing CD44 and e-cad within the OS cell lines were rare. G292 
had the largest population of co-expressing cells (1.15 %) when analysed using flow 
cytometry and was the only OS cell line found to contain cells expressing both markers. OS 
CD44+ e-cad+ cells were identified within paraclones (Figure 3.18.1) and meroclones (Figure 
3.18.2) of G292. In contrast MCF7 contains heterogenous expression of both CD44 and e-
cad in the colony hierarchies, cells which were highly expressing both CD44 and e-cad were 
found in the centre of holoclones, whilst cells only expressing CD44 were identified in 
paraclonal cells (Figure 3.18.3). 
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Figure 3.18: Continued overleaf 
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Figure 3.18: Colony morphologies containing CD44 and e-cad positive cells in G292 and 
MCF7. G292 (Images 1 and 2) and MCF7 (3) were grown on coverslips (1050 cells/cm2) for 
4 days. CD44/e-cad expressing cell were demonstrated by dual-colour fluoresence, 
coverslips were stained with to-pro-3 (blue nuclei), PE labelled CD44 antibody (red 
membrane) and FITC labelled e-cadherin antibody (green). (A) E-cadherin expressing cells, 
(B) CD44 expressing cells, (C) nuclei and (D) overlay of all 3 markers. Arrow indicates a cell 
highly expressing both e-cadherin and CD44. Image representative of at least 4 images. 
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3.7 Evaluation of sarcosphere forming ability of OS cell lines and MCF7 
Growing cells within serum starved low attachment conditions was originally used to select 
neuronal multipotent stem cells (Reynolds and Weiss, 1992). This technique has also been 
used to study stem cells within cancers. In osteosarcoma the spherical colonies produced 
in non-adherent conditions are termed sarcospheres, have increased expression of the 
stem cell transcription factors Nanog and Oct 3/4 as well as mesenchymal markers (Gibbs 
et al., 2005). In breast cancer spherical colonies were found to have enhanced ability to 
form xenotransplantable tumours, demonstrating the enrichment of CSC within these cell 
populations (Grimshaw et al., 2008). 
In this study cell lines were tested by seeding cells single cells at 10,000 cells/non-adherent 
6 well plate, and grown in the presence of 20 ng/ml bFGF and EGF along with B27 
supplement, which was replenished every 3 days throughout the experiment (Section 
2.2.4). After 7 days colony size was assessed before passaging sarcospheres and re-seeding 
at 210 cells/cm2 and growing for a further 7 days after which colony size and number were 
assessed. When counting sarcospheres only colonies ≥ 40 µM were included.  
The appearance of the sarcospheres was markedly different to mammospheres produced 
by MCF7, which were produced under the same conditions as sarcospheres. In general OS 
primary sarcospheres did not have the classical spherical shape with smooth appearance. 
They were less uniform in shape and often visibly composed of clusters of cells, the uneven 
shape is most apparent in Cal72 and MG63 which are clearly composed of a colony of cells 
giving it a rougher appearance. In contrast MCF7 produced large spherical colonies with an 
almost smooth appearance making identifying individual clusters of cells challenging 
(Figure 3.19). 
After the cells had been passaged and grown for a further 7 days to form secondary 
sarcospheres, the sarcospheres in all cell lines except 143B and MNNG-HOS were visibly 
smaller in size. Cal72, HOS and U2OS produced no colonies greater than 40 µM, the only 
cells present were single cells, which had failed to  divide. The secondary colonies produced 
by 143B and MNNG-HOS were more irregular in shape than the primary sarcospheres 
(Figure 3.9).  
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Figure 3.19: Continued overleaf. 
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Figure 3.19: Images of sarcospheres produced from OS cell lines and MCF7. Primary 
sarcospheres grown for 7 days and secondary sarcosphere grown for a further 7 days post 
primary sarcosphere passage. Images representative of 12 images. Scale bar represents 
100 µM. 
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3.7.1 Evaluation of primary sarcosphere sizes in OS cell lines and MCF7 
All cell lines tested were able to produce primary sarcospheres after the initial 7 days of 
growth and images were taken from four parts of each well, allowing sarcosphere size to 
be analysed (Section 2.2.4). Sarcosphere sizes present within each image could then be 
assessed using ImageJ. In addition during the passage of sarcospheres cell counts were 
made, making it possible to assess the number of living cells present within each cell line. 
Comparison of primary spherical colony formation indicated that growth rates were 
variable across the cell lines. All cell lines were compared to one another and Cal72, G292 
and U2OS produced significantly smaller colonies than MCF7 (Figure 3.20). When 
comparing the number of living cells present at this stage of the experiment U2OS had the 
lowest number of 3000 cells, which indicates that 70 % of the cells had died since seeding 
(Figure 3.21) and suggests that the majority of U2OS cells are undergoing cell death in 
response to the low-attachment conditions. All other cell lines had a significant increase in 
living cells when compared to U2OS. Although Cal72 and HOS had a significantly elevated 
number of cells compared to U2OS, they still contained less living cells cells than the 10000 
seeded, suggesting they are also unsuited to the sarcosphere assay conditions. MNNG-HOS, 
SaOS-2 and MCF7 contained the most living cells with a total of 30000 cells (Figure 3.21). 
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Figure 3.20: Analysis of primary sarcosphere sizes in OS cell lines and MCF7. Sarcosphere 
size assessed using ImageJ. Statistical significance calculated using Tukey’s post hoc 
analysis, by comparing all samples to one another, Cal72, G292 and U2OS were found to 
be significantly different when compared to MCF7 (* p <0.05, ** p <0.01). Cell lines tested 
in triplicate and presented as mean and standard deviation. 
 
 
Figure 3.21: Analysis of number of cells present after passage of primary sarcospheres. 
Statistical significance calculated using Tukey’s post hoc analysis, all cell lines compared to 
one another, Cal72, HOS and U2OS contain significantly less cells than SaOS-2 and MCF7, 
U2OS also contains significantly less cells than MNNG-HOS (* p <0.05,  **p <0.01). Cell lines 
tested in triplicate and presented as mean and standard deviation. 
 
0
0.02
0.04
0.06
0.08
0.1
0.12
143B Cal72 G292 HOS MG63 MNNG
HOS
U2OS SaOS-2 MCF7
R
e
la
ti
ve
 s
iz
e
 o
f 
sa
rc
o
sp
h
er
e
Cell line
* *
**
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
143B Cal72 G292 HOS MG63 MNNG
HOS
U2OS SaOS-2 MCF7
N
u
m
b
er
 o
f 
ce
lls
Cell line
**
*
*
Chapter 3. Results  
109 
 
3.7.2 Evaluation of secondary sarcospheres in OS cell lines and MCF7 
After sarcospheres had been passaged and grown for a further 7 days (secondary 
sarcospheres), sarcosphere sizes were again analysed using ImageJ. In addition sarcosphere 
forming efficiency (SFE) was assessed using the equation outlined in the methods section 
(Section 2.2.4). Both SFE and colony size, although variable between cell lines, produced a 
similar result when comparing SFE (%) and colony size of the same cell line. Cal72, HOS and 
U2OS produced no spherical colonies, G292 produced the lowest SFE of 0.62 % and one of 
the lowest colony sizes of 0.27 (relative units) so was used for comparison with other cell 
lines to assess a statistical increase in colony formation (Figure 3.22.A). 143B and MNNG-
HOS both had significantly larger colonies and enhanced SFE compared to G292, the 
remaining cell lines MG63, SaOS-2 and MCF7 had similar SFE of 1.3 %, 0.95 % and 0.9 % 
respectively (Figure 3.22.B). 
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(A) Sarcosphere size 
 
(B) Sarcosphere forming efficiency 
 
Figure 3.22: Analysis of cell line relative sarcosphere sizes of and sarcosphere forming 
effciency (SFE) of secondary sarcospheres. A) Analysis of relative sarcosphere sizes, B) 
Analsis of SFE of secondary sarcospheres. Statistical significance calculated by using Tukey’s 
post hoc analysis comapring all samples, G292, MG63, SaOS-2 and MCF7 were significantly 
smaller than 143B and MNNG-HOS (*p <0.05, **p <0.01). All results repeated in triplicate 
and presented as mean and standard deviation. 
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3.7.3 Correlation of CSC marker expression with sarcosphere forming efffciency 
Pearson’s correlation coeffcient was used to identify if the populations of cells expressing 
CSC markers analysed using flow cytometry (Section 3.2) correlated with increased 
spherical colony formation (Table 3.3). Analysis consisted of comparing either primary 
sarcosphere size against CSC marker expression or secondary sarcsosphere forming 
efficiency compared to CSC marker expression. CD117 has been identified specifically as an 
OS CSC marker, therefore MCF7 was excluded from this analysis.  
Primary sarcosphere forming ability correlated poorly with the expression of all CSC 
markers tested (ALDH, CD117 and CD44). CD44 expression when analysed as a sole marker 
produced a negative correlation of -0.66, CD44+/e-cad- cells produced a positive 
correlation of 0.67. CD117 had the closest relationship with formation of secondary 
sarcospheres, however this was a weak correlation of 0.58 (Table 3.3).  
 
Table 3.3: Pearson correlation coefficient analysis of primary or secondary spherical 
colony formation with CSC marker expression. Cell lines included in analysis were 143B, 
Cal72, G292, HOS, MG63, MNNG-HOS, U2OS SaOS-2 and MCF7. Due to CD117 not being an 
established breast CSC marker, MCF7 was not included in CD117 analysis. No statistical 
significance was observed. 
Cancer stem cell marker Primary sarcospheres Secondary sarcospheres 
ALDH 0.10  -0.25 
CD117 0.21 0.58 
CD44 -0.66 0.40 
CD44+ / e-cadherin+ 0.67 -0.08 
CD44+ / e-cadherin- -0.08 0.44 
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3.8 Presence of ALDH and CD117 expressing cell within sarcosphere colonies 
To identify whether sarcospheres contained cells expressing OS CSC markers (ALDH and 
CD117) secondary sarcospheres from 143B were stained for these markers. 143B was 
selected because of the ability of this cell line to form robust sarcospheres. Cell membranes 
were identified using CD44 along with To-pro-3 for nuclei. The ALDH stain must be used on 
living cells so all sarcosphere staining procedures were conducted upon non-fixed cells. 
 
3.8.1 ALDH expression within 143B sarcosphere 
ALDH expressing cells were found within all sarcospheres analysed and the number of cells 
expressing ALDH increased in proportion with sarcosphere size. The smallest 143B 
sarcosphere analysed (Figure 3.23.1) contained several ALDH positive cells which were 
located mainly in the centre of the sarcosphere. The intermediate sized sarcosphere 
contained ALDH positive cells which were spread throughout the colony (Figure 3.23.2), 
whilst the sarcosphere largest in size contained regions either positive or negative for ALDH 
(Figure 3.23.3). The lower half of the largest sarcosphere contained the highest proportion 
of ALDH positive cells whilst the upper left side contained almost no ALDH positive cells, 
suggesting that ALDH cells may aggregate together as colonies grow larger. 
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Figure 3.23.1: Cells expressing ALDH within a small 143B sarcosphere. Description below 
(3.22.3). 
 
 
Figure 3.23.2: Cells expressing ALDH within a intermediate sized 143B sarcosphere. 
Description below (3.32.3). 
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Figure 3.23.3: Cells expressing ALDH within a large 143B sarcosphere. Figures 3.30.(1,2 
and 3) Demonstrated by dual-colour fluoresence, 143B sarcospheres were co-stained with 
to-pro-3 (blue nuclei), PE labelled CD44 antibody (red membrane) and ALDH using 
ALDEFLUOR reagent (green). (A) ALDH expressing cells, (B) CD44 expressing cells, (C) nuclei 
and (D) overlay of all 3 markers. Each image representative of 2 images. 
 
3.8.2 CD117 expression within 143B sarcosphere 
143B sarcospheres were tested for the expression of the CSC marker CD117, when 
sarcospheres were co-stained with CD44 no cells CD117 cells were identified. To ensure 
that CD44 antibodies fluoresence were not masking the presence of CD117 positive cells, 
sarcospheres were tested without CD44. CD117 staining was identified in only two 
colonies, a single cell stained positively in a large colony (Figure 3.24.1) and the cell surface 
of a single cell in a small collection of cells (Figure 3.24.2) was also weakly stained for 
CD117. The rarity of CD117 cells sarcosphere is in stark contrast to monolayer 143B cells 
when analysed using flow cytometry contained a population of 6.4 % (Figure 3.7).  
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Figure 3.24.1: Cells expressing CD117 within a 143B sarcosphere. Description below 
3.30.2. 
 
Figure 3.24.2: Cells expressing CD117 within a 143B sarcosphere. Demonstrated by dual-
colour fluoresence, 143B sarcospheres were co-stained with to-pro-3 (blue nuclei) and FITC 
labelled CD117 antibody (green). (A) CD117 expressing cells, (B) nuclei and (C) overlay of 
the markers. Images representative of 1 image. 
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3.9 Discussion 
CSC identification has been made possible through the isolation of cells expressing 
extracellular proteins such as CD44 (Al-Hajj et al., 2003), CD117 and the intracellular 
enzyme ALDH (Wang et al., 2011) (Section 1.2.2). Within breast carcinoma ALDH expressing 
cells have been found to have enhanced tumourigenic properties with the potential to self-
renew and re-capitulate tumour heterogeneity (Ginestier et al., 2007). In this study ALDH 
was found to be heterogeneously expressed in OS cell lines (0.9 % – 61 %).  The HOS cell 
line had 61 % of cells expressing ALDH and would therefore be predicted to have a high 
number of putative CSC and the greatest tumourigenic capabilities compared to other OS 
cell lines.  
 
Although OS cells are notoriously difficult to grow via xenotransplantation and often fail to 
form tumours (Jia et al., 1999), HOS has been identified as non-tumourigenic in a mouse 
model, whereas 143B and MNNG-HOS were tumourigenic (Luu et al., 2005). This 
contradicts the predicted tumourigenicity of HOS based on ALDH expression, therefore, 
ALDH expression may not represent a CSC marker in OS. In breast cancer cell lines selecting 
ALDH expressing cells does not universally select for cells with enhanced clonogenicity 
(Hwang-Verslues et al., 2009). In melanoma ALDH positive and negative cells had an equal 
ability to form spherical colonies and xenograftable tumours. Interestingly ALDH negative 
cells could only self-renew, whilst ALDH positive cells could differentiate in to ALDH 
negative and recapitulate the original ALDH expression profile (Prasmickaite et al., 2010). 
Although the ability of a CSC to recapitulate the original tumour heterogeneity is a 
fundamental CSC property (1.2.1), melanoma mouse models now suggest that most 
tumourigenic CSC populations are only able to self-renew (Held et al., 2010).  
 
The tyrosine kinase receptor CD117, has previously been found to be an OS CSC marker 
(Adhikari et al., 2010) and associated with a poor chemotherapy response (Miiji et al., 2011). 
Analysis of CD117 in the OS cell lines demonstrated that it was heterogeneously expressed. 
The majority of cell lines (G292, MNNG-HOS, U2OS and SaOS-2), all contained populations 
below 0.02 % and, due to the extremely small size of these populations it is possible that 
they are in fact just an artefact of cellular background fluorescence or non-specific antibody 
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binding. U2OS was found to have one of the smallest CD117 populations of 0.008 %, which 
is smaller than the 0.6 % observed by Tang et al., (2011). Their study used a different CD117 
detection method and co-stained with the mesenchymal marker STRO-1, which could 
account for the discrepancy between findings. MG63 was the only OS cell line with no 
CD117 expression. In contrast to MG63, 143B contained a significantly larger population of 
CD117 cells than all other cell lines. HOS contained the second largest CD117 population, 
interestingly 143B is derived from the HOS cell line via Ki–ras+ transformation  (Hensler et 
al., 1994), which has thus resulted in the up-regulation of CD117.  
 
Carcinomas with increased expression of the adhesion protein CD44 have been shown to 
comprise CSC with enhanced clonogenicity (Harper et al., 2010). OS formation occurs in a 
genetically manipulated mouse model (APC+/min and P53+/tm1), in which the tumour 
suppressors APC and P53 are mutated.  Knockout of CD44 in this mouse model did not 
affect tumour formation but did reduce OS metastasis when tested in a small sample of 
mice (24 mice) (Weber et al., 2002). The reliance of cancer upon CD44 for migration is 
supported by the finding that a bi-specific anti-CD44 antibody reduced tumour growth and 
metastasis of the B cell lymphoma cell line 38C-13 in NOD/SCID mice  (Avin et al., 2004). 
Due to the importance of CD44 for non-malignant cellular functions (Camp et al., 1993), bi-
specific CD44 antibodies which also target tumour specific tumour antigens are important 
to circumvent any impact upon healthy cells. In this study the expression of CD44 across all 
OS cell lines was high with CD44 expressing cells ranging from 69 % (U2OS) to 99 % (SaO-
S). The high levels of CD44 indicate that the OS cell lines tested would have a propensity to 
migrate and metastasise, additionally, MSC also highly express CD44 (Lee et al., 2004), 
therefore, the similar expression level of OS and MSC could indicate that OS arises from an 
MSC progenitor. The high expression of CD44 in cell lines is consistent with the findings in 
the literature, in which a high proportion of U2OS, MG63 and SaOS-2 cells were found to 
express CD44 when analysed using flow cytometry (Gillette et al., 2004, Tirino and 
Desiderio, 2008). In contrast MCF7 had a significantly lower expression of CD44 (4.9 %), this 
small population may include an MCF7 population with enhanced tumourigenic properties. 
MCF7 CD44 expressing cells have been shown to have an increased tumourigenicity and 
migrative capabilities (Yan et al., 2013), in addition, oncogene transformed human 
mammary epithelial cells and the breast cancer cell line MCF10A, contain a population of 
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cells with a mesenchymal phenotype and express CD44+ (Morel et al., 2008). Therefore, the 
expression of CD44 in breast cancer, may be associated with the acquisition of a 
mesenchymal phenotype as malignant cells undergo EMT and acquire the ability to 
metastasise.  
 
In addition to CD44, cells were simultaneously stained for the cell to cell adhesion protein 
e-cadherin (e-cad). E-cad has been used as a marker to identify cells with an epithelial 
phenotype and decreased expression has been linked to increased cancer aggressiveness 
(Siitonen et al., 1996). In all OS cell lines expression of e-cad was low or in the case of U2OS 
absent. In contrast the breast cancer cell line contained a large population of e-cad 
expressing cells (66.9 %). E-cad is expressed by epithelial cells (Damsky et al., 1983) and 
loss of this protein is associated with the acquisition of a mesenchymal phenotype (von 
Schlippe et al., 2000) (Section 1.2.5). Therefore, e-cad expression in MCF7 confirms the 
epithelial phenotype of this cell line and conversely its absence in OS cell lines is further 
evidence of their mesenchymal phenotype. Cell lines were also analysed for the 
mesenchymal marker vimentin (vim), all OS cell lines highly expressed the protein with over 
90% of the population expressing this marker. This is consistent with a study staining SaOS-
2 which found that this cell line highly express vim (Veselska et al., 2008). Interestingly OS 
cell lines with an epithelial morphology (Cal72 and SaOS-2) all highly expressed vim with 
SaOS-2 containing a larger population than the fibroblastic cell lines (G292 and MG63). 
Therefore OS cells with an epithelial morphology may have elevated expression of 
mesenchymal markers compared to the fibroblastic cells types. Vim is a marker associated 
with mesenchymal stem cells (Potapova et al., 2004), the high expression of vim in the OS 
cells lines is further suggestive evidence that they originate from a mesenchymal stem cell 
(MSC) progenitor. MSC have been identified as the cellular origin of alternative sarcomas 
such as Ewings’s sarcoma (Riggi et al., 2005). Due to the potential of OS tumours to 
demonstrate multi-lineage differentiation (adipocyte, chondrocyte and osteoblast) (Klein 
and Siegal, 2006) the cellular origin of OS has been hypothesised as MSC (Tang et al., 2008), 
however no conclusive evidence is currently available.  Human MSC have been found to 
initiate in vivo OS like tumours when genetically transformed with telomerase, simian virus 
40 large T antigen and H-Ras. Although these tumours replicated the complex genomic 
rearrangements of OS they were devoid of bone matrix and failed to invade cortical bone, 
Chapter 3. Results  
119 
 
which was possibly due to the genetic alterations used to manipulate the MSC (Li et al., 
2009). Published data has found MCF7 cells to be negative for vim expression (Uchino et 
al., 2010), in this study MCF7 cells were found to contain a small population of vim 
expressing cells (0.15 %). This may represent a true population of vim positive cells, 
however the low expression level could also be attributed to non-specific antibody binding 
or due to Uchino et al (2010) using microscopy to analyse immunofluorescence.  
 
To analyse the epithelial or mesenchymal characteristics of the CD44 populations, each cell 
line was co-stained for CD44 along with either e-cad or vim. Using this technique four 
different populations were identified. Using e-cad as an example, the populations included 
cells positive for both markers (CD44+/e-cad+), a population positive for CD44 only (CD44+ 
/e-cad-), cells expressing e-cad only (CD44-/e-cad+) and negative for both markers (CD44-
/e-cad-). The phenotype CD44-/e-cad+ were rare in OS and observed in only Cal72, HOS and 
MNNG-HOS. This result was in contrast to MCF7 which contained 31 % of cells expressing 
e-cad (CD44-/e-cad+) and the largest population (3.8 %) of CD44+/e-cad+ expressing cells. 
This is consistent with published data, where a large proportion (40 %) of MCF7 cells have 
been found to express e-cad (Vermeulen et al., 1995). Interestingly OS cells expressing e-
cad were found mainly in the CD44 population, apart from G292 these CD44+/e-cad+ 
expressing cells were rare comprising only 0.1 % – 0.5 % of cells. This phenotype could 
represent a more proliferative and less migratory CSC population than CD44+/e-cad- cells. 
Work carried out in squamous cell carcinoma found that there were in fact two separate 
CSC phenotypes present. One is migratory and associated with CD44 expression and 
reduced epithelial marker expression, the other is highly proliferative and associated with 
expression of CD44 and epithelial markers such as e-cad (Biddle et al., 2011). However, 
further tests will be required to confirm this in the migratory and proliferative properties 
of CD44+/e-cad+ and CD44+/e-cad- cells. 
 
The majority of OS CD44 cells also expressed vim (CD44+/vim+), OS cell lines contained a 
CD44+/vim+ population between 91 – 99 %. Vim has been found to be up-regulated in 
primary OS compared to benign bone tumours (Li et al., 2010) and in breast cancer 
enhanced vim expression  was found to correlate with enhanced occurrence of metastasis 
(Domagala et al., 1994). In addition sarcomas lacking CD44 are unable to metastasise 
Chapter 3. Results  
120 
 
(Weber et al., 2002), therefore this population of CD44+/vim+ could be hypothesised to 
have enhanced migratory capabilities to all other CD44/vim phenotypes.     
 
The presence of the colony hierarchies within cell lines is further putative evidence of the 
presence of CSC. Holoclones have been found to contain CSC (Li et al., 2008) and were 
identified within all the cell lines along with meroclones which comprise an amplifying 
population of cells and the terminally differentiated paraclones. The OS holoclones 
displayed the classic densely packed arrangement of cells and excluding MG63 and Cal72 
all holoclones were circular or oval in shape. Cal72 displayed more of an angular holoclone 
which was more rectangular in shape, whilst MG63 did display rectangular holoclones it 
also contained a unique holoclonal shape which contained pointed projections, making it 
form a star like shape. This unique MG63 holoclone still fulfilled all the holoclone criteria; 
tightly packed cells of a uniform size with a smooth layer of cells surrounding the colony 
(Locke et al., 2005). The paraclones formed by the OS cell lines were often composed of 
cells which were often highly dispersed and each cell would often independently migrate. 
This was especially true of the fibroblastic (MG63 and G292) and mixed (143B and HOS) OS 
cells lines, and suggests that these cell lines may be more prone to migration due to the 
ability of these cells to rapidly detach from one another and travel large distances apart. It 
has been shown that 143B which has a mixed morphology is able to migrate 2.7 times faster 
than the epithelial SaOS-2 (Rainusso et al., 2011), suggesting that OS cell lines containing 
fibroblastic cells may have enhanced migratory abilities.  In vitro the OS cell lines are 
categorised in to either epithelial, fibroblastic or a mixture of both cell types, however, 
whether this morphology has any clinical relevance is unclear. Epithelioid osteosarcomas 
do occur and are characterised by poorly differentiated cancers, which demonstrate 
characteristics of carcinomas such as gland formation (Klein and Siegal, 2006), however, it 
has not been specified whether cell lines with a epithelial morphology were initiated from 
epithelioid OS tumours (Rochet et al., 1999). In carcinoma the acquisition of a fibroblastic 
morphology is indicative of a cancer cell undergoing EMT (Mani et al., 2008), an opposing 
process may occur in OS in which cells acquire an epithelial phenotype.  In a case study of 
one epithelial OS tumour, OS cells were found to acquire an epithelial phenotype, which 
was attributed to tumour progression and increased intra-tumour heterogeneity (Kramer 
et al., 1993).  
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The presence of cells expressing the putative CSC markers (ALDH, CD117 and CD44) in the 
colony hierarchies were identified using confocal microscopy when cells were grown at low 
density. OS cell lines, which according to flow cytometry express high levels of ALDH (≥ 
10 %), were found to contain ALDH expressing cells not only in the holoclones. This 
contradicts the hypothesis that ALDH and holocolones represent the CSC populations. In 
G292, HOS and 143B the ALDH expressing cells were present in all the colony hierarchies. 
These highly expressing ALDH cell lines often contained clusters of cells all positioned 
adjacent to one another with high ALDH expression. Wang et al., (2011) found that the 
morphologically uncharacterised OS cell line OS99-1 contained a large population of ALDH 
expressing cells (45 %) and was able to form xenograftable tumours. However, the 
presence of ALDH positive cells in all hierarchies suggests either that ALDH or the colony 
hierarchies are not CSC identification methods in these highly expressing OS cell lines. 
Alternatively it is possible that ALDH expression is a dynamic state with cells switching 
between two phenotypes. Although a rare event, melanoma ALDH- cells taken from 
primary tumours, have been found to differentiate in to ALDH+ cells when transplanted in 
to NOD/SCID mice (Prasmickaite et al., 2010).  
 
In 143B, G292, MG63 and SaOS-2 holoclones were present which lacked the presence of 
any ALDH positive cells. These holoclones could represent the evolution of a holoclone to 
a meroclone, whereby cells go through a phase of transient amplification. Whether OS 
ALDH expressing cells initiate holoclone formation is unknown, the prostate cancer cell line 
PC3 is able to produce holoclones and the colony hierarchy replicates that observed by 
Locke et al (2005). However, PC3 cells either ALDH+ or ALDH- can give rise to holoclones and 
ALDH expression could be switched on and off. Interestingly paraclones were found to 
contain the largest proportion of ALDH expressing cells with holoclones containing 
predominantly ALDH low expressing cells. It was hypothesised that although ALDH 
expressing cells have enhanced clonogenicity, ALDH expression may be transiently 
switched on and off accounting for ALDH- cells giving rise to ALDH+ cells. In addition the 
high expression in paraclones may be unrelated to self-renewal, suggesting that based on 
proliferation two populations of ALDH expressing cells may be present (Doherty et al., 
2011). The lack of ALDH expression in holoclones within all OS cell lines indicates that a 
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similar pattern of transient ALDH expression may also be occurring, therefore further 
research is required to investigate the ability of OS ALDH- cells to form holoclones. 
 
Analysis of CD117 expression within the colony hierarchies at low density proved 
challenging, even 143B with the largest CD117 positive population (according to flow 
cytometry) contained very few CD117 expressing cells. When CD117 positive cells were 
identified the expression level was very low and it was restricted to cells from very small 
holoclones and small patches within large meroclones. A contrasting expression profile was 
observed when 143B was grown to a higher confluency (80 %), at these higher cell densities 
CD117 expression was increased and could be identified throughout a colony but localised 
to small sites upon each cell membrane. This increase in CD117 expression suggests that 
cell density may play a role in protein expression. It has been found that high grade primary 
OS tumours which express CD117 have staining within a large number of cells throughout 
the tumour samples. In clinical samples of 20 OS tumours that were tested for CD117, 
expression ranged from 5 % – 90 % (Sulzbacher et al., 2007), which is much greater than 
the 0.075 – 6.36 % observed in OS cell lines when tested at 70 – 90 % confluency. Therefore, 
in vitro cell culture conditions may lead to a down-regulation of CD117, whereas the 
tumour environment may provide appropriate signals to enhance CD117 expression. The 
lack of this environment when growing cells in vitro could explain the rarity of these cells 
observed during confocal microscopy analysis. In order to identify if tumour environment 
does affect CD117 expression, the assessment of CD117 expression from tumours formed 
from OS cell lines in vivo would be an important experiment. 
 
Colony hierarchies were also co-stained for CD44 and e-cad, these CD44+/e-cad+ cells 
proved to be rare and were only identified in G292 colonies. According to flow cytometry 
analysis G292 contains the largest CD44+/e-cad+ population, however, the lack of these cells 
in other OS cell lines suggests their presence may be affected by either the low cell density 
required for identification of the colony hierarchies or the fixation required for antibody 
staining. For cell fixation an optimum concentration for paraformaldehyde is 
recommended at 0.5 – 1 % (Van Ewijk et al., 1980). Although 4 % paraformaldehyde has 
been reported as a cell fixative of breast cancer and OS cell lines with no adverse effect on 
protein structure (Chambon et al., 2003, Fawdar, 2010). It is possible that the 4 % used 
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within this study is damaging the CD44 and e-cad proteins which is attributing to the lack 
of cells positive for these markers.  
 
OS holoclones have been identified as highly proliferative whereas paraclones will divide 
several times before undergoing cell death (Fawdar, 2010). G292, CD44+/e-cad+ cells were 
found within large merclones and paraclonal colonies, suggesting it does not represent a 
CSC marker. The level of e-cad expression from both of these cell types was very low and 
contained one positive cell within each colony hierarchy. MCF7 cells produced 
heterogenous staining for CD44 and e-cad. MCF7 cells CD44+/e-cad+ positive were found 
within holoclonal colonies, whilst CD44+/e-cad- cells were associated with paraclonal 
colonies. Cells expressing high levels of CD44 (CD44high) and low levels of CD24 (CD24low) 
have been identified as breast CSC (Al-Hajj et al., 2003). Further characterisation of these 
breast cancer CD44high/CD24low cells found they expressed low levels of e-cad and had 
undergone EMT (Mani et al., 2008). The presence of CD44+/e-cad- cells within paraclones is 
putative evidence that breast CSC which have undergone EMT have a paraclonal 
morphology. This finding contradicts the colonal hierarchy, however it is plausible if EMT 
CSC do exist in vitro they must acquire an ability to migrate. A migrating CSC must be detach 
itself from a colony which is indicative of a paraclone morphology.          
 
Neuronal cells with the ability to form spherical colonies in low attachment serum starved 
conditions have been identified as multipotent stem cells (Reynolds et al., 1992). In general 
the appearance of OS sarcospheres is not a classic spherical colony as was produced in 
MCF7. Mammospheres are frequently spherical in shape with a smooth appearance, in 
contrast sarcospheres were irregular in shape and individual cells could be clearly defined. 
Primary sarcospheres were present in all cell lines, whereas secondary sarcospheres could 
not be grown in Cal72, HOS or U2OS. It has been found that mammospheres can be 
passaged only 5 times before growth was inhibited. This inhibition was attributed due to 
an increase in cell senescence (Dey et al., 2009). All OS cell lines had smaller sized secondary 
sarcospheres compared to primary sarcospheres, therefore, a senescence mechanism 
could also be occurring in OS cell lines but at a significantly quicker rate in Cal72, HOS and 
U2OS. 143B and MNNG-HOS both had a significantly greater sarcosphere forming efficiency 
and size than all other cell lines, which has been replicated in published data (Rainusso et 
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al., 2011). Rainusso et al 2011, found that 143B and MNNG-HOS produced significantly 
larger sarcospheres than MG63, SaOS-2 and U2OS. 143B and MNNG-HOS are both derived 
from the HOS cell line and have been transformed using N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG-HOS) and Ki-ras for 143B. These transformed cell lines were 
found to be highly tumourigenic and metastatic when grown within a mouse model, in 
contrast HOS was unable to form tumours (Luu et al., 2005). The ability of 143B and MNNG-
HOS increased tumourigenicity and sarcosphere forming ability suggests that these cell 
lines harbour a larger population of CSC.  
 
To identify whether CSC marker expression correlated with sarcosphere forming ability 
Pearson’s correlation coefficient analysis was used. This analysis produced the strongest 
positive correlation (0.67) when correlating CD44+/e-cad+ expression with primary 
sarcosphere size. However, cells CD44+/e-cad+ correlated poorly with secondary 
sarcosphere size (-0.08), in which CD117 expression had the strongest correlation (0.58). 
CD117 has been demonstrated to be an OS CSC marker (Adhikari et al., 2010), therefore OS 
CD117 expressing cells may have enhanced sarcosphere forming abilities. Although the lack 
of a statistically significant correlation between these two factors makes this conclusion 
questionable.  
 
Sarcospheres were stained for the presence of cells expressing CD44, ALDH and CD117 
using confocal microscopy. All sarcospheres tested expressed CD44 on the membrane of 
all cells so was used to define cell membranes. ALDH positive cells were present within all 
sarcospheres tested, the number of cells expressing ALDH was found to increase as colonies 
grew larger. ALDH expressing  MG63 cells are able to survive anoikis and  have a higher 
sarcosphere forming ability than ALDH negative cells (Honoki et al., 2010), therefore, a CSC 
which is able to generate more ALDH expressing cells will be able to grow in to a larger 
sarcosphere. In the largest sarcosphere observed highly expressing ALDH cells were found 
to cluster in groups, CSC have been found to reside within a tumour niche which provides 
appropriate signals to maintain a stem cell phenotype (Iwasaki and Suda, 2009). It could be 
possible that as a sarcosphere grows larger the ALDH expressing cells cluster together and 
form a niche in order to maintain their ALDH positive phenotype.  
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As was observed with OS cells grown as a monolayer, CD117 cells in sarcospheres were 
very rare and not present within the majority of sarcospheres. CD117 has been identified 
as an OS CSC marker (Adhikari et al., 2010) and OS CSC have an enhanced ability to form 
sarcospheres (Rainusso et al., 2011). Therefore, the lack of CD117 expressing cells within 
the sarcospheres suggests that it may not be expressed by OS CSC within the panel of cell 
lines tested. CD117 has been found to be expressed in 20 % of OS cancers and over 
expression of CD117 has no impact on prognosis (Sulzbacher et al., 2007). This finding 
suggests that the use of CD117 as a CSC marker may be restricted to a small subset of OS 
tumours which are not included in the cell lines analysed within this study.   
 
In order to further characterise OS cell lines for the presence of putative CSC, each cell line 
has been screened for the ability to form the colony hierarchies, expression of putative CSC 
markers, epithelial and mesenchymal markers and the ability to form sarcospheres in low 
attachment conditions. This study has demonstrated that the colony hierarchies identified 
by Locke et al (2005) are also replicated in all the OS cell lines tested, in contrast putative 
OS CSC markers (ALDH and CD117) are heterogeneously expressed across the cell lines. The 
expression of these markers did not correlate with an enhanced ability to form 
sarcospheres, suggesting that cells expressing these proteins are not CSC. This finding is 
supported by cells highly expressing ALDH (> 10 % subpopulation), containing ALDH 
positive cells within paraclones and meroclones. In addition holoclones were identified 
which lacked ALDH expressing cells, indicating that ALDH expression may be transient and 
could potentially be switched on and off as has been observed in the prostate cancer cell 
line PC3 (Doherty et al., 2011). Clinical OS tumours have a higher level of CD117 expression 
when compared to the cell lines tested in this study, an increase in CD117 expression was 
observed when increasing cell density in vitro therefore the tumour microenvironment may 
increase CD117 expression. The carcinoma CSC marker CD44 was highly expressed in all OS 
cell lines in addition to the mesenchymal marker vimentin, both markers are also highly 
expressed in mesenchymal stem cells, highlighting the mesenchymal phenotype of OS cells 
in vitro. Furthermore a population of CD44+/e-cad- cells were identified which produced a 
positive correlation with primary sarcosphere forming ability. This suggests that this 
population may be enriched in CSC, however, further evidence is required to confirm the 
tumourigenicity of these cells.
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4.1 Introduction  
In the last 30 years improvements have been made in the treatment and management of 
OS tumours. Despite the toxic nature of chemotherapeutics they form the core 
therapeutics of any OS treatment strategy. A standard treatment program utilises the DNA 
intercalating agents cisplatin and doxorubicin  with either the dihydrofolate reductase 
antagonist methotrexate, alkylating agent ifosfamide or the topoisomerase inhibitor 
etoposide (Anninga et al., 2011) (Section 1.3). In addition to chemotherapy, surgery also 
provides an invaluable tool for improving relapse free survival. It has been reported that 36 
% of patients who had surgical removal of metatstatic OS tumours were relapse free after 
3 years, compared to 0 % of patients who did not have surgery (Ferrari et al., 2003). The 
poor survival rate of metastatic OS is often due to the chemo-resistant nature of secondary 
tumours (Yen, 2009), which is highlighted by prognoses being largely based upon pre-
operative response to chemotherapy (Bielack et al., 2002).  
The platinum based chemotherapeutics which include cisplatin (cis), were discovered by 
accident 40 years ago when platinum electrodes were being used to subject cells to 
electromagnetic radiation (Rosenberg et al., 1965). The products identified were used to 
treat sarcoma growth within mice, which resulted in marked tumour regression (Rosenberg 
and Vancamp, 1969). The mechanism by which OS resists the toxic effect of 
chemotherapeutics varies depending upon the mode of action.   Platinum based 
chemotherapeutics cause cell apoptosis upon intracellular activation, they covalently bind 
to purine DNA bases forming DNA adducts resulting in the activation of a number of signal 
transduction pathways including DNA repair, cell cycle arrest and apoptosis (Kelland, 2007). 
Some cancers are intrinsically resistant to cis (Perego et al., 1999) due to a number of 
different mechanisms including reduced membrane permeability (Santini et al., 2001), 
mutated P53 (Martelli et al., 2007) and loss of DNA mismatch repair proteins (Perego et al., 
1999) (Section 1.3.2).  
The dihydrofolate reductase (DHFR) inhibitor methotrexate (MTX) was one of the earliest 
chemotherapeutic agents to be identified as a result of work carried out by Sidney Farber, 
who initially trialed folic acid as a possible leukaemic treatment. This led to an acceleration 
of disease progression and the first realisation that a folic acid antagonist may be of use, 
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the subsequent use of MTX led to temporary leukaemia remission (Farber et al., 1948). 
Resistance to MTX can occur via different mechanisms, which include acquisition of 
enhanced DHFR expression or decreased expression of folate acid receptors, which reduces 
the ability of MTX to enter the cell (Guo et al., 1999)  (Section 1.3.4).  
Doxorubicin (dox) represents the anthracycline class of chemotherapeutics which is 
commonly used to treat OS (Singal and Iliskovic, 1998). Anthracyclines have the widest 
spectrum of activity against human cancers, only a few tumour types are unresponsive 
(Weiss, 1992). Dox intercalates with the DNA, however the mechanism by which it evokes 
cell death is debatable. Resistance to dox has been observed in cells with the loss of the 
cell cycle regulator P53 or enhanced expression of the protein Bcl2 which forms Bcl2-Bax 
homodimers. This stabilisation of Bax increased apoptosis through Bax induced 
cytochrome  c release in to the cytoplasm (Zhao et al., 2009) (Section 1.3.1).  
In breast cancer CSC pose a specific therapeutic challenge based on their enhanced 
resistance to chemotherapy allowing tumours to re-grow even when the majority of 
differentiated cells are removed (Gong et al., 2010) (Section 1.3.4). Putative CSC within OS 
cell lines have been found to have an enhanced cisplatin and doxorubicin resistance 
(Honoki et al., 2010). These cells had elevated expression of ALDH, which was suggested as 
a mechanism for the observed resistance due to  due to the detoxification capabilities of 
ALDH  (Honoki et al., 2010). OS cells expressing the CSC marker CD117 have also been found 
to have enhanced doxorubicin resistance due to drug efflux through enhanced expression 
of ATP binding cassette transporters  (Adhikari et al., 2010). The elevated resistance of OS 
CSC to chemotherapeutics therefore represents a possible mechanism of enriching a CSC 
population. In breast cancer this has been found to occur during patient chemotherapy 
programs, in which CSC are enriched within tumours post chemotherapy treatment 
(Creighton et al., 2009). In vitro data now suggests that OS putative CSC can also be 
enriched using MTX in the U2OS cell line  (Tang et al., 2011). This approach provides a 
method for isolating CSC without having to sort cells based on the expression of specific 
markers thus enabling the phenotype of drug resistant cells to be characterised within a 
heterogenous population of cells. 
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Aims 
To test the sensitivity of a range of OS cell lines to three chemotherapeutics (cisplatin, 
doxorubicin and methotrexate). Based on the median lethal doses (LD50) of each cell line, 
a short exposure to the chemotherapeutic will be used to enrich a drug resistant population 
of cells. The expression of CSC markers, clonogenicity and stem cell properties will be tested 
in the drug treated populations.  The contribution of ALDH to chemo-resistance in the OS 
cell lines will be assessed using the ALDH inhibitor diethylaminobenzaldehyde (DEAB). The 
specific objectives which will be tested on a panel of OS cell lines and MCF7 are as follows: 
 
 Establish the LD50 for cisplatin, doxorubicin and methotrexate. 
 Select a population of drug treated cells using methotrexate, cisplatin and 
doxorubicin at sub-lethal doses. 
 Analyse the expression of OS CSC markers (ALDH and CD117) in drug treated cells.  
 Test the growth rates of methotrexate treated cells. 
 Test the sarcosphere forming efficiency of MG63 methotrexate treated cells. 
 Establish the LD50 of the ALDH inhibitor diethylaminobenzaldehyde  (DEAB)  
 Analyse if DEAB exposure enhances chemotherapeutic sensitivity of selected cell 
lines in response to methotrexate, cisplatin and doxorubicin. 
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4.2 Chemotherapy sensitivity of OS cell lines and MCF7 
Commonly used OS treatment regimes incorporate the chemotherapeutics cis, dox and 
MTX (Anninga et al., 2011) (Section 1.3). To analyse the sensitivity to these 
chemotherapeutic agents, cell lines were grown in increasing concentrations of the drugs 
and cell viability assessed using an MTT assay (Section 2.3.1). Cis and dox were exposed to 
cells for two days, MTX which took longer for cell death to be observed was exposed for 
five days. In order to establish the median lethal dose (LD50) for a chemotherapeutic agent, 
linear regression analysis of each dose response curve was used to identify the drug 
concentration which killed 50 % of cells (Table 4.1).  All cell lines exhibited varying 
sensitivities to the chemotherapeutic agents (Figure 4.1. A, B, C, D, E and F), in response to 
cisplatin (Figure 4.1B). U2OS demonstrated the greatest resistance to cis with the highest 
LD50 of 18 µM and 143B the lowest (0.38 µM) (Figure 4.1B). Cell lines with the greatest LD50 
to doxorubicin (Figure 4.1 C and D) did not correlate with the highest LD50 for cisplatin.  For 
example MG63 had the largest dox LD50 of 0.76 µM and SaOS-2 with the lowest of 0.15 µM 
(Figure 4.1D). Interestingly SaOS-2 had an opposing resistance to MTX with the largest LD50 
(0.09 µM) and HOS the lowest (0.02 µM) (Figure 4.1 E and F).  
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(A) Cal72 – MCF7 
 
(B) MG63 – 143B 
 
Figure 4.1: Continued overleaf 
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(C) Cal72 – MCF7 
 
 
(D) MG63 – 143B 
 
 
Figure 4.1: Continued overleaf 
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(E) Cal72 – MCF7 
 
(F) MG63 – 143B 
Figure 4.1: Dose response curves for Cisplatin (A and B) and Doxorubicin (C and D) and 
methotrexate (D and E) dose response curves for OS cell lines and MCF7. Concentration 
range of 0 -50 µM was used for cisplatin, 0 - 3 µM for doxorubicin and methotrexate 0 - 3 
µM. Cisplatin and doxorubicin were incubated with cells for 48 hours and methotrexate for 
5 days. Each experiment was repeated in triplicate in 3 separate experiments (n=3 
independent replicates), results are presented as mean and standard error. 
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Table 4.1: Comparison of cisplatin, doxorubicin and methotrexate median lethal doses 
(LD50) in OS cell lines and MCF7. Statistical significance calculated by comparing to MCF7, 
*p = <0.05, **p = <0.01 (Tukey’s post hoc analysis). LD50 presented as average 
concentration and standard error (Std error) 
 
Cell line Cisplatin LD50 (µM) 
± Std error 
Doxorubicin LD50 
(µM) 
± Std error 
Methotrexate LD50 
(µM) 
± Std error 
143B 3.8 ± 0.73 ** 0.47 ± 0.06 0.05 ± 0.004 
Cal72 8.6 ± 0.37 * 0.36 ± 0.09 0.06 ± 0.004 * 
G292 13.0 ± 1.80  0.65 ± 0.15 0.08 ± 0.004 ** 
HOS 10.1 ± 1.05 *  0.34 ± 0.01 0.02 ± 0.001 
MG63 15.0 ± 1.89 0.76 ± 0.42 0.08 ± 0.006 ** 
OS99-1 10.5 ± 0.67 0.59 ± 0.04 N/A 
U2OS 18.0 ± 1.53 0.46 ± 0.02 0.03 ± 0.003 
SaOS-2 14.0 ± 3.61 0.15 ± 0.11 0.09 ± 0.007 ** 
MCF7 16.5 ± 2.20 0.57 ± 0.18 0.03± 0.001 
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4.3 Clonogenicity assessment of cisplatin and doxorubicin treated cells in selected OS cell 
lines and MCF7  
To identify if cis and dox exposure enriches for a CSC population with enhanced clonogenic 
properties. The following cell lines, U2OS, MG63, MCF7 and HOS were chosen because each 
OS cell line represents one of the different OS morphologies (U2OS is epithelial, MG63 is 
fibroblastic and HOS is mixed). MCF7 was included for comparison to a commonly used 
epithelial carcinoma cell line. Each cell line was exposed to a concentration equivalent to 
their LD50 (Table 4.1), after exposure to these drugs for 2 days cells were seeded at a low 
density (2.4 – 3.8 cells/cm2) and grown for up to 12 days. No colonies were present, 
suggesting that the exposure to these drugs at an LD50 concentration caused all the cells to 
undergo cell death. The LD50 concentration of cis and dox was halved to equal the LD25 
concentration, again cells were exposed for two days and seeded at a clonal density but no 
colonies formed. After being exposed for 48 hours to cis and dox LD25 the appearance of 
each cell line was consistent with the cell morphology prior to drug addition.  Except for 
MCF7 each OS cell line had undergone some growth in the presence of cis and dox, which 
was apparent with the increased cell density after 48 hours (Figure 4.2).  
To establish if cell communication is important for cell line recovery post drug treatment, 
U2OS and MG63 cells were seeded cells at a higher density (1 in 4 passage) post 48 hour 
drug treatment. Interestingly both cell lines when re-seeded at high density the drug 
treated cells had a fibroblastic appearance (Table 4.3 and table 4.4). In the case of U2OS 
(Figure 4.3) and MG63 (Table 4.4), after cis exposure these cells would undergo some 
growth but growing colonies were characterised with dendrite-like structures connecting 
cells to one another. These colonies stopped growing after 9 days. U2OS (Figure 4.3) and 
MG63 cells (Figure 4.4), did not form any colonies after dox exposure. Surviving cells were 
very large in size and had a fibroblastic morphology, often with long dendrite-like structures 
extending from the cells but would not form colonies.  
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Cell line 
  
Prior to drug addition 48 hrs Cis LD25  
exposure 
(10 – 18 µM) 
48 hrs dox  LD25 
exposure 
(0.34 – 0.76 µM) 
 
HOS 
   
 
MG63 
   
 
U2OS 
   
 
MCF7 
   
 
Figure 4.2: Appearance of OS cell lines and MCF7 after 48 hours of cisplatin or doxorubicin 
LD25 exposure. Representative of 4 images, scale bars represent 100 µm. 
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Chemotherapeutic 3 days recovery 6 days recovery 
 
Cisplatin 
  
 
Doxorubicin 
  
 
Figure 4.3: U2OS cells exposed to LD25 of either cisplatin or doxorubicin. Cells exposed to 
drugs for 48 hours then passaged and re-seeded at high density (1 in 4) and allowed to 
recover in the absence of drug. Representative of 4 images, scale bar represents 100 µm. 
 
 
Chemotherapeutic 3 days recovery 6 days recovery 
 
Cisplatin 
  
 
Doxorubicin 
 
 
 
Figure 4.4: MG63 cells exposed to LD25 of either cisplatin or doxorubicin. Cells exposed 
to drugs for 48 hours then passaged and re-seeded at high density (1 in 4) and allowed to 
recover in the absence of drug. Representative of 4 images, scale bar represents 100 µm. 
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4.4 Analysis of putative CSC marker expression in cisplatin and doxorubicin treated cells 
in selected OS cell lines and MCF7 
To identify if 48 hour exposure of cis and dox led to enhanced expression of cancer stem 
cell markers (ALDH, CD117 and CD44). Cells were exposed for 48 hour to LD25 drug 
concentration, after which cells were labelled with CSC marker antibodies (CD117 or CD44) 
or substrates (ALDH) and analysed using flow cytometry (Section 2.8).  
 
Both cis and dox possessed auto-fluorescence which interfered with the phycoerythrin (PE) 
channel of the flow cytometer, this made the analysis of these markers utilising PE 
fluorescence inaccurate. Uptake of both cis and dox by all cell lines tested resulted in an 
increase in the PE fluorescence of the cells. In order to set a baseline PE fluorescence which 
can be used to identify the increase in PE fluorescence, an unstained population was 
compared to a stained population to identify an increase (Section 3.2). However due to the 
increased fluorescence of cis and dox treated cells this led to the baseline  PE fluorescence 
of the unstained cells to be increased (Figure 4.5.B), which is evident when comparing to a 
normal population of non-drug treated cells (Figure 4.5.A). This increased PE background 
fluorescence is important for either PI staining (when distinguishing live from dead cells) or 
identifying CD44 positive cells, hence making analysis of these markers inaccurate. This 
masking effect is evident when comparing CD44 populations observed in untreated cells 
(68.6 %), which was reduced in cis treated (6.4 %) and dox treated cells (2.64 %) (Table 4.2). 
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(A)       (B) 
Figure 4.5: Auto-fluorescence of doxorubicin and cisplatin exposed cells detected by flow 
cytometry analysis in HOS cell line. HOS cells untreated (A) or treated with LD50 
concentration of doxorubicin (B). This experiment was tested in once in for both cis and 
dox exposure. 
 
Table 4.2: Identification of CD44 positive populations of HOS cells when comparing 
untreated cells with cis and dox exposed cells. Untreated cells tested in triplicate, cis and 
dox LD50 treated cells tested once. 
Marker Untreated Cis LD50 
(10.1µM) 
Dox LD50 
(0.34µM) 
CD44 (%) 68.6 ± 6.8 6.4 2.64 
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4.5 Growth rates of methotrexate exposed cell in selected OS cell lines and MCF7 
The dihydrofolate reductase inhibitor MTX, has been previously used to enrich putative CSC 
in the OS cell lines U2OS and MG63 (Tang et al., 2011). Tang et al (2011) was able to enrich 
putative OS CSC based upon exposure to 100 ng/ml and 300 ng/ml MTX for 5 days with 
surviving cells having increased clonogeneicity and sarcosphere forming ability compared 
to untreated cells. The LD50 of the OS cell lines tested ranged from 20 nM to 80 nM (Table 
4.1), based on the cell MTX sensitivities two concentrations were chosen, 5 nM was 
selected because all cell lines could form colonies after 5 days exposure and also 50 nM to 
identify if an increased MTX concentration would more efficiently enrich drug resistant 
cells. The concentrations utilised by Tang et al (2011) equated to 220 nM (100 ng/ml) and 
660 nM (300 ng/ml), these concentrations were tested but no cells survived after 5 days of 
MTX exposure. 
Images taken of the cells after 5 days of MTX exposure (Figure 4.6) show that at 5 nM MTX 
all cell lines (HOS, MG63, U2OS and MCF7) grew at a similar rate to the untreated cells (0 
nM) and had reached 100 % confluency after 5 days. At 50 nM MTX cell growth was reduced 
in HOS, MCF7 and U2OS which all displayed below 30 % confluency, in contrast MG63 
growth rate was least effected reaching approximately 95 % confluency. Interestingly a 
common feature of cells which had grown in 50 nM MTX was the acquisition of a 
fibroblastic appearance with the presence of dendrite-like structures connecting cells 
together.  
After the cells had been exposed to 5 nM and 50 nM MTX concentrations they were 
passaged and seeded at a clonal density (2.4 – 3.8 cells/cm2). Colonies were allowed to 
form in the absence of MTX for 14 days (media was changed every 3 days), after which 
colonies were stained using crystal violet and size assessed using ImageJ® (Figure 4.7). 
Growing HOS and U2OS in 50 nM MTX resulted in no colony formation, whilst the MG63 
and MCF7 formed colonies in both MTX concentrations. Interestingly no significant change 
in colony size was observed in response to 5 nM and 50 nM MTX, suggesting that the cell 
lines (HOS, MG63, U2OS and MCF) treated with MTX have the same growth rates as the 
untreated cells (Figure 4.7). 
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Figure 4.6: Images of OS cell lines (HOS, MG63 and U2OS) and MCF7 in response to 
methotrexate exposure at 0, 5 and 50 nM. 15625 cells/cm2 were seeded images taken 
after 5 days of MTX exposure. Representative of 4 images, scale bar represents 100 µm. 
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Figure 4.7: Assessment of colony size of HOS, MG63, U2OS and MCF7 exposed to MTX 
concentrations (0, 5 and 50 nM). Cells were seeded at 15625 cells/cm2 and grown in the 
presence of methotrexate for 5 days before seeding at a clonal density (2.4 – 3.8 cells/cm2) 
and growing for a further 14 days (Section 2.3.2). Colony size assessed using ImageJ. Results 
tested in triplicate and data presented as mean and standard deviation. Statistical 
significance assessed using Tukey’s post hoc analysis for 0, 5 and 50 nM treated cells for 
each cell line. No statistical significance observed.  
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4.6 Presence of putative cancer stem cells in methotrexate treated OS and MCF7 cells 
lines 
OS CSC have been found to have an enhanced resistance to chemotherapeutics (Adhikari 
et al., 2010) (Section 1.3), and the colony hierarchies (holoclones, meroclones and 
paraclone) have been shown to contain CSC within the holoclones from a prostate cancer 
cell line (Li et al., 2008). Holoclones are therefore at the base of this cellular hierarchy and 
can give rise to rapidly amplifying meroclones which will eventually terminally differentiate 
and become paraclones (Section 1.2.3). The identification of holoclones, therefore provides 
a method for identifying putative CSC without the requirement for analysis of surface or 
intracellular CSC protein markers. Although in chapter 3 of this thesis, it was shown that OS 
cell lines highly expressing ALDH contain these ALDH+ cells within all three colony 
hierarchies (Section 3.6.1), which could indicate that CSC may reside within all colony 
hierarchies.    
The colony hierarchy frequency present after MTX treatment was assessed by exposing 
cells to MTX for 5 days. Cells were then re-seeded at a clonal density and grown for 14 days 
in the absence of MTX, after which colony hierarchies were assessed (Section 2.3.2). Due 
to the sensitivity of HOS and U2OS to MTX no colonies survived at 50 nM MTX in HOS and 
less than 10 colonies were present in MCF7. HOS was the only cell line to have a statistically 
significant change, which resulted in a reduction in holoclones present in 5 nM MTX 
compared to 0 nM MTX (Figure 4.4). No change in colony hierarchy frequency was observed 
in response to MTX in the cell lines MG63 (Figure 4.8.B), U2OS (Figure 4.8.C) and MCF7 
(Figure 4.8.D). MCF7 50 nM MTX exposed colonies were not included in the analysis due to 
less than 30 colonies being present (Figure 4.8.D). 
 
4.6.1 Cancer stem markers expressed by methotrexate treated cells 
MTX treated cells were also analysed for the expression of CSC markers (ALDH and CD117). 
Cells (15625 cells/cm2) were seeded and allowed to attach for 24 before addition of MTX. 
After short term exposure to MTX (5 days) cells were harvested and stained for the markers 
and analysed by flow cytometry (Section 2.8.6). HOS which contains the largest population 
of ALDH cells (60.6 %) according to flow cytometry (Section 3.2.2), had a significantly 
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greater population of ALDH cells at all MTX concentrations compared to the other cell lines 
tested (Figure 4.9.A). However, HOS was the only cell line which did not have an increase 
in ALDH expression in response to 5 nM MTX, suggesting that the ALDH positive cells in 
HOS are not MTX resistant. In contrast MG63, U2OS and MCF7 had an increase in the 
percentage of ALDH positive cells in response to 50 nM MTX (figure 4.9.B). MG63 was the 
only cell line to have a significant enrichment in ALDH expressing cells at 5 nM MTX, 
suggesting that ALDH positive cells have enhanced MTX resistance compared to cells 
lacking ALDH expression in MG63 and to a lesser extent U2OS and MCF7.    
MTX exposure altered the expression of CD117 in both MG63 and U2OS, in the absence of 
MTX neither cell line expressed CD117, however, in response to MTX both cells were found 
to express the cell surface receptor (Figure 4.10). Exposure to 5 nM MTX resulted in MG63 
cells containing a CD117 population of 0.45 %, whereas U2OS contained 0.05 %. Increasing 
the concentration to 50 nM led to an increase in CD117 expression in U2OS, whilst in MG63 
a decrease of cells expressing CD117 was observed (Figure 4.10). 
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 (A) HOS     (B) MG63 
 
 
` (C) U2OS     (D) MCF7 
  
Figure 4.8: Analysis of the frequency of the colony hierarchies in methotrexate treated 
HOS, MG63, U2OS and MCF7 cells. HOS (A), MG63 (B), U2OS (C) and MCF7 (D) cells were 
seeded at 156 cells/mm2 and grown in the presence of methotrexate (0, 5 or 50 nM)  for 5 
days before seeding at a clonal density (2.4 – 3.8 cells/cm2) and growing for a further 14 
days. Colony hierarchy was assessed by counting the first 30 colonies prior to crystal violet 
staining. No colonies were present in 50 nM MTX of HOS or U2OS cells. Results tested in 
triplicate. Significance calculated using Tukey’s post hoc analysis (p = <0.05), MCF7 50 nM 
treated cells not included because less than 30 colonies were present. 
 
0
2
4
6
8
10
12
14
16
Holoclone Meroclone Paraclone
N
u
m
b
er
 o
f 
co
lo
n
ie
s
Colony hierarchy
0 nM
5 nM
*
0
2
4
6
8
10
12
14
16
18
Holoclone Meroclone Paraclone
N
u
m
b
er
 o
f 
co
lo
n
ie
s 
Colony hierarchy
0 nM
5 nM
50 nM
0
5
10
15
20
25
Holoclone Meroclone Paraclone
N
u
m
b
er
 o
f 
co
lo
n
ie
s
Colony hierarchy
0 nM
5 nM
0
2
4
6
8
10
12
14
16
18
20
Holoclone Meroclone Paraclone
N
u
m
b
er
 o
f 
co
lo
n
ie
s
Colony hierarchy
0 nM
5 nM
50 nM
Chapter 4. Results  
146 
 
0
10
20
30
40
50
60
70
80
HOS MG63 U2OS MCF7
%
 o
f 
ce
lls
 e
xp
re
ss
in
g 
A
LD
H
Cell line
***
***
***
(A) (B)
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
MG63 U2OS MCF7
%
 o
f 
ce
lls
 e
xp
re
ss
in
g 
A
LD
H
Cell line
0 nM
5 nM
50 nM
*
**
*
**
 
Figure 4.9: Presence of ALDH expressing cells in MG63, U2OS ansd MCF7 MTX treated 
cells. A) ALDH expression of HOS, MG63, U2OS and MCF7 after 5 days exposure to MTX (0, 
5 and 50 nM).  HOS had a significantly larger proportion of ALDH cells at all concentrations. 
Tukey’s post hoc analysis *** = <0.0001. B) ALDH expression of MG63, U2OS and MCF7 in 
response to MTX (0, 5 and 50 nM). Significance calculated using Tukey’s post hoc analysis, 
* = <0.05, ** = <0.01 and *** < 0.001 . Analysis compared to 0 nM MTX ALDH populations. 
Samples tested in triplicate. 
 
Figure 4.10: Presence of CD117 expressing cells in MG63, U2OS and MCF7 MTX treated 
cells. CD117 expression of MG63, U2OS and MCF7 after 5 days exposure to MTX (0, 5 and 
50 nM).  Significance calculated using Tukey’s post hoc analysis, * = <0.05. Experiment 
tested in triplicate. 
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4.7 Effect of cell density on ALDH expression in selected OS cell lines and MCF7 
Exposure to 50 nM MTX enriched ALDH expressing cells in the following cells lines; MG63, 
U2OS and MCF7 (figure 4.5.B). To obtain this result cells were seeded at high density (15600 
cells/cm2), allowed to attach for 24 hours before adding the MTX for 5 days and then 
analysing ALDH expression. At MTX concentrations of 0 nM and 5 nM, cells would have 
reached 100 % confluency at the time of ALDH analysis, however, the 50 nM MTX treated 
cells had a reduced growth rate so confluency would be 90 % in MG63 and < 30 % in the 
remaining cell lines (HOS, U2OS and MCF7). Therefore an important experiment is to 
ensure that cell density is not affecting the expression of the CSC markers. To test this 
MG63 and MCF7 cells were seeded at 1310, 5240 and 21000 cells/cm2 so that cells grown 
for 6 days at different densities could be compared for ALDH expression. ALDH was 
monitored after 6 days because this reflected the incubation time utilised in the MTX 
treated ALDH expression experiment (Section 2.8.7).  
 
In both MG63 and MCF7 ALDH expression was found to be significantly lower (p = <0.01) 
in the highest seeding densities (21053 cells/cm2) (figure 4.11A and B), MG63 was found to 
have a reduced expression at 5263 cells cm2 (figure 4.11.A). Therefore at higher cell 
densities the presence of ALDH positive cells is reduced. Suggesting that the increase in 
ALDH expression observed in response to 50 nM MTX may be a result of the MTX 
decreasing growth, which decreases cell density leading to enhanced ALDH expression.  
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 (A) MG63 
 
 (B) MCF7 
 
Figure 4.11: Analysis of effect of cell density upon ALDH expression. A) MG63 or B) MCF7 
cells were seeded at either 1316, 5263 or 21053 cells/cm2, grown for 5 days and the tested 
for ALDH expression. Significance calculated by comparing to 12500 cells using Tukeys post 
hoc analysis, *p<0.05 ** p < 0.01. Results tested in triplicate. Data presented as mean and 
standard deviation. 
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4.8 Correlation of cancer stem cell marker expression with chemotherapeutic resistance 
in osteosarcoma cell lines and MCF7 
OS cells expressing either CD117 or ALDH, have been sorted using flow cytometry and were 
reported to have an enhanced chemotherapeutic resistance (Honoki et al., 2010, Adhikari 
et al., 2010). However, whether the expression of these markers in an unsorted population 
of cells correlates with in vitro chemotherapy resistance is absent within the literature. In 
order to identify if the expression of the CSC markers ALDH and CD117 correlates with an 
enhanced chemotherapeutic resistance, the LD50 from OS cells lines (except OS99-1) and 
MCF7 were compared with the population sizes  expressing the CSC markers identified 
using flow cytometry to see if a correlation existed (section 3.2). Both linear regression and 
Pearsons’s correlation coefficient were used to assess the correlation between the two 
variables.  
Correlating CSC marker expression with LD50 concentrations for all chemotherapeutics 
tested produced a negative correlation (Figures 4.12 – 4.17). Pearson’s correlation 
coefficient analysis confirmed that increased putative CSC marker expression is related to 
increased sensitivity to chemotherapeutic treatment, in particular CD117 expression 
produced a strong negative correlation with cisplatin (-0.70) (Figure 4.11), which was 
supported by producing a statistically significant negative Pearson’s correlation of -0.84 
(Table 4.3). ALDH expression produced weak negative correlations with all drugs tested (cis, 
dox and MTX), however, according to Pearson’s correlation none were statistically 
significant. 
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Figure 4.12: Linear regression analysis of cell line (143B, Cal72, G292, HOS, MG63, U2OS, 
SaOS-2 and MCF7) cisplatin LD50 concentration against ALDH expression. The correlation 
coefficient (R2) is 0.01 and Pearson’s correlation coefficient of -0.31. 
 
 
 
Figure 4.13: Linear regression analysis of cell line (143B, Cal72, G292, HOS, MG63, U2OS, 
SaOS-2 and MCF7) doxorubicin LD50 concentration against ALDH expression. The 
correlation coefficient (R2) is 0.06 and Pearson’s correlation coefficient of -0.24. 
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Figure 4.14: Linear regression analysis of cell line (143B, Cal72, G292, HOS, MG63, U2OS, 
SaOS-2 and MCF7) methotrexate LD50 concentration against ALDH expression. The 
correlation coefficient (R2) is 0.25 Pearson’s correlation coefficient of -0.50. 
 
 
 
Figure 4.15: Linear regression analysis of cell line (143B, Cal72, G292, HOS, MG63, U2OS, 
SaOS-2 and MCF7) cisplatin LD50 concentration against CD117 expression. The correlation 
coefficient (R2) is 0.69 and a spearmanns rank correlation coefficient of -0.84. 
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Figure 4.16: Linear regression analysis of cell line (143B, Cal72, G292, HOS, MG63, U2OS, 
SaOS-2 and MCF7) doxorubicin LD50 concentration against CD117 expression. The 
correlation coefficient (R2) is 0.006 and Peasron’s correlation coefficient of -0.07. 
 
 
Figure 4.17: Linear regression analysis of cell line (143B, Cal72, G292, HOS, MG63, U2OS, 
SaOS-2 and MCF7) methotrexate LD50 concentration against CD117 expression. The 
correlation coefficient (R2) is 0.016 and Pearson’s correlation coefficient of -0.013. 
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Table 4.3: Pearson’s correlation coefficient of cell lines CSC marker expression and 
chemotherapy LD50. The cell lines 143B, Cal72, G292, HOS, MG63, U2OS, SaOS-2 and MCF7 
were correlated for the expression of cancer stem cell markers (ALDH and CD117) against 
the LD50 concentrations of the chemotherapeutic agents cisplatin, doxorubicin and 
methotrexate (** = p < 0.01). 
Chemotherapeutic ALDH CD117 
Cisplatin -0.31  -0.84** 
Doxorubicin -0.24 -0.07 
Methotrexate -0.50 -0.13 
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4.9 Sarcosphere forming ability of MG63 methotrexate exposed cells 
Growing cells in serum starved low attachment conditions allows spherical suspension 
colonies to form which are enriched in stem cells (Reynolds et al., 1992). This technique 
was used by Rainusso et al., (2011) to study OS CSC and it and they reported that cells with 
an enhanced sphere forming ability also have enhanced tumourigenicity. 
If MTX treatment enriches for CSC we would predict to see an increase in enhanced 
sarcosphere formation. To test this, the cell line MG63 was chosen for its ability to form 
secondary sarcospheres (Section 3.7) and the enrichment of ALDH and CD117 expressing 
cells in response to MTX (figure 4.9 and 4.10). MG63 cells were seeded at a high density 
(15600 cells/cm2), allowed to attach for 24 hours before being treated with MTX for 5 days, 
after which cells were passaged and seeded (1052 cells/cm2) in to the serum starved low 
attachment conditions. After 7 days primary sarcosphere size was assessed from 5 images 
of each well using ImageJ, passaged and seeded (210 cells/cm2) and grown for a further 7 
days to form the secondary sarcospheres. Secondary sarcospheres were assessed by 
counting all sarcospheres ≥ 40 µm and calculating the sarcosphere forming efficiency (%) 
(MG63 MTX treated sarcosphere assay procedure summarized in figure 4.18). 
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MG63 cells seeded at high density (15600 cells/cm2) 
 
Media changed and replaced with MTX containing media (0, 5 and 50 nM)  
 
MTX treated cells seeded at 1052 cells/cm2 in serum starved low attachment conditions 
 
Primary sarcosphere size assessed then passaged and re-seeded at 210 cells/cm2 serum 
starved low attachment conditions 
 
  Secondary sarcosphere forming efficiency assessed 
Figure 4.18: MG63 methotrexate treated sarcosphere assay procedure. 
 
The appearance of primary sarocpsheres when treated with 5nM was similar to untreated 
cells, the colonies were of an oval shape with a rough appearance. Cells treated with 50 nM 
MTX also formed primary sarcospheres and also had a rough appearance but more irregular 
in shape. These cells did not produce the oval shape observed in the lower concentrations. 
Secondary sarcospheres across all the concentrations had the same appearance, they were 
observed to be smaller in size than the primary sarcospheres and had an irregular shape 
(Figure 4.19). 
MG63 cells treated with 5nM MTX were found to have an increased primary sarcosphere 
size compared to untreated sarcospheres (Figure 4.20). This increase in sarcosphere size 
suggests that exposing OS cells to 5 nM MTX enriches a population of cells with a higher 
growth rate in low attachment conditions. In contrast cells exposed to 50 nM MTX had no 
change in colony size, suggesting that the increased concentration negates the effects 
caused by 5 nM. Analysis of secondary sarcospheres demonstrated that no change in 
sarcosphere size was observed in either 5 nM or 50 nM MTX (Figure 4.21). The lack of any 
24 hours 
5 days 
7 days 
7 days 
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change suggests that the effect of 5 nM MTX upon primary sarcospheres may be a transient 
effect which is lost upon passage.  The cell line U2OS was also assessed for sarcosphere 
forming efficiency in response to 0 nM, 5 nM and 50 nM MTX, however, no secondry 
sarcospheres were present in all concentrations suggesting that MTX exposure does not 
enrich U2OS cells with the ability to grow in low attachment conditions. 
 
 
Cell line 
(phenotype, 
cancer type) 
No passage (7 days) 1 passage (14 days) 
MG63 
(0 nM 
methotrexate) 
 
 
 
 
 
MG63 
(5 nM 
methotrexate) 
 
 
  
 
MG63 
(50 nM 
methotrexate) 
 
 
  
 
Figure 4.19: Images of MG63 sarcospheres in response to methotrexate exposure (bar = 
100 µM). Images representative of 4 images. 
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Figure 4.20: Analysis of primary sarcosphere size in MG63. Five images per well were 
analysed using ImageJ. 5 nM MTX treated cells contained significantly larger colonies. 
Significance calculated by comparing each treatment sarcosphere size using Tukey’s post 
hoc analysis (*p = <0.05), 5 nM sarcospheres significantly larger than 0 nM and 50 nM. 
Results tested in triplicate and presented as mean and standard deviation. 
 
 
Figure 4.21: Analysis of secondary sarcosphere forming efficiency. Sarcosphere forming 
efficiency was calculated by counting all spheres ≥ 40 µM and dividing this by the number 
of cells seeded. No significant difference was observed (Tukey’s post hoc analysis). Results 
tested in triplicate and presented as mean and standard deviation. 
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4.10 Effect of ALDH inhibition on methotrexate sensitivity upon selected OS cell lines and 
MCF7 
ALDH has been identified as not only a OS CSC marker (Wang et al., 2011) but also as a 
mechanism to enhance chemo-resistance (Honoki et al., 2010) (Section 1.3.4). The ALDH 
specific inhibitor  diethylaminobenzaldehyde (DEAB) has been used  in vitro to sensitise 
breast cancer cells to chemotherapeutics (doxorubicin and paclitaxel) and radiation (Croker 
and Allan, 2012). To identify if DEAB also sensitises OS cell lines to chemotherapeutics the 
toxicity of DEAB was first assessed to obtain LD50 concentrations for each cell line. The cell 
lines HOS, MG63, U2OS and MCF7 were selected because the OS cell lines represent each 
morphology (fibroblastic, epithelial and mixed) and MCF7 for comparison to a commonly 
used epithelial breast cancer cell line. DEAB LD50 were assessed by exposing cells seeded at 
high density (15600 cells/cm2) to DEAB for 2 days then assessing cell death using an MTT 
assay (Section 2.3.1).  
 
MG63 had the highest DEAB LD50 whilst MCF7 had the lowest (Table 4.4). Interestingly 
sensitivity to DEAB did not correlate with the level of ALDH expression in each cell line 
(Table 4.9) as HOS which had the highest ALDH expression was not the most effected by 
DEAB. This suggests that the ALDH population size does not dictate DEAB sensitivity.  No 
enhancement in drug sensitivity upon HOS, U2OS and MCF7 was observed when a DEAB 
concentration equivalent to the LD50 for each cell line was combined with MTX at an LD25. 
In contrast, a reduction in MG63 cell viability was observed when comparing exposure to 
DEAB and MTX against MTX and a vehicle control (ethanol) (Figure 4.23). This observation 
suggests that the ALDH cells in MG63 may have an elevated MTX resistance, however the 
reduction is small and extending the length of time exposed to MTX and DEAB may enhance 
this effect. Cisplatin and doxorubicin co-exposure with DEAB experiments were only tested 
in HOS and U2OS, however, each drug effected cell lines in different ways. Cis and DEAB 
co-exposure caused a reduction in U2OS cell viability (figure 4.24), whilst dox co-exposure 
reduced HOS cell viability. This indicates that the ALDH cells from U2OS are attributing to 
cis resistance, whilst HOS ALDH are dox resistant (figure 4.25). This finding implies that 
ALDH populations within different OS cell lines are resistant to different drugs.  
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Figure 4.22: DEAB dose response curve of HOS, MG63, U2OS and MCF7. Cell lines were 
grown for 2 days in DEAB, before assessing cell number using an MTT assay. Linear 
regression was used to DEAB LD50 for each cell line. Results tested in triplicate in three 
separate experiments (n = 3 independent replicates). Data presented as mean and standard 
error. 
 
Table 4.4: DEAB LD50 concentrations and percentage of cells expressing ALDH HOS, MG63, 
U2OS and MCF7. Percentage of cells expressing ALDH was assessed in section 3.2.2. 
Statistical significance calculated using Tukey’s post hoc analysis (**p = <0.01) and 
comparing all cell lines to one another. HOS has statistically larger ALDH expressing 
population than MCF7, MG63 and U2OS. No significant difference was observed when 
comparing DEAB LD50 concentrations. 
Cell line DEAB LD50 µMol 
± Std error 
% of cells expressing 
ALDH   
± Std deviation 
HOS 94.03 ± 19.14 60.60 ± 9.67 ** 
MG63 115.83 ± 63.56 2.14 ± 0.14 
U2OS 87.25 ± 12.58 2.13 ± 0.78 
MCF7 81.30 ± 7.78 2.36 ± 0.35 
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(A) HOS      (B) MG63 
  
 (C) U2OS      (D) MCF7  
Figure 4.23: Cell sensitivity to MTX LD25 and DEAB LD50 in HOS, MG63, U2OS and MCF7. 
The cell lines A) HOS, B) MG63, C) U2OS and D) MCF7 were exposed to their specific DEAB 
LD50 concentration and MTX LD25 concentration. Ethanol was used to as a vehicle control 
for the DEAB. Significance calculated using Tukey’s post hoc analysis (*p =0.05 and **p 
=<0.01).  Each result was tested in triplicate in three separate experiments (n = 3), data 
presented as mean and standard error.  
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(A) HOS     (B) U2OS 
Figure 4.24: Cell sensitivity to cis LD25 and DEAB LD50 in HOS and U2OS. The cell lines A) 
HOS and B) U2OS were exposed to their specific DEAB LD50 concentration and cis LD25 
concentration. Ethanol was used as a vehicle control for DEAB. Significance calculated using 
Tukey’s post hoc analysis (*p = <0.05, **p = <0.01).  Each result was tested in triplicate, 
data presented as mean and standard deviation.  
 
 (A) HOS     (B) U2OS 
Figure 4.25: Cell sensitivity to dox LD25 and DEAB LD50 in HOS and U2OS. The cell lines A) 
HOS and B) U2OS were exposed to their specific DEAB LD50 concentration and cis LD25 
concentration. Ethanol was used as a vehicle control for DEAB. Significance calculated using 
Tukey’s post hoc analysis (*p = <0.05, **p = <0.01).  Each result was tested in triplicate, 
data presented as mean and standard deviation.  
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4.11 Discussion 
OS cell lines were tested for their sensitivity to three commonly used OS 
chemotherapeutics, the drugs cisplatin (cis), doxorubicin (dos) and methotrexate (MTX). 
Cell lines demonstrated differing sensitivities depending upon the drug used, which is 
attributed to the mechanism of toxicity utilised by the drug and mutations present within 
each cell line, conferring either resistance or susceptibility (Holohan et al., 2013). In 
response to the DNA intercalating agent cis U2OS had the highest LD50 of 18 µM, which is 
consistent with published data in which U2OS was found to have a cis LD50 of 17.6 µM 
(Martelli et al., 2007). Interestingly Martelli et al (2007) also found that having a wild type 
p53 conferred greater resistance than a mutant copy. p53 status may be relevant as MCF7 
(Fan et al., 1995) and U2OS with the largest cis LD50 were the only cell lines with wild type 
p53, the remaining cell lines contain a mutant copy and in particular, G292, MG63 and 
SaOS-2 completely lack endogenous P53 (Chen et al., 1990, Chandar et al., 1992). 
Functional P53 has been found to protect against cis cell death by repairing cis induced 
DNA lesions (Fan et al., 1995). Interestingly Fan et al (1995), identified that an operational 
G2 checkpoint compensates for loss of p53 by providing a mechanism to repair drug 
induced DNA lesions. 143B has the lowest cis LD50 of 3.8 µM it expresses a mutant P53 
(Mohseny et al., 2011, Ottaviano et al., 2010) and is also the most rapidly dividing OS cell 
line (Fawdar, 2010), therefore, loss of P53 function and decreased G2 checkpoint may be 
accounting for its elevated sensitivity to cis. 
 
p53 status may also contribute to resistance to the DNA intercalating agent Dox but using 
an opposing mechanism to cis resistance.  Dox DNA damage in cells with wild type p53 
induces apoptosis through activation of the caspase cascade with activation of Bax leading 
to outer membrane pore formation and release of cyotochrome C (Katiyar et al., 2005). In 
OS, loss of p53 leads to doxorubicin resistance due to an inability to activate caspase 3 in 
response to DNA damage (Tsang et al., 2005). Results presented in this chapter showed 
that MG63 had the highest dox LD50 and lacking endogenous p53 (Chandar et al., 1992) 
supports this finding, however, MCF7 and U2OS with the third and fifth highest dox LD50 
and functional P53 do not support this hypothesis. The protein Bcl-2 is commonly up-
regulated in OS and has been identified as a means of overcoming doxorubicin apoptosis. 
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This occurs through inhibition of cytochrome C release and reducing the formation of Bax-
Bax homodimers which insert in the outer mitochondrial membrane which leads to pore 
formation in response to DNA damage. Inhibiting Bcl-2 in MG63 has been found to sensitise 
cells to dox treatment (Zhao et al., 2009). The nucleolar protein neuroguidin/CANu1 is 
upregulated in U2OS and provides increased doxorubicin resistance (Park et al., 2011a). 
Although the pathway through which neuroguidin/CANu1 signals is unclear it has been 
hypothesised to inhibit p21 and stabilize Bcl-2, therefore up-regulation of Bcl-2 maybe one 
mechanism through which U2OS can resist dox even with the presence of a wild type P53 
gene. 
 
SaOS-2 was the most resistant to the dihydrofolate reductase (DHFR) inhibitor MTX, 
producing a MTX LD50 of 0.09 µM and HOS had the lowest LD50 of 0.02 µM. Two common 
mechanisms of OS MTX resistance is the down regulation of the folate receptor (FC) present 
in 65% of tumours and over expression of the enzyme DHFR (Guo et al., 1999). Over 
expression of DHFR has been attributed to a gene frequently altered in OS, retinoblastoma 
(Rb). Rb negatively regulates the expression of E2F transcription factors which increase the 
expression of cell cycle proteins such as DHFR (Li et al., 1997). SaOS-2 has a defective copy 
of Rb (Ory et al., 2007), whilst in contrast HOS and U2OS with the lowest MTX LD50 both 
have functional Rb (Serra et al., 2004), therefore, loss of Rb and up-regulation of DHFR 
could be one mechanism for enhancing OS MTX resistance. However, other factors such as 
down regulation of the folate receptor in Rb negative cells have also been found to be 
important in MTX resistance (Serra et al., 2004). 
 
Following chemotherapy treatment breast cancers have been shown to be enriched in cells 
expressing CSC markers (Creighton et al., 2009), which suggests that CSC have enhanced 
resistance to chemotherapeutics. In order to identify if cis or dox exposure led to an 
enrichment of cells with enhanced clonogenicity, the colony formation of U2OS, MG63, 
U2OS and MCF7 in response to cis or dox LD50 exposure was assessed. Due to the toxicity 
of the LD50 concentrations no colonies formed, reducing the concentration to an LD25 also 
produced no colonies due to cell death. The reason for this observation may be related to 
cis and dox causing cell death via DNA intercalation. Therefore, cell death is delayed until 
cell division occurs and the LD50 concentrations obtained from the dose response curves 
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overestimate the number of living cells. Allowing cells to recover from cis and dox exposure 
before assessing the cell death could have been used to minimise this effect. Another factor 
which may be important for cell resistance to chemotherapeutics is interaction with 
surrounding cells. It was found that after cells were exposed to cis and dox and re-seeded 
at high density, colonies would survive for a short period (9 days) if they made contact with 
surrounding cells. Surviving cells had a fibroblastic morphology with dendrites connecting 
cells to one another. A similar observation has been observed OS cell lines in response to 
MTX treatment, whereby the surviving cells had a fibroblastic appearance and were 
characterised by the presence of dendrite-like structures (Tang et al., 2011).  
 
Cis and dox exposure enhanced the PE auto-fluorescence of treated cells, making analysis 
of CSC markers impractical because this change in cell appearance would mask that of cells 
stained with fluorophores and dyes utilising the PE channel. Flow cytometry analysis of 
either CD44 expression of the presence of dead cells (based on propidium iodide staining) 
was inaccurate, as both the CD44 PE conjugated antibody and prodidium iodide required 
the PE channel for analysis. As a consequence the flow cytometry analysis of cis and dox 
treated cells was abandoned. 
 
MTX has been successfully used to enrich a population of putative OS CSC with enhanced 
clonogenicity and CD117 expression in U2OS and MG63 cell lines (Tang et al., 2011). The 
same experimental design was used in section 4.4, where cells were exposed to MTX and 
then re-seeded at low density. The concentration of MTX used by Tang et al (2011) of 660 
nM and 220 nM, formed no colonies so a concentration of 5 nM and 50 nM was used 
instead. The reason for this discrepancy is unknown, MTX was sourced from the same 
supplier, therefore, MTX batch variation could be contributing to this observation although 
unlikely. The appearance of cells which survived in 50 nM MTX had a fibroblastic 
appearance as observed by Tang et al (2011) in response to high (220 nM and 660 nM) MTX 
concentrations. However, only MCF7 and MG63 produced colonies in the 50 nM MTX, and 
no difference in colony size was observed across the MTX concentrations. This suggests 
that the MTX treated cells have the same growth rates as untreated cells. The colony 
hierarchies can be used to assess the presence of putative CSC through the identification 
of holoclones (Li et al., 2008). Using this method MTX treated cells were compared to 
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identify if exposure increased the presence of putative CSC. Across all cell lines tested no 
significant increase in holoclones or any other hierarchy was observed suggesting that MTX 
is not selecting for a specific colony hierarchy. Within HOS a decrease in holoclones was 
observed in response to 5 nM MTX, this indicates that HOS holoclones have an enhanced 
sensitivity to MTX. Holoclones have been identified to contain CSC in the prostate cancer 
cell line PC3 (Li et al., 2008), if CSC also reside in HOS holoclones, this could account for this 
cell line having the lowest MTX LD50 because MTX induced loss of CSC would inhibit HOS 
growth and survival. If this hypothesis is correct it would indicate that ALDH is not a CSC 
marker in HOS, because ALDH+ cells were present in all three colony hierarchies (Section 
3.6.1).  
 
The study by Tang et al (2011) found that MTX treated U2OS cells had an increased 
expression of CD117 and stro-1 and additionally ALDH expression has been found to confer 
MTX resistance (Takebe et al., 2001). To identify if exposure to MTX enriched for expression 
of these putative CSC markers after MTX treatment, cells were stained for CSC marker 
expression and analysed using flow cytometry. CD117 expression was enhanced in both 
U2OS and MG63 as neither cell line expressed the protein without MTX, whereas both 5 
nM and 50 nM MTX treament led to the emergence of a CD117 population. In MG63 the 
CD117 population was largest at 5 nM with 0.45 % of cells expressing the marker and then 
significantly decreased at 50 nM to 0.02 %. U2OS contained a CD117 population of 
approximately 0.1 % at both 5 and 50 nM. Possible mechanisms through which OS CD117 
expressing cells resist chemotherapeutics is via increased expression of ATP binding 
cassette transporters. This has been identified in OS and has been implicated in the efflux 
of chemotherapeutics and development of tumours with multi-drug resistance in CD117 
expressing cells (Adhikari et al., 2010).  
 
ALDH expression was increased 20 fold in HOS at all concentrations of MTX compared to 
other cell lines, which reflects the large population of ALDH expressing cells present within 
HOS (section 3.2.2). HOS was the only cell line which did not have an increase in ALDH 
expressing cells in response to MTX. This suggests that either HOS ALDH expressing cells do 
not have enhanced MTX resistance or alternatively the high ALDH expression observed in 
HOS (Section 3.2.2) may be due to its deregulated expression, therefore, is unable to be 
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elevated in response to chemotherapeutics. In contrast MG63, U2OS and MCF7 all had an 
increase in ALDH expression at 50 nM MTX, with MG63 also presenting an increase at 5 nM 
MTX. Therefore ALDH expression in these cell lines appears to be related to MTX resistance. 
ALDH has been proposed to confer chemotherapeutic resistance in OS via drug 
detoxification, enhanced DNA repair mechanisms and overexpression of cell membrane 
drug efflux transporters (Honoki et al., 2010).  
 
The observed increase in ALDH expression in response to MTX appears to be a result of the 
experimental design. Cells were seeded at a high density (15600 cells/cm2) allowed to 
attach for 24 hours before MTX was added to cells and exposed for 5 days, cells at low 
concentrations of MTX would become over confluent, to test whether this over confluency 
effects ALDH expression cells were seeded at a range of densities and then grown for 6 
days before analysing ALDH expression. In both MG63 and MCF7 cell lines increasing 
density was found to decrease ALDH expression. Interestingly MG63 had lower expression 
at 5263 cells/cm2, whilst MCF7 did not, which may represent the faster rate of MG63 
division which allows it to become confluent at the lower cell density. This observation also 
occurs when OS cell lines are murine xenotransplanted, as a dramatic reduction in ALDH 
expression is observed in the resulting in vivo derived tumours than the original cell line 
(Wang et al., 2011). The decrease in ALDH expression was attributed to the change in 
growth conditions during xenotransplantation, however, the results in this chapter suggest 
that cell density is also a contributing factor. At high cell density ALDH expression is 
decreased, the mechanism by which ALDH expression is controlled could be via a cytokine 
network. In breast cancer IL-8 signaling via phosphoinositide 3-kinase has been found to 
enhance the presence of ALDH expressing CSC (Singh et al., 2013). Targeting IL-8 could 
therefore provide a mechanism to target CSC (Ginestier et al., 2007). 
 
To assess whether MTX exposure could increase the presence of putative CSC, a 
sarcosphere assay was used to test the sphere forming ability of MG63 after MTX exposure. 
MG63 was selected because of its ability to form secondary sarcospheres (section 3.7.2) 
and the enrichment of both ALDH and CD117 expressing cells in response to MTX. In OS 
cell lines increased sarcosphere forming ability correlated with enhanced tumourigenic 
capabilities in vivo (Rainusso et al., 2011). The sarcosphere assay therefore provides a 
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method for identifying if the increased expression of CSC markers is related to an increased 
presence of putative CSC. Results from the previous chapter demonstrate that large 
sarcospheres contained a higher proportion of cells expressing the putative CSC marker 
ALDH (Section 3.8.1), which indicates that ALDH expressing cells may drive sarcosphere 
growth. Images taken of primary sarcospheres from cells treated without MTX and 5 nM 
MTX, demonstrated both conditions produced sarcospheres with the same spherical rough 
appearance, however 50 nM treated cells produced less regular sarcospheres shapes which 
were not spherical. MG63 has been found to contain a heterogenous population of cells all 
with varying tumourigenicities, drug resistance and holoclonal morphologies (Lou et al., 
2010). Therefore, the change in shape of 50 nM MTX sarcospheres could reflect the 
selection of a particular MG63 drug resistant subpopulation. MTX 5 nM treated MG63 cells 
produced larger primary sarcospheres than 0 nM and 50 nM MTX treated cells. This 
observation suggests that exposure at 5 nM MTX enriches spherical colony forming cells, 
however the same effect is not observed at 50 nM MTX. Upon passage of these 
sarcospheres and subsequent growth of secondary sarcospheres, the presence of 
increased spherical colony formation was lost and both 5 nM and 50 nM MTX treatments 
resulted in similar sarcosphere formation. Tang et al (2011) found that 220 nM and 660 nM 
MTX treatment also led to increased sarcosphere formation of MG63 cells, however, only 
primary colony formation was assessed. Therefore, MTX may transiently increase the 
presence of sarcosphere forming cells, which is lost upon passage and growth of secondary 
sarcospheres. OS cell lines have been demonstrated to contain putative CSC which are 
quiescent (Rainusso et al., 2011), in breast cancer mammospheres can only be passaged 5 
times before growth is inhibited through quiescence (Dey et al., 2009). Passaging of MG63 
sarcospheres, therefore, may lead to CSC cells undergoing quiescence which could account 
the reduction in sarcosphere forming efficiency in 5 nM MTX treated secondary 
sarcospheres.   
 
MTX 5 nM treated MG63 cells not only had enhanced primary sarcosphere formation but 
also increased expression of CD117 and ALDH. Both CD117 and ALDH have been implicated 
in OS CSC and enhanced drug resistance (Adhikari et al., 2010, Wang et al., 2011, Honoki et 
al., 2010), therefore the expression of these markers within the cell lines may correlate 
with drug resistance. This hypothesis was tested using Pearson’s correlation coefficient cell 
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line LD50 concentrations were correlated with CSC marker expression (ALDH and CD117) 
(section 3.2). CD117 expression correlated weakly with dox and MTX, but produced a 
strong negative correlation with cis, suggesting that CD117 expression is not related to drug 
resistance. This poor correlation may be related to highly expressing CD117 cell lines such 
as 143B not displaying resistance to these drugs. To explore this hypothesis 143B with the 
highest CD117 according to flow cytometry analysis expression (6.36 %) (Section 3.2.3) was 
removed from analysis, which produced weaker correlations and produced Pearson’s 
correlations closer to 0 for all chemotherapeutics. CD117 expressing cells from this cell line 
appeared to be more sensitive to the drug exposure, therefore producing low LD50 values. 
CD117 expression correlated weakly with dox nd MTX LD50, therefore, CD117 expressing 
cells are susceptible to cis but not dox or MTX, indicating that CSC could be targeted using 
specific drugs. Cell line ALDH expression correlated with a weak negative correlation with 
cell line LD50 for all drugs tested, no statistical significance was observed for any of the 
correlations, suggesting increased cell line ALDH expression has no impact upon 
chemotherapeutic resistance.  
 
ALDH expression has been demonstrated to enhance chemotherapeutic resistance (Honoki 
et al., 2010), the mechanism by which ALDH isoenzymes provide chemoresistance has not 
been fully elucidated for all ALDH isoenzymes. ALDH enzymes detoxify aldehyde 
compounds, which may be common drug resistance mechanism to all ALDH enzymes 
(Moreb et al., 2012). In the human corneal cell ALDH3A1 is also localised to the nucleus and 
in response to DNA damage has been found to inhibit cell division and promote cell survival 
(Pappa et al., 2005). It is unclear if all ALDH enzymes are involved with cell cycle control, 
however, if so this may indicate that ALDH enzymes are intricately involved with 
chemoresistance. The hypothesis that ALDH positive cells are more resistant to 
chemotherapy can be tested using the specific ALDH inhibitor DEAB, which has been 
identified as a competitive inhibitor of ALDH1 and ALDH2 enzymes (Moreb et al., 2012). 
This procedure has been successfully used by Crocker and Allan (2012), they exposed 
ALDH+/CD44+  breast cancer cells and found that this sensitised them to dox and the mitosis 
inhibitor paclitaxel (Croker and Allan, 2012).  To analyse whether DEAB has the same effect 
in OS cell lines the toxicity of DEAB for the selected cell lines (HSO, MG63, U2OS and MCF7) 
was identified. The LD50 for DEAB identified MG63 as the most resistant with an LD50 of 
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115.83 µMol and MCF7 as the least with an LD50 of 81.30 µMol. Interestingly ALDH 
population size did not reflect sensitivity to DEAB, HOS with the largest population of ALDH 
positive cells > 60 % (Section 3.2.2) was not the most susceptible to DEAB with the second 
largest DEAB LD50 of 94.03 µMol. In comparison MG63 with one of the smallest ALDH 
populations (2.14 %), was most resistant to DEAB. The Aldefluor kit is a pan ALDH detection 
kit. Therefore, the specific ALDH detected is not known ,however, it would be of interest to 
analyse if OS cell lines express the same ALDH isoforms and whether different isoforms are 
responsible for OS chemotherapy resistance. 
 
To identify if ALDH expression through DEAB sensitised cell lines to chemotherapeutics, OS 
cell lines and MCF7 were exposed to their DEAB LD50 concentration in combination with 
the chemotherapuetic LD25. When combining DEAB with MTX an increase in cell death was 
only observed in MG63, no increase in cell death was observed in the remaining cell lines 
(HOS, U2OS and MCF7). Suggesting that only MG63 ALDH cells comprise a MTX resistant 
population of cells. When co-incubating DEAB with cis or dox (DEAB + cis/dox) the OS cell 
lines responded differently. HOS ALDH cells were sensitive to dox, whilst U2OS to cis, 
suggesting that the ALDH cells present within each OS cell line may be sensitive to a 
different drug. The CSC phenotype within cancer subtypes or even the same subtype is not 
uniform (Visvader and Lindeman, 2008), within breast cancer cell lines ALDH was not found 
to be a marker of increased tumourigenicity in all cell lines tested (Hwang-Verslues et al., 
2009).  Breast CSC have also been found to be more sensitive than the bulk population of 
cells to cyclophosphamide, treatment with this drug reduced the ALDH population of cells 
and led to reduced tumour formation (Zielske et al., 2010). These findings highlight the 
highly variable nature of CSC within the same cancer types and different responses they 
can have to specific drugs. 
 
A limitation of DEAB exposure as a mechanism for reducing the presence of putative CSC, 
is the affect DEAB has upon the balance between CSC division and differentiation. Assuming 
ALDH expressing cells are CSC, treating them with DEAB may not be an efficient mechanism 
for reducing the CSC population. Breast cancer studies have demonstrated that treating 
cell lines with DEAB actually increases the CSC population, this finding appears 
counterintuitive but could be explained due to ALDH being a requirement for early 
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differentiation. Therefore inhibition of this enzyme results in the inhibition of 
differentiation and an increase in the size of the CSC population (Ginestier et al., 2009).   
 
To summarise the findings of this chapter OS cell lines display heterogenous sensitivities to 
the chemotherapeutic agents (cis, dox and MTX) and P53 status may be a determining 
factor. Functional P53 may protect against cis conversely P53 loss may contribute to dox 
resistance. Previous studies have demonstrated that MTX exposure enriches cells with CSC 
properties (Tang et al., 2011), results from this chapter show that MG63 cells treated with 
5 nM MTX have an increased primary sarcosphere proliferation rate. In response to MTX 
treatment both U2OS and MG63 increased expression of the putative CSC markers CD117 
and ALDH. The increased ALDH expression was found to be attributed to increased cell 
density and not MTX in MG63 and MCF7. To further examine the role ALDH plays in 
chemotherapeutic resistance the ALDH inhibitor DEAB was combined with LD25 
concentrations of cis, dox and MTX. In response to DEAB MG63 was sensitised to MTX, 
U2OS to cis and HOS to dox. This finding highlights that the ALDH expressing cells within 
different OS tumours are sensitive to different classes of chemotherapeutics.  
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5.1 Introduction 
The development and maintenance of all cells within every organ of the body is tightly 
regulated by a complex network of protein signaling molecules (ligands) (Orsi and Tribe, 
2008). These ligands are recognised by cell membrane spanning receptors, which allow 
signal transduction to occur upon ligand receptor interaction. The location of the cell which 
releases the ligand will dictate the type of cell signaling, therefore four types of signaling 
can occur; autocrine, juxtacrine, paracrine and endocrine (Singh and Harris, 2005) (Section 
1.4).   
Bone is a highly specialised tissue which plays a crucial role in internal support and 
maintaining calcium homeostasis (Weiner et al., 1999). Bone is composed of three cell 
types; osteoblasts which can regulate the mineralisation of bone and are found near the 
bone surface along with osteoclasts which are responsible for bone resorption. Osteoblasts 
can differentiate to become osteocytes which are found within the bone interior, these 
cells are responsible for the synthesis of the bone matrix and to a lesser extent bone 
resorption (Bilezikian et al., 2008). Therefore, signaling networks within bone are focused 
on ensuring bone resorption and synthesis is balanced. For example Wnt ligands have been 
found to affect bone density in mice through their effect on osteoblasts (Bodine et al., 
2004), whereas osteoblasts have been found to release RANK which increases osteoclast 
bone resorption (Burgess et al., 1999) and osteoprotegerin which inhibits this process 
(Schoppet et al., 2002) (Section 1.4.1).  
Cell signaling that stimulates cell proliferation is a common mechanism by which cancer 
cells promote growth. Cancer cells have been found to utilise a variety of signaling 
mechanisms (section 1.4.2). Holoclones from the OS cell line HOS have been found to 
secrete a paracrine factor which helps support the growth of paraclonal cells, which 
suggests that differentiated OS cells are reliant upon progenitor cells for survival, however 
the identity of this factor was never established (Fawdar, 2010). A number of cytokines 
involved in tumour progression have been identified in OS including 
phosphoglucludingcose isomerase (PGI), which has been found to enhance migration and 
growth of the cell line MG63 (Niinaka et al., 2010) (Section 1.4.3). Hepatocyte growth 
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factor, which is released by several OS cell lines (Cal72, MG63 and SaOS-2) has been 
hypothesised as a mechanism to promote the aggressive nature of OS tumours (Rochet et 
al., 1999). 
 
Aims 
HOS holoclonal cells have been shown to secrete a paracrine factor which supports the 
growth and survival of paraclones (Fawdar, 2010), however, the cytokine network 
responsible for this observation was not established. In order to elucidate the cytokines 
responsible for OS growth a panel of OS cell lines will be used to analyse media conditioned 
by the cell lines (cell line conditioned media) for the presence of growth factors. 
Conditioned media with growth enhancing properties will be screened for the presence of 
candidate proteins. The specific objectives of this study which will be tested upon a panel 
of 8 OS cell lines and the breast cancer cell line MCF7 as a control, are as follows: 
 Assessment of OS cell lines and MCF7 proliferation rates in response to conditioned 
media taken from the same or different cell lines. 
 Identification of candidate growth factors through the cytokine expression analysis 
of growth enhancing conditioned media. 
 Analysis of the expression profile of candidate growth factors from cell lines. 
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5.2 Paracrine signaling in OS cell lines and MCF7 in response to 24 hour conditioned 
media 
To assess whether the OS cell lines utilised paracrine signalling to enhance growth, each 
cell line was grown at low cell density in the absence and presence of its own conditioned 
media (conditioned media was collected after 24 hours exposure to confluent cells) 
(Section 2.4.1). Upon reaching a suitable colony size (approximately 1 - 2 mm) colonies 
were fixed and stained with crystal violet and colony size was assessed using ImageJ 
(Section 2.4.2). The majority of OS cell lines produced a significant increase in colony size 
in response to conditioned media (Figure 5.1), however, 143B, HOS, and MCF7 did not 
respond to their conditioned media whereas MG63 produced the largest increase in colony 
size in response to its own conditioned media.  
 
To determine if the paracrine effect is unique to each cell line the conditioned media from 
a selected cell line was tested upon another. The media from two cell lines which 
responded with an increase in colony size (U2OS and MG63) were compared with a non-
growth enhancing conditioned media (HOS and MCF7) in the following cell lines; MG63, 
U2OS, HOS and MCF7. U2OS and MG63 conditioned media produced equal growth 
enhancement in responsive cell lines (MG63 Figure 5.2.A and U2OS Figure 5.2.B). U2OS 
media was found to evoke a significant increase in growth of the previously unresponsive 
HOS cell line (Figure 5.2.C) and also in MCF7 (Figure 5.2.D), suggesting that U2OS secretes 
a growth factor which is common to other OS cell lines and also the unrelated MCF7 cells. 
In all OS cell lines tested MCF7 conditioned media had no effect on colony formation, 
suggesting that it lacks the expression of a growth enhancing factor. Interestingly, HOS 
conditioned media, which did not enhance growth of HOS and MCF7, produced an increase 
in growth in MG63 and U2OS (Figure 5.2.A and 5.2.B). This Indicates that HOS may produce 
low levels of a growth factor which may only be detected by MG63 and U2OS. 
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Figure 5.1: Average colony size of OS cell lines and MCF7 exposed to either conditioned 
(collected after 24 hours exposure to confluent cells) or unconditioned media. Only 143B, 
HOS and MCF7 did not respond to their conditioned media and had no significant increase 
in colony size. All OS cell lines and MCF7 tested have been analysed by measuring colony 
size using ImageJ®.  Data presented as mean and standard deviation, n=3 (* = 0.05, ** = 
0.005 ***= 0.0005; unpaired T-test). 
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(A) MG63               (B) U2OS 
  
 
(C) HOS                                    (D) MCF7     
  
 
     
     
Figure 5.2: Response of HOS, MG63, U2OS and MCF7 cells to 24 hour conditioned media 
from growth increasing and non-growth responsive conditioned media. MG63 (A), U2OS 
(B), HOS (C) and MCF7 (D) cell lines tested using unconditioned and conditioned media from 
each cell line to assess the growth enhancement of each cell line. Colony size was assessed 
using ImageJ. Data presented as mean and standard deviation (n=3), significance calculated 
by comparing to MCF7 conditioned colony size (* = <0.05, ** = <0.01; Tukey’s post hoc 
analysis). 
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5.3 Assessment cell density during 24 hour media conditioning for HOS, MG63, U2OS and 
MCF7 cells 
 
The cell density during the conditioning of the media was assessed in order to determine if 
the growth enhancement of conditioned media from MG63 and U2OS (Figure 5.2) was 
related to an increased number of cells at confluency. After 24 hours of conditioned media 
collection (Section 2.4.1) HOS, MG63, U2OS and MCF7 cells density was assessed through 
cell trypsinisation and counting using a haemocytometer. It was found that MCF7 
contained a higher density of cells compared to the OS cell lines (Figure 5.3). The OS cell 
lines all contained similar cell densities, suggesting that the number of cells present is not 
responsible for the variation in growth enhancing properties of conditioned media.    
 
 
 
 
 
 
Figure 5.3: Cell density of HOS, MG63, U2OS and MCF7 for 24 hour conditioned media 
collection. Cell lines were grown under the same conditions as used for conditioned media 
collection. After reaching confluency media was changed and after 24 hours cell density 
was assessed. Data presented as mean and standard deviation (n=3), significance 
calculated by using Tukey’s post hoc analysis and comparing OS cell lines to MCF7 (p ** = 
< 0.01). 
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5.4 Analysis of paracrine growth signaling in sarcoma cell lines 
To identify if non-osteosarcoma sarcoma cell lines express and respond to paracrine growth 
factors, conditioned media from three different sarcoma cell lines was compared to U2OS 
conditioned media (which enhanced growth in all cell lines tested (Figure 5.2)). The 
sarcoma cell lines selected were HT1080 (fibrosarcoma), SKLNS1 (leiomyosarcoma) and 
RDES-1 (Ewing’s sarcoma). Each was tested with its own conditioned media and U2OS 
conditioned media, however, RDES-1 cells detached from the growth surface making 
colony size assessment impractical due to absence of colony formation. HT1080 cell 
conditioned media was found to produce a greater increase in its own colony size 
compared to U2OS conditioned media (Figure 5.4.A) indicating that it also expressed a 
growth factor, therefore, media from this cell line was also used to test on SKLNS1. 
Interestingly no significant increase in colony size was observed in SKLNS1 cells in response 
to U2OS or HT1080 but its own conditioned media increased colony size (Figure 5.4.B). 
RDES-1 conditioned media did not produce an increase in growth in U2OS cells suggesting 
it does not produce a paracrine growth factor, however HT1080 and SKLNS1 produced an 
equivalent increase in colony size when compared to U2OS conditioned media (Figure 
5.4.C).  
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   (A) HT1080 cells             (B) SKLNS1 cells 
 
    
     (C) U2OS cells 
 
Figure 5.4: Growth response of sarcoma cell lines (HT1080 and SKLNS1) and U2OS to 
conditioned media from U2OS and sarcoma cell lines. HT1080 cells (A), SKLNS1 cells (B) 
and U2OS cells (C) were tested with conditioned media form the same cell line and 
alternate cell lines to identify growth effected by the conditioned media. All sarcoma cell 
lines tested have been analysed by measuring colony size using ImageJ. Results tested in 
triplicate (n=3), data presented as mean and standard deviation. Statistical significance 
calculated by comparing to unconditioned colony size (* = <0.05, ** = <0.01 Tukey’s post 
hoc analysis). 
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5.5 Analysis of U2OS cell confluency and cell exposure time upon the growth enhancing 
properties of conditioned media  
Conditioned media was collected from U2OS cells once they reached approximately 100 % 
confluency (Section 2.4.1), however, this method does not take in to consideration exact 
cell densities. Therefore, to identify if cell density may contribute to variation in the growth 
potential of the conditioned media, media was collected from confluent cells and lower 
confluencies (70 and 90 %). U2OS cells were selected because this cell line produces a 
robust paracrine growth response in previous experiments (Figure 5.2 and 5.4). Results 
show that conditioned media from U2OS cells at 70 % and 90 % did not significantly alter 
the colony size compared to 100 % conditioned media, indicating that although a lower 
concentration of paracrine growth factors may be present in the lower confluencies this 
has no discernible impact on growth rates (Figure 5.5). The length of time in which the 
media was exposed to confluent U2OS cells was also tested to identify if increased time of 
conditioned media cell exposure affected colony growth rates. Media which had been 
exposed to U2OS cells for longer periods was found to produce significantly larger colonies 
(Figure 5.6).  
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Figure 5.5: Growth effect of U2OS conditioned media taken after 24 hours exposure to 
U2OS cells at 70, 90 and 100 % confluency. Conditioned media collected from U2OS cells 
at 70, 90 and 100 % produced colonies of an equivalent size. U2OS colony size analysed 
using ImageJ®. Results tested in triplicate, data presented as mean and standard deviation. 
No significant difference observed (Tukey’s post hoc analysis). 
 
 
 
Figure 5.6: Growth effect of U2OS conditioned media collected from confluent U2OS cells 
after 24, 48 and 72 hours. Compared to 24 hour U2OS conditioned media, media taken 
from cells after 24 and 72 hours produced significantly larger colonies. U2OS colony size 
has been assessed using ImageJ®. Results tested in triplicate, data presented as mean and 
standard deviation, significance calculated by comparing to unconditioned colony size (* = 
<0.05, ** = <0.01 Tukey’s post hoc analysis). 
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5.6 Paracrine signaling in OS cell lines and MCF7 in response to 24 hour and 72 hour 
conditioned media 
Conditioned media taken from U2OS cells after 72 hours produced a greater enhancement 
of colony size compared to 24 hour conditioned media (Figure 5.6), therefore, 72 hour 
conditioned media from the cell lines HOS, MG63, U2OS and MCF7 was analysed to identify 
if it also had altered growth enhancing properties compared to 24 hour conditioned media.  
Compared to MCF7 conditioning both MG63 and U2OS cells responded with increased 
colony size in response to MG63 and U2OS conditioned media at 24 and 72 hours (Figure 
5.7.A and figure 5.7.B), HOS conditioned media increased MG63 colony size to the same 
size at 24 and 72 hours of conditioning and U2OS cells only responded to 24 hour HOS 
conditioned media. As was observed in 24 hour media HOS and MCF7 cells had increased 
colony size in response to U2OS 72 hour conditioned media, however, this was not a 
significant increase for U2OS 72 hour conditioned media due to 72 hour MCF7 conditioned 
media also increasing HOS and MCF7 cell growth (Figure 5.7.C and 5.7.D). In contrast to 24 
hour conditioned media, 72 hour MG63 conditioned media resulted in the largest colony 
sizes in HOS cells. This suggested that after 72 hours of MG63 media conditioning the 
concentration of a particular growth factor, had increased to a level which was capable of 
enhancing the colony size of HOS.      
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 (A) MG63                 (B) U2OS 
   
  (C) HOS                          (D) MCF7 
   
Figure 5.7: Response of HOS, MG63, U2OS and MCF7 cells to 24 hour and 72 hour 
conditioned media. MG63 (A), U2OS (B), HOS (C) and MCF7 (D) tested using unconditioned 
and conditioned media from each cell line to assess the growth enhancement of each cell 
line. All cell lines tested (MG63, U2OS, HOS and MCF7) have been analysed by measuring 
colony size using ImageJ®. Average unconditioned colony size was subtracted from 
conditioned colony. Data presented as mean and standard deviation, n=3, significance 
calculated by comparing to MCF7 colony size (* = <0.05, ~ = <0.01; Tukey’s post hoc 
analysis). 
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5.7 Analysis of the growth response of U2OS and HOS cells to 72 hour conditioned media 
within a 96 well assay 
 
A 96 well growth assay was developed due to the large quantities of media required for the 
colony formation assays (55 cm2 growth area) and to minimise any inaccuracies associated 
with manually measuring colonies to assess growth. This assay used minimal volumes of 
media (100 µl), which allowed the number of replicates for each condition to be increased 
and cell growth to be assessed by measuring the well absorbance following staining with 
MTT (Section 2.4.3). To analyse the growth response in a 96 well assay, 72 hour conditioned 
media from MG63, U2OS, HOS and MCF7 was tested upon U2OS and HOS cells. As was 
observed in the colony formation assay (Figure 5.7) U2OS and MG63 conditioned media 
increased the growth rate of U2OS cells using the 96 well assay, however, HOS conditioned 
media had no impact upon growth (Figure 5.8.A). HOS cells only responded with increased 
growth to U2OS conditioned media (Figure 5.8.B) using the 96 well assay, which is in 
contrast to the colony formation assay, where it was observed that MG63 conditioned 
media also increased HOS growth (Figure 5.7.C). These results demonstrate that although 
a 96 well assay format may be less sensitive to growth responses, it provides an efficient 
assay for the assessment of growth in response to conditioned media. 
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      (A) U2OS 
 
 
                       (B) HOS 
 
Figure 5.8: Response of HOS and U2OS cells to 72 hour conditioned media from HOS, 
MG63, U2OS and MCF7 in a 96 well assay. To assess the practicality of a 96 well 
conditioned media assay U2OS (A), and HOS (B) cells were tested using unconditioned 
(complete media) and 72 hour conditioned media from HOS, MG63, U2OS and MCF7 to 
assess the growth of each cell line. All cell lines tested (MG63, U2OS, HOS and MCF7) have 
been analysed by staining cells with MTT and measuring absorbance at 530 nm. Data 
presented as mean and standard error, each sample tested 16 times in three separate 
experiments (n= 3 independent replicates), significance calculated by comparing to MCF7 
conditioned colony size (* = <0.05, ** = <0.01 Tukey’s post hoc analysis). 
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5.8 Assessment of colony hierarchy frequency in response to conditioned media in HOS, 
U2OS and MCF7 cells 
 
The colony hierarchies identified by Locke et al., (2005) have been used to identify prostate 
CSC in the cell line PC3, through the isolation of cells from the holoclonal morphology (Li et 
al., 2008) (Section 1.2.3). In OS MG63 holoclones possess enhanced clonogenicity and 
proliferated more rapidly (Lou et al., 2010). Based on these findings it could be 
hypothesised that the increased colony size in response to U2OS conditioned media (Figure 
5.7), could be due to a paracrine factor which is maintaining cells in a holoclonal 
morphology. To test this hypothesis cell lines (HOS, U2OS and MCF7) were seeded at a 
clonal density (2 – 4 cells cm2) and exposed to 24 hour conditioned media (from HOS, MG63, 
U2OS and MCF7 cells) for 9 – 14 days (approximately 100 colonies would form per plate), 
after which the first 30 colony hierarchies from each plate were recorded using an inverted 
microscope (Section 2.4.2).  
 
An observation which was consistent in all three cell lines tested (HOS, U2OS and MCF7) 
was an increased paraclone frequency in response to MCF7 conditioned media (Figure 5.9). 
MCF7 conditioned media also caused a decrease in meroclone formation in both HOS and 
MCF7 (Figure 5.9). In response to MG63 conditioned media HOS cells responded with a 
decrease in holoclone frequency (Figure 5.9.A), the same response was not observed in 
U2OS, which contained an enhanced frequency of holoclones and meroclones in response 
to its own conditioned media as well as HOS and MG63 conditioned media (Figure 5.9.B). 
In addition, these same conditioned media (HOS, MG63 and U2OS) also produced 
enhanced colony formation in U2OS (Figure 5.7), therefore, U2OS appears to respond to 
paracrine factors from these cell lines which enhance the presence of holoclonal and 
meroclonal colonies. 
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(A) HOS 
 
       (B) U2OS 
 
       (C) MCF7 
 
Figure 5.9: Colony hierarchy frequency in response to 24 hour conditioned media in HOS, 
U2OS and MCF7 cell lines. After exposure to conditioned media 30 colony hierarchies were 
recorded in HOS (A), U2OS (B) and MCF7 (C) cell lines. Data presented as mean and 
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standard deviation, n=3, significance calculated by comparing to unconditioned colony 
frequency (* = <0.05, ** = <0.01 Tukey’s post hoc analysis). 
 
5.9 Cytokine profiling of HOS, MG63, U2OS and MCF7 72 hour conditioned media 
Cytokines have been found to increase proliferation in carcinomas (Westley and Rochefort, 
1980, Loberg et al., 2007), sarcomas (Li et al., 2011), leukaemia (Digel et al., 1989) and 
neuroblastoma (Airoldi et al., 2004). In order to identify candidate cytokines proteins which 
may confer enhanced growth in OS cell lines and MCF7, 72 hour conditioned media from 
HOS, MG63, U2OS and HOS were analysed using a human cytokine profiler (Section 2.5.1). 
The array detects 36 different cytokines which are commonly used in cell signaling 
networks. U2OS and MG63 conditioned media were selected because U2OS consistently 
produced increased growth in all cell lines tested and MG63 media enhanced growth in 
U2OS and MG63 cells (Figures 5.7). It was predicted therefore that the conditioned media 
from both of these cell lines will contain a growth factor that is not present in MCF7 
conditioned media (as this did not produce growth enhancement). The response to HOS 
conditioned media consistently produced growth enhancement in U2OS and MG63, never 
in HOS and inconsistently in MCF7 (Figures 5.7). These findings suggest that although HOS 
may express a growth factor it may be at a lower concentration than MG63 and U2OS.  
Based on the observed growth promoting effects of the conditioned media, cytokines 
which could be considered candidate growth factors must be present within MG63 and 
U2OS, absent within MCF7 and weakly expressed in HOS.  The cytokine array identified two 
proteins which fulfilled this criteria. Both IL-8 and CCL-2 were expressed in U2OS and MG63 
media, weakly in HOS and absent in MCF7 (Figure 5.10). Analysis of the pixel density of the 
each spot identified in the cytokine array confirmed the expression profile of CCL-2 and IL-
8, with MG63 producing a pixel density above 6000 for IL-8 and CCL-2 and U2OS produced 
pixel densities of 4977 for IL-8 and 5637 for CCL-2 (Figure 5.11). HOS conditioned media 
contained lower concentrations and produced pixel densities of 336 for IL-8 and 263 for 
CCL-2 and neither proteins were detected in MCF7 conditioned media (5.11). MCF7 
conditioned media was found to contain less proteins within its conditioned media 
compared to the OS cell lines (Figure 5.11). All cell lines expressed IL-5, IL-23, macrophage 
inhibitory factor (MIF), serpin E1 and RANTES (also known as CCL-5). HOS was found to 
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secrete the greatest number of cytokines, but the majority were only present at low 
concentrations which is evident because of the low relative pixel density (< 500) of each 
spot (Figure 5.11).   
 
(A) MG63 
 
(B) U2OS 
 
(C) HOS 
 
(D) MCF7 
 
   
Figure 5.10: Images of the cytokine array of HOS, MG63, U2OS and MCF7 72 hour 
conditioned media.  Using R&D systems human cytokine profiler (Cat no. ARY005), 72 hour 
conditioned media from MG63 (A), U2OS (B), HOS (C) and MCF7 (D) was tested and exposed 
on to X-ray film for 10 mins before developing. Red rectangle denotes IL-8 location and blue 
trapezium denotes CCL-2 location, all cytokines are spotted on to the array in duplicate.   
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Table 5.1:  Position of cytokines in cytokine array used in figure 5.10. 
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Table 5.1: Continued overleaf 
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Figures 5.11: Densitometry analysis of cytokines present on the cytokine array of HOS, 
MG63, U2OS and MCF7 72 hour conditioned media. Cytokines which were present in the 
cytokine array from MG63, U2OS, HOS and MCF7 72 hour conditioned media were tested 
for pixel density using ImageJ. In order to normalise all cytokine spots with background 
staining, the pixel density of the blot around each spot was analysed and the total 
background pixel density was averaged and subtracted from each positive result, to 
calculate the relative pixel density.  Data presented as mean and standard deviation, n=2. 
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5.10 Expression profile of CCL-2 and IL-8 from sarcoma cell lines and MCF7 
The cytokine array (Figure 5.10) identified the proteins IL-8 and CCL-2 as candidate growth 
promoting factors in OS conditioned media. Commercially available ELISA kits for IL-8 and 
CCL-2 (BioLegend®) (Section 2.5.2) were used In order to establish the concentration of the 
cytokines within 24 hour and 72 hour conditioned media (Appendix II). 
The pattern of IL-8 expression as measured by ELISA did not correlate with the conditioned 
media growth enhancement observations (Figure 5.12.B). 143B cells which was found not 
to produce an enhanced colony sizes in response to its own conditioned media was found 
to secrete more IL-8 than HT1080, SKLNS1 and U2OS (Figure 5.13), which all produced 
conditioned media which increased colony size (Figure 5.12.B). Both 24 hour and 72 hour 
conditioned media from MG63, U2OS, HOS and MCF7 were reciprocally tested upon each 
cell line to identify if the growth enhancing properties of each conditioned media were 
observed in the other cell lines (Figure 5.7). U2OS 24 hour conditioned media was found to 
be the most growth enhancing media when compared to MG63 and enhanced the growth 
of all cell lines tested, whereas MG63 conditioned media had no effect on HOS or MCF7 
(Figure 5.7). U2OS 24 hour and 72 hour conditioned media IL-8 concentration is statistically 
lower than MG63, which would therefore indicate that IL-8 is not a growth factor (Figure 
5.14). This is supported by Pearson’s correlation coefficient analysis of IL-8 concentration 
with the change in colony size in response to a cell lines conditioned media. This produced 
a positive correlation of 0.6, however, this correlation was not statistically significant (Table 
5.2). 
CCL-2 expression was found to more closely resemble the observed growth responses to 
conditioned media. When comparing 24 hour conditioned media to the non-growth 
responsive media from 143B, it was found that all cell lines which responded with increased 
growth to their media (Figure 5.12.A) (Cal72, G292, MG63, HT1080, SKLNS1, U2OS and 
SaOS-2) contained elevated concentrations of CCL-2 compared to non-growth enhancing 
media (Figure 5.15). When analysing the 24 hour and 72 hour conditioned media of MG63 
and U2OS 24 hour conditioned media was found to contain an elevated concentration 
compared to MG63 media (Figure 5.16). As U2OS 24 hour conditioned media was found to 
enhance colony growth in all cell lines tested, whereas MG63 was unable to in HOS and 
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MCF7 (Figure 5.7), this is consistent with the growth responses observed. Interestingly 72 
hour MG63 media contained elevated quantities of CCL-2 compared to U2OS (Figure 5.16), 
HOS and MCF7 conditioned media contained a significantly lower concentration of CCL-2 
than MG63 conditioned media at 24 and 72 hours. Correlating colony growth increases 
with CCL-2 24 hour conditioned media concentration also supports CCL-2 as a candidate 
growth factor, producing a statistically significant positive correlation of 0.67 (Table 5.2).  
 
 
Figure 5.12: Analysis of CCL-2 and IL-8 concentration of conditioned media from sarcoma cell lines 
and MCF7 and the growth response of each cell line to its conditioned media. The concentration 
of CCL-2 (A) and IL-8 (B) was assessed upon 24 hour conditioned media using a commercially 
available ELISA. The change in growth rate was assessed by identifying the change in colony size of 
unconditioned colonies compared to conditioned colonies. Data presented as mean and standard 
deviation (n = 3). Statistical significance calculated by comparing to MCF7 IL-8, CCL-2 concentration 
or change in colony size (Tukey’s post hoc analysis, ~p = <0.01) 
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Figure 5.13: Concentration of IL-8 in 24 hour conditioned media from sarcoma cell lines 
and MCF7. A commercially available IL-8 ELISA was used to assess IL-8 concentration. 143B 
conditioned media had no growth enhancing effect (Figure 5.1), therefore was used for 
comparison to identify statistically significant changes in IL-8 expression. Data presented as 
mean and standard deviation, n=3, significance calculated by comparing to 143B IL-8 
concentration (* = <0.05, ** = <0.01 Tukey’s post hoc analysis). 
 
 
Figure 5.14: Comparison of IL-8 concentration of 24 hour and 72 hour conditioned media 
from MG63, U2OS, HOS and MCF7. A commercially available IL-8 ELISA was used to assess 
IL-8 concentration. Statistical significance was calculated by comparing to MG63 24 and 72 
hour IL-8 concentration. Data presented as mean and standard deviation, n=3, significance 
calculated by comparing to MG63 IL-8 concentration (** = <0.01 Tukey’s post hoc analysis). 
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Figure 5.15: Concentration of CCL-2 in 24 hour conditioned media from sarcoma cell lines 
and MCF7. A commercially available CCL-2 ELISA was used to assess CCL-2 concentration. 
143B conditioned media had no growth enhancing effect (Figure 5.12.A), therefore was 
used for comparison to identify statistically significant changes in CCL-2 expression. Data 
presented as mean and standard deviation, n=3, significance calculated by comparing to 
143B CCL-2 concentration (* = <0.05, ** = <0.01 Tukey’s post hoc analysis). 
 
 
 
 
Figure 5.16: Comparison of CCL-2 concentration of 24 hour and 72 hour conditioned 
media from MG63, U2OS, HOS and MCF7. A commercially available CCL-2 ELISA was used 
to assess CCL-2 concentration. Statistical significance was calculated by comparing 24 hour 
CCL-2 concentration to MG63 24 hour and 72 hour concentration. Data presented as mean 
and standard deviation, n=3, significance calculated by comparing to MG63 CCL-2 
concentration (* = <0.05, *** = <0.0005 Unpaired T-test). 
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 (A) CCL-2        (B) IL-8 
  
Figure 5.17: Linear regression analysis of CCL-2 or IL-8 concentration of OS cell lines and 
MCF7 24 hour conditioned media against colony size change in response to growth in 
conditioned media. CCL-2 (A) and IL-8 (B) data presented as mean values, all conditions 
tested in triplicate. 
 
 
Table 5.2: Pearson’s correlation coefficient of sarcoma cell lines and MCF7 colony size 
change in response to auto conditioning with either CCL-2 or IL-8 24 hour conditioned 
media concentration. Pearson’s correlation coefficient was calculated using graph pad (* 
= p <0.05). 
 CCL-2 
(P value) 
IL-8 
(P value) 
Pearson’s correlation 
coefficient 
0.67 
(0.04)* 
0.60 
(0.15) 
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5.11 Discussion 
In order to identify if OS cell lines and MCF7 secrete a paracrine growth factor, conditioned 
media from each cell line was used to assess its impact on colony formation. The OS cell 
lines Cal72, G292, MG63, U2OS and SaOS-2 all responded with increased colony size in 
response to their conditioned media, indicating that these OS cell lines secrete a paracrine 
factor which increases growth. Although this factor may enhance cell proliferation, its role 
in protection against apoptosis has not been established. Therefore, the paracrine factor 
can only be described as increasing growth, which is the net cellular gain after cell death 
and proliferation. 143B, HOS and MCF7 do not release or respond to a paracrine signalling 
molecule. In the subsequent experiment two cell lines which responded with increased 
growth (U2OS and MG63) were compared with two cell lines which did not respond (MCF7 
and HOS). The results indicate that the unresponsive cell line HOS could be encouraged 
grow in the presence of U2OS and MG63 conditioned media, this increase was statistically 
significant in response to U2OS conditioned media indicating it has a greater ability to 
enhance growth. This finding demonstrates that OS shares a common paracrine signalling 
factor, which is supported by the finding that HOS enhanced the growth of MG63 and U2OS 
cells. The inability of HOS conditioned media to enhance its own proliferation suggests that 
it may be less responsive to the growth factor in comparison to MG63 and U2OS.  
 
In this chapter OS conditioned media (U2OS) was found to evoke a significant increase in 
the growth of the breast cancer cell line MCF7, which suggests that the paracrine signalling 
factor released by U2OS may have an effect on multiple cancer types. MCF7 cellular 
proliferation has been demonstrated to increase in response to SDF-1 which is released by 
cancer associated fibroblasts (Orimo et al., 2005). No cell line tested responded with 
increased growth to MCF7 conditioned media, therefore, this cell line does not secrete a 
growth factor and in vivo may obtain growth signals from surrounding fibroblasts in a 
paracrine fashion. MCF7 had the highest cell density when conditioned media was 
collected as compared to MG63, U2OS, HOS and MCF7.  This indicates that the growth 
enhancing properties of conditioned media are independent of cell density. 
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To further characterise the growth enhancing potential of U2OS conditioned media, 
conditioned media collected at different cell densities and cell exposure times was 
compared. It was found that a confluency ranging from 70 % – 100 % did not alter the 
growth properties of the conditioned media but increasing the exposure time did. 
Conditioned media exposed to cells for 72 hours was found to increase growth more than 
24 and 48 hour conditioned media. Analysis of the growth enhancing properties of 72 hour 
conditioned media using reciprocal analysis of MG63, U2OS, HOS and MCF7 cells, 
demonstrated that U2OS and MG63 cells produced the same response as was observed in 
24 hour conditioned media (MG63, U2OS and HOS conditioned media increased growth of 
both cell lines). HOS and MCF7 cells responded with increased growth to U2OS media which 
was also observed in response to 24 hour media. MCF7 cells also responded with increased 
growth to HOS conditioned media and HOS cells responded to MG63 conditioned media at 
72 hours. This finding suggests that MG63 cells do secrete growth factors which can 
influence multiple cell lines, however, the concentration at 24 hours is too low to achieve 
this.  
 
In order to increase the volume of reagents required for the growth assessment of 
conditioned media, 72 hour conditioned media from the same four cells lines (HOS, MG63, 
U2OS and MCF7) was tested in a 96 well format upon HOS and U2OS cells. This assay may 
present a less sensitive assay to measure growth than assessing colony size as HOS 
conditioned media had no effect upon on U2OS. In addition HOS cells did not respond with 
enhanced growth to MG63 conditioned media, which had been observed to increase 
colony size. Therefore, although the 96 well format does not exactly mirror the results of 
the colony size assay it does present a more efficient method to assess growth in response 
to conditioned media. 
 
In order to assess whether the growth enhancing properties of OS is common to other types 
of sarcoma, conditioned media from a Ewing’s sarcoma (RDES-1), fibrosarcoma (HT1080) 
and leiomysarcoma (SKLNS1) was tested upon the same cell line and upon U2OS cells. 
RDES-1 cells were loosely attached so would not form colonies making this cell line 
inappropriate for testing growth enhancement. HT1080 and SKLNS1 both produced growth 
factors which increased growth upon the same cell line and also U2OS cells. This finding 
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suggests that these cell lines may share a common growth factor with U2OS, to further 
elucidate this hypothesis SKLNS1 proliferation was tested using its own conditioned media 
and also HT1080 and U2OS conditioned media. SKLNS1 was found to respond only to its 
own conditioned media but not in response to HT1080 or U2OS media. Two explanations 
could explain this observation, either SKLNS1 utilise an alternative growth factor to HT1080 
and U2OS. Alternatively, SKLNS1 conditioned media may contain higher concentrations of 
the same cytokine and SKLNS1 cells have a reduced sensitivity.  
 
Isolated holoclonal cells from the MG63 cell line have been shown to have enhanced 
clonogenicity and proliferate more rapidly in vitro than non-holoclonal cells (Lou et al., 
2010). In order to assess whether growth enhancing conditioned media also enhances the 
presence of holoclones. The colony hierarchy frequencies were assessed in the presence of 
24 hour conditioned media, by the reciprocal testing of the cell lines HOS, U2OS and MCF7 
with each of their conditioned media along with MG63 conditioned media. U2OS cells 
which responded with increased growth in response to U2OS, HOS and MG63 conditioned 
media also responded with an elevated presence of holoclones and mercolones. Therefore, 
the enhanced growth in U2OS cells in response to paracrine factors could be linked to 
enhancing the maintenance of holoclonal cells. Assessment of putative CSC based on 
mammosphere forming ability has demonstrated that IL-8 signalling inhibition can 
decrease putative CSC in breast cancer cells ex vivo (Singh et al., 2013) and also decreases 
tumour growth in vivo (Ginestier et al., 2010). A cytokine present in OS conditioned media 
could therefore be promoting the growth of holoclones by maintaining the CSC phenotype 
in U2OS. The same increase in holoclones was not observed in HOS or MCF7, suggesting 
that holoclonal increase is not attributing to their enhanced growth in response to 
conditioned media. One observation common to all cell lines tested was in response to 
MCF7 conditioned media, which resulted in an increase in paraclones in all cell lines tested. 
Additionally HOS and MCF7 also had a reduced frequency of holoclones and meroclones. 
This reduction in amplifying colony types and shift toward the differentiated paraclonal 
colonies with limited proliferative properties could be attributed to MCF7 conditioned 
media inability to enhance growth. MCF7 has been identified to display characteristics of 
differentiated mammary epithelial tissue (Soule et al., 1973), therefore, may release a 
cytokine which enhanced differentiation in not only MCF7 but also OS cell lines. 
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In order to identify candidate growth factors responsible for the paracrine effects 
conditioned media cells from cell lines that enhanced growth (MG63 and U2OS) was 
compared to conditioned media which did not enhance growth (MCF7). In addition HOS 
conditioned media was also tested which enhanced growth but only upon MG63 and U2OS. 
These cell lines had an increased sensitivity to growth enhancing conditioned media, 
therefore HOS conditioned media is predicted to contain a lower growth factor 
concentration. Based on these findings any candidate growth factor must be highly 
expressed by U2OS and MG63, absent in MCF7 and weakly expressed by HOS. IL-8 and CCL-
2 were two cytokines to fit these criteria so were hypothesised to act as growth factors in 
OS conditioned media. The complement component 5 (C5) was also expressed by all three 
cell lines, however was not further tested due to its established role in innate immunity 
(Gerard and Gerard, 1991).  
 
Interestingly, all of the cell lines tested expressed the following cytokines; MIF, IL-5, IL-23, 
serpinE1 and RANTES. MIF was originally identified because it could inhibit monocyte 
migration in vitro (George and Vaughan, 1962), its expression has been associated with 
poor prognosis in soft cell sarcomas (Takahashi et al., 2013) and it has been found to act as 
a growth factor in eosphageal squamous cell carcinoma in vivo (Wang et al., 2014). IL-5 
recruits and differentiates eosinophils (Dubucquoi et al., 1994), IL-23 has been found to 
play a role in the suppression of innate immune responses against cancer cells, through the 
induction of murine tumours after exposure to carcinongens (3-methylcholanthrene). Mice 
lacking IL-23 have reduced fibrosarcoma formation and metastasis, however, this 
protection was lost if natural killer cells were absent, suggesting it suppresses immune 
response to cancer cells (Teng et al., 2010). SerpinE1 is a serine protease inhibitor which is 
important for blood clot breakdown, fibrinolysis and tissue repair (Bauman et al., 2002). Its 
role in cancer progression may seem contradictory, as metastasis relies upon tissue 
breakdown and dissemination of cancer cells, however, serpinE1 has been found as a 
marker of poor oral carcinoma prognosis (Gao et al., 2010). siRNA inhibition of serpinE1 in 
cell lines of fibrosarcoma (HT1080) and breast cancer (MDA-MB-231) has been shown to 
decrease in vivo tumour formation of these cell lines, which was attributed to increased 
cancer cell apoptosis (Fang et al., 2012). RANTES is a chemotractant for a variety of 
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leukocytes including eosinophils (Kameyoshi et al., 1992) and plasma and tissue levels 
correlate with breast and cervical cancer stage (Niwa et al., 2001). The cytokines with 
shared expression from the cell lines have a common role in inflammation and tissue repair, 
tumours have been shown to arse from sites of chronic inflammation (Anderson and Wong, 
2010). Therefore the cytokine expression profile from these cell lines indicates that 
maintaining the expression of inflammatory cytokines is important for continual cancer 
growth in vitro. 
 
In order to further characterise the IL-8 and CCL-2 expression profile from sarcoma cell lines 
and MCF7, the concentration of IL-8 and CCL-2 was quantified in conditioned media 
(collected after 24 hours growth) using an ELISA.  No correlation was observed between IL-
8 expression and the enhanced growth rates observed in response to conditioned media.  
This was particularly evident in the U2OS conditioned media which consistently increased 
growth and was found to contain less IL-8 than 143B conditioned media which had no 
growth enhancing effect. This finding was supported when correlating IL-8 concentration 
with increase in colony size observed in response to conditioned media from the same cell 
line, which was not found to produce a statistically significant Pearson’s correlation. In 
contrast, CCL-2 conditioned media concentration closely resembled the growth 
enhancement observed. Cell lines which produced conditioned media with an elevated 
concentration of CCL-2 were correlated with increased cell line growth at low density. 
 
CCL-2 has been shown to increase the proliferation and migration of prostate cancer cells 
in vitro. Interestingly the CCL-2 was hypothesised to originate not from tumour cells but 
bone marrow endothelial cells (Loberg et al., 2006). Media taken at 24 hours from U2OS 
cells was found to secrete a higher concentration than MG63, however, at 72 hours the 
conditioned media from MG63 contained an elevated concentration compared to U2OS. 
This finding indicates that U2OS CCL-2 expression although rapid after 24 hours may be 
decrease over time, whereas MG63 cells continually secrete CCL-2 at a consistently high 
rate. In response to the glycoprotein oncostatin U2OS cells have been found to express 
CCL-2, interestingly the CCL-2 mRNA levels peaked after 8 hours, which led to rapid CCL-2 
secretion over 24 hours and the rate of secretion decreased after 48 hours and 72 hours 
(Kok et al., 2009), which could explain the reduction in U2OS CCL-2 expression over time.  
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The growth enhancing properties of conditioned media from the cell lines MG63 and in 
particular U2OS has been established. The growth factors secreted from U2OS are able to 
enhance growth in not only alternative OS cell lines but sarcoma cell lines and MCF7 as well, 
indicating the presence of a common cancer growth factor. The growth enhancement in 
response to conditioned media was not found to be related to an increase in holoclones, 
however, the conditioned media from MCF7 which did not increase proliferation was found 
to increase the presence of paraclones, suggesting that this media may enhance the 
differentiation of these cell lines. The cytokine profiles of the cell lines tested, indicates that 
inflammatory cytokines are closely related to cancer progression in OS cell lines. IL-8 and 
CCL-2 were identified as candidate growth factors in growth enhancing conditioned media, 
which have both been identified in carcinoma proliferation. IL-8 has been demonstrated to 
enhance the symmetrical division of breast CSC (Singh et al., 2013, Ginestier et al., 2010), 
CCL-2 has been shown to increase prostate cancer proliferation and migration (Loberg et 
al., 2006, Loberg et al., 2007). Therefore, further investigation will be important to further 
understand the role these cytokines play in OS in vitro cell growth. 
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6.1 Introduction 
OS cell lines have been demonstrated to secrete a paracrine factor which enhances both 
OS and MCF7 growth (Section 5.2), the proteins IL-8 and CCL-2 were identified as candidate 
OS growth factors which may be responsible for this growth (Section 5.10). In response to 
tumour necrosis factor α (TNFα) the OS cell lines HOS, MG63, U2OS and SaOS-2 have been 
found to alter their expression profile with increased expression of the cytokines CCL-2 and 
IL-8 (Grigolo et al., 1999). CCL-2 and IL-8 are two cytokines which have been implicated in 
cancer progression, CCL-2 was originally identified for its role in inflammation and is a 
potent chemotractant factor for monocytes (Matsushima et al., 1989) and is utilised by 
osteoblasts for recruitment of monocytes to aid with osteolysis (Williams et al., 1992) 
(Section 1.4.4). CCL2 signals via the G-protein coupled receptor CCR2 and has been found 
reliant upon phosphatidyl-inositiol-3-kinase (PI3K) for intracellular signal transduction in 
both monocyte chemotaxis and in vitro prostate cancer growth (Terashima et al., 2005, 
Loberg et al., 2006) (Section 1.4.4). In OS CCL2 secreted from the cell line MG63 has been 
attributed to cancer progression through the recruitment of tumour associated 
macrophages (TAM) (Graves et al., 1989). Solid tumours contain not only cancer cells but a 
large number of non-malignant cells (Pollard, 2004), these non-malignant cells frequently 
include TAM. In breast cancer TAM have been found to promote tumour progression by 
expressing TNFα, vascular endothelial growth factor and basic fibroblast growth factor, 
which have been implicated in angiogenesis (Lewis et al., 1995). The chemokine IL-8 signals 
via the CXCR1 and CXCR2 receptors (Park et al., 2011b) it has a potent chemotractive effect 
upon neutrophils (Yoshimura et al., 1987), therefore plays an important role in acute 
inflammatory responses. IL-8 is expressed by a wide range of cancer types including cancers 
including breast, colon, gastric, melanoma, pancreatic and B-cell chronic lymphocytic 
leukaemia (Lippitz, 2013), in breast cancer IL-8 has been demonstrated to not only increase 
cancer invasiveness (Freund et al., 2003) but also the presence of putative CSC based on 
the expression of ALDH and mammosphere formation (Charafe-Jauffret et al., 2009) 
(Section 1.4.5).  
The reliance of cancer cells upon growth factors and signaling molecules provides a 
therapeutic target to inhibit their growth or progression. These treatments often provide 
treatment strategies with decreased toxicity and high affinity for cancer cells (Heinrich et 
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al., 2003, Fisher et al., 1998, Fisher et al., 1994). Two successful examples of this targeted 
treatment strategy in breast cancer include the estrogen receptor antagonist tamoxifen, 
which has been found to reduce breast cancer incidence by 50 % in high risk patients (Fisher 
et al., 1998) and humanized monoclonal antibody trastuzumab which inhibits signal 
transduction via HER2 (Owens et al., 2004) (Section 1.4.6).  
 
Aims 
In order to establish the role CCL-2 and IL-8 play in OS proliferation, recombinant CCL-2 and 
IL-8 will be supplemented in to unconditioned media to assess changes in proliferation. In 
addition IL-8 and CCL-2 receptor anatagonism and gene knockown through RNA 
interference (RNAi) will be analysed to assess the impact upon cell line growth. This study 
will use OS cell lines HOS and U2OS. MG63 will also be used to replace HOS for low 
attachment assays in which HOS is unsuited. The specific objectives within this chapter are 
as follows: 
 Assessment of the in vitro role of candidate growth factors in OS growth through 
receptor inhibition, gene expression knockdown and cytokine supplementation. 
 Assessment of low attachment colony formation (sarcosphere assay and soft 
agarose assay) in response to recombinant CCL-2.  
 Analysis of gene expression in response to candidate cytokine and growth 
enhancing conditioned media to identify genes associated with enhanced 
proliferation.  
 
 
 
 
 
 
 
Chapter 6. Results  
207 
 
6.2 Effect of IL-8 and CCL-2 receptor antagonism on HOS and U2OS growth rates 
The cytokines IL-8 and CCL-2 have been identified as potential growth enhancing factors 
produced in OS conditioned media (Section 5.10). Receptor antagonists were used in the 
presence of growth enhancing media (MG63 and U2OS 72 hour conditioned media) in 
order to identify whether these cytokines contribute to OS growth. The CXC chemokine IL-
8 has been found to signal via the CXCR1 and CXCR2 G-protein coupled receptors (Park et 
al., 2011b) (Section 1.4.5). In order to analyse the impact of IL-8 antagonists on the growth 
rate HOS and U2OS, cells were grown for 8 – 9 days and cell density was assessed using an 
MTT assay (Section 2.4.4).  No significant decrease in growth was observed in conditioned 
or unconditioned media for either U2OS or HOS cells in response to 200 ng/ml of CXCR1 
and CXCR2 antagonist antibodies (Figure 6.1). Increasing the concentration of the CXCR1 
inhibitory antibody 10 fold to 2 µg/ml also had no significant effect on the growth rates of 
either HOS or U2OS (Figure 6.2). These findings suggest that the IL-8 present in U2OS and 
MG63 conditioned media is not responsible for the growth enhancement observed in HOS 
and U2OS proliferation (Section 5.7).  
CCL-2 is specific for the G-protein coupled receptor CCR2 and CCR2 signal transduction can 
be inhibited using a specific CCR2 antagonist RS 504393 (Section 2.4.4). Using RS 504393 at 
a concentration of 1 µM had no significant effect on growth of HOS and U2OS cells when 
grown in unconditioned media and MG63 72 hour conditioned media (Figure 6.3). 
However, increasing the concentration to 10 µM significantly reduced the growth (Figure 
6.3). These findings suggest that both HOS and U2OS utilise CCR2 signaling to enhance 
proliferation. In addition, the increased growth observed in U2OS and HOS cells in response 
to MG63 conditioned media (Section 5.7) is attributed to the expression of CCL-2 from 
MG63 cells. CCR2 antagonism reduced the growth of U2OS cells in response to U2OS 
conditioned media (Figure 6.4.A), however it had no significant effect on HOS proliferation 
in the presence of U2OS conditioned media (Figure 6.4.B).     
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(A) U2OS 
 
(B) HOS 
 
Figure 6.1: IL-8 receptor anatagonism of U2OS and HOS cells growth in unconditioned, U2OS and 
MG63 72 hour conditioned media in the presence or absence of 200 ng/ml CXCR1 and CXCR2 
inhibitory antibodies. U2OS (A) and HOS (B) cells were grown in unconditioned (red bars), U2OS 
conditioned (green bars) and MG63conditioned (blue bars) in the absence and presence of CXCR1 
and CXCR2 antagonist antibodies (200 ng/ml).  Data presented as mean and standard error, all 
samples repeated in sextruplicate in 3 separate experiments (n = 3 independent replicates). Tukey’s 
post hoc analysis used to assess significance by comparing no antagonist present to antagonist in 
unconditioned, U2OS conditioned and MG63 conditioned cells. No significant difference observed 
between conditions. 
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 (A) U2OS 
 
(B) HOS 
 
Figure 6.2: IL-8 receptor anatagonism of U2OS and HOS cells growth in unconditioned, U2OS and 
MG63 72 hour conditioned media in the presence or absence of 2 µg/ml CXCR1 inhibitory 
antibody. To analyse the effect CXCR1 receptor antagonism upon OS growth U2OS (A) and HOS (B) 
cells were grown in unconditioned (red bars), U2OS conditioned (green bars) and MG63 blue bars 
in the absence and presence of  CXCR1 antagonist antibodies (2 µg/ml). Data presented as mean 
and standard error, all samples repeated in sextruplicate in 3 separate experiments (n = 3 
independent replicates). Tukey’s post hoc analysis used to assess significance by comparing to no 
antagonist present to antagonist in unconditioned, U2OS conditioned and MG63 conditioned cells. 
No significant difference observed between conditions. 
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(A) U2OS 
 
(B) HOS 
 
Figure 6.3: RS 504393 CCR2 receptor antagonism (1 µM) of U2OS and HOS cells growth in 
unconditioned, U2OS and MG63 72 hour conditioned media. To analyse the effect CCR2 receptor 
antagonism upon OS growth U2OS (A) and HOS (B) cells were grown in unconditioned (red bars), 
U2OS conditioned (green bars) and MG63 (blue bars) in the absence and presence  CCR2 anatgonist 
(1 µM).  Data presented as mean and standard error, all samples repeated in sextruplicate in 3 
separate experiments (n = 3 independent replicates). Unpaired T-test used to assess statistical 
significance by comparing to no antagonist present to antagonist in unconditioned, U2OS 
conditioned and MG63 conditioned cells. No significant difference observed between conditions. 
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(A) U2OS 
 
 
(B) HOS 
 
Figure 6.4: CCR2 receptor antagonism (10 µM) of U2OS and HOS cells growth in unconditioned, 
U2OS and MG63 72 hour conditioned media.  To analyse the effect CCR2 receptor antagonism 
upon OS growth U2OS (A) and HOS (B) cells were grown in unconditioned (red bars), U2OS 
conditioned (green bars) and MG63 conditioned (blue bars) in the absence and presence  CCR2 
anatgonist (10 µM). Data presented as mean and standard error, all samples repeated in 
sextruplicate in 3 separate experiments (n = 3 independent replicates). Significance calculated using 
an unpaired T-test (*= < 0.05). 
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6.3 Growth reponse of HOS, MCF7 and MG63 cells to IL-8 and CCL-2 
To establish whether CCL-2 or IL-8 enhanced growth when supplemented individually or 
when combined in unconditioned media, the colony size after exposure to 2 ng/ml of both 
cytokines was analysed. Both HOS and MCF7 did not respond to either cytokines when 
supplemented indivdually or when combined in to unconditioned media (Figure 6.5.A and 
B). In contrast MG63 responded to CCL-2 when used as a single suplement and produced a 
significant increase in colony size compared to unconditioned colonies and CCL-2 and IL-8  
co-supplemeted colonies (Figure 6.5.C).   
(A) HOS     (B) MCF7 
  
    (C) MG63 
 
Figure 6.5 Growth reponse of HOS, MCF7 and MG63 to CCL-2 and IL-8. 2 ng/ml of IL-8, CCL-2 or IL-
8 and CCL-2 was tested on HOS (A), MCF7 (B) and MG63 (C). Cells grown in 6 well dishes and colony 
size was assessed using ImageJ. Statistaical significance assessed using Tukey’s posy hoc analysis 
(*p = <0.05). 
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6.4 Growth response of HOS and U2OS to recombinant CCL-2 in a 96 well growth assay 
The use of a CCR2 antagonist reduced the growth rates of both HOS and U2OS (Figure 6.4). 
To assess the effect of CCL-2 upon growth, recombinant CCL-2 was supplemented in to 
complete media and growth was assessed using a 96 well MTT assay (Section 2.4.3). CCL-2 
used at a concentration of 10 ng/ml did not enhance the growth of either U2OS or HOS 
(Figures 6.5 and 6.6). An increased CCL-2 concentration of 100 ng/ml resulted in enhanced 
growth in U2OS (Figure 6.6) and HOS (Figure 6.7). Both HOS and U2OS cells were also grown 
in U2OS 72 hour conditioned media to compare the growth enhancement of the 
conditioned media to recombinant CCL-2. Both HOS and U2OS responded with increased 
growth in response to U2OS conditioned media as previously observed (Section 5.8). U2OS 
72 hour conditioned media contains 22 ng/ml of CCL-2 according to the CCL-2 ELISA 
(Section 5.11). Recombinant CCL-2 at a concentration of 100 ng/ml did not enhance 
proliferation to the same degree as U2OS media, therefore, the lower concentration of 
CCL-2 secreted by U2OS suggests that either the recombinant protein has less activity 
compared to the native version expressed by U2OS or another growth factor is responsible 
for the increased proliferation.  
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Figure 6.6: Supplementation of recombinant CCL-2 in to complete media to assess the 
growth affect upon U2OS cells. U2OS cells were exposed to 10 and 100 ng/ml recombinant 
CCL-2 and also U2OS 72 hour conditioned media (U2OS cond) for a growth comparison. 10 
ng/ml CCL-2 had no effect on growth but 100 ng/ml increased growth. Data presented as 
mean and standard error, all samples repeated in sextruplicate in 3 separate experiments 
(n = 3 independent replicates). Significance calculated using Tukey’s post hoc analysis by 
comparing to unconditioned cells (**= < 0.01). 
 
Figure 6.7: Supplemention of recombinant CCL-2 in to complete media to assess the 
growth affect upon HOS cells. HOS cells were exposed to 10 and 100 ng/ml recombinant 
CCL-2 and also U2OS 72 hour conditioned media (U2OS cond) for a growth comparison. 
CCL-2 at 10 and 100 ng/ml had no effect on growth but U2OS conditioned media increased 
growth. Data presented as mean and standard error, all samples repeated in sextruplicate 
in 3 separate experiments (n = 3 independent replicates). Significance calculated using 
Tukey’s post hoc analysis by comparing to unconditioned cells (*= <0.05, ** = <0.01). 
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6.5. Assessment of soft agarose colony formation in response to recombinant IL-8 and 
CCL-2 in the OS cell lines MG63 and U2OS 
The soft agarose assay is an in vitro assay which has been found to replicate cancer growth 
rates observed in vivo (Courtenay, 1976), therefore, soft agarose colony formation 
represents an in vitro technique to assess the in vivo tumourigenicity of a cell line. MG63 
and to a lesser extent U2OS have been demonstrated to produce colonies in soft agarose, 
whereas, HOS was unable to form colonies (Fawdar, 2010). Based upon these findings 
U2OS and MG63 were selected to be grown in the soft agarose assay in the presence of 
recombinant CCL-2 and IL-8 to assess the effect of these cytokines upon colony formation. 
According to ELISA results MG63 72 hour conditioned media contained the highest 
concentration of CCL-2 and IL-8 (Section 5.11) and therefore concentrations which 
replicated these were chosen (CCL-2 concentration of 36.4 ng/ml and IL-8 a concentration 
of 9 ng/ml). Colony formation was monitored over 12 – 15 days beyond this point a 
monolayer formed on the agarose and the media acidified (Section 2.2.5). MG63 cells were 
found to produce colonies of a greater size than U2OS and MG63 colonies were oval in 
shape unlike the irregular shapes produced by U2OS (Table 6.1). U2OS cells were found to 
produce a greater number of colonies in response to CCL-2 (Figure 6.8), which suggests that 
U2OS may rely on CCL-2 signaling to promote growth in vivo. MG63 cells did not respond 
to CCL-2 (Figure 6.9) suggesting that it may not be a universal growth factor in all OS 
tumours. Neither U2OS nor MG63 responded to IL-8 (Figures 6.9 and Figure 6.10), 
indicating that this cytokine does not have a role in soft agarose colony formation in U2OS 
and MG63. 
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Cytokine 
supplement 
MG63 
(12 days growth) 
U2OS 
(15 days growth) 
Unconditioned 
 
 
  
Recombinant 
CCL-2 
(36.4 ng/ml) 
 
 
Recombinant 
IL-8  
(9 ng/ml) 
  
Figure 6.8: Appearance of MG63 and U2OS soft agarose colonies formed in the absence 
and presence of recombinant CCL-2 and IL-8. Cells seeded at a density of 1053 cells/cm2 
and grown for 12 – 15 days under standard culture conditions. Scale bars represent 100 
µM. 
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Figure 6.9: Number of U2OS colonies present in the soft agarose assay in response to CCL-
2 and IL-8. U2OS cells were seeded at 1 x 10 cells/6 well and allowed to grow for 15 days 
in the absence and presence of 36.4 ng/ml CCL-2 and 9 ng/ml IL-8. Colonies ≥ 85 µM were 
counted and data presented as mean and standard deviation, all samples tested in 
triplicate (n = 3). Significance calculated using Tukey’s post hoc analysis by comparing CCL-
2 to unconditioned and IL-8 (* = <0.05). 
 
 
Figure 6.10: Number of MG63 colonies present in the soft agarose assay in response to 
CCL-2 and IL-8. MG63 cells were seeded at 1 x 10 cells/6 well and allowed to grow for 12 
days in the absence and presence of 36.4 ng/ml CCL-2 and 9 ng/ml IL-8. Colonies ≥ 85 µM 
were counted and data presented as mean and standard deviation, all samples tested in 
triplicate (n = 3). Tukey’s post hoc anlysis used to assess statistical significance, no 
significant difference observed. 
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6.6. Assessment of sarcosphere formation in response to recombinant IL-8 and CCL-2 in 
the OS cell line MG63 
The sarcosphere assay was originally proposed to select multi-potent neuronal cells 
(Reynolds et al., 1992), however, this assay has also been utilised to select for CSC which 
are able to grow within these serum depleted and low attachment conditions. OS cell lines 
have been screened for their sarcosphere forming ability, MG63 has been found to produce 
secondary sarcospheres (Section 3.7) so was used to identify if IL-8 or CCL-2 and any effect 
sarcosphere forming ability. A concentration of 2 ng/ml recombinant IL-8 or CCL-2 was 
supplemented in to growth media, which was chosen to reflect the concentration identified 
in U2OS 24 hour condtioned media (0.65 ng/ml IL-8 and 1.3 ng/ml CCl-2) (Section 5.11). 
U2OS 24 hour conditioned media was found to enhance growth in MG63 (Section 5.7), 
therefore, selecting a concentration higher than U2OS conditioned media could be 
hypothesised to increase MG63 sarcosphere formation. 
Exposure of MG63 cells to IL-8 and CCL-2 did not alter the appearance of primary 
sarcospheres. In all conditions tested the primary sarcosphere appearance was oval shaped 
as was observed when grown in unconditioned media.  However IL-8 and CCL-2 exposed 
sarcospheres presented a smoother appearance and individual cells within the spherical 
colony were less identifiable (Figure 6.11). Assessment of the size of these primary 
sarcospheres indicated that MG63 sarcospheres conditioned with IL-8 or CCL-2 did not 
have an increased size (Figure 6.12), suggesting that IL-8 and CCL-2 does not enhance the 
proliferation of primary sarcospheres or this was masked by the sarcospheres having a 
more compact shape. Secondary sarcospheres generated from all the conditions tested had 
a similar appearance which was characterised by a small colony size with individual cells 
clearly visible. However, IL-8 and CCL-2 conditioned cells produced colonies with a more 
spherical shape than the irregular shape of unconditioned colonies (Figure 6.11). Analysis 
of the sarcosphere forming efficiency of secondary sarcospheres showed that exposure to 
IL-8 and CCL-2 did not alter the sarcosphere forming efficiency of MG63 (Figure 6.13), 
suggesting that IL-8 and CCL-2 do not enhance the formation of sarcospheres in MG63.   
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Figure 6.11: Appearance of MG63 primary and secondary sarcosphere formed in the 
absence and presence of recombinant CCL-2 and IL-8. MG63 cells seeded at a density of 
1053 cells/cm2 and grown for 7 days to form primary sarcospheres before passaging and 
re-seeding at 211 cells/cm2 and allowing secondary sarcospheres to form over 7 days under 
standard culture conditions. 2 ng/ml of IL-8 and CCL-2 were supplemented in to 
sarcosphere media. Scale bars represent 100 µM, images representative of 4 images. 
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Figure 6.12: Analysis of primary sarcosphere sizes in MG63 in response to IL-8 and CCL-2. 
MG63 cells were either unconditioned (no cytokine) or exposed to either 2 ng/ml IL-8 or 
CCL-2, sarcosphere size assessed using ImageJ. All results repeated in triplicate (n = 3), 
presented as mean and standard deviation. Statistical significance was assessed using 
Tukey’s post hoc analysis. No significance was observed when comparing all condition 
combinations. 
 
 
Figure 6.13: Analysis of secondary sarcosphere forming efficiency of MG63 cells in 
response to IL-8 and CCL-2. MG63 cells were treated with either unconditioned (no 
cytokine) media or media supplemented with either 2 ng/ml IL-8 or CCL-2. Sarcosphere 
forming efficiency (SFE), was assessed by counting each sarcosphere ≥ 40 µM. All results 
repeated in triplicate (n = 3), presented as mean and standard deviation. Statistical 
significance was assessed using Tukey’s post hoc analysis. No signifiance was observed 
when comparing all condition combinations. 
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6.7 Analysis of CXCR1, CXCR2 and CCR2 expression in OS cell lines and MCF7 
IL-8 and CCL-2 have been identified as potential growth factors in OS cell lines (Section 
5.11), therefore, identifying if the cell lines express the appropriate cognate receptors is 
necessary to evaluate whether receptor expression is linked to the observed proliferation 
response to conditioned media. IL-8 has been shown to signal via two different G-protein 
coupled receptors; CXCR1 and CXCR2 (Park et al., 2011b) (Section 1.4.5), whereas CCL-2 is 
specific to only one receptor CCR2 (Section 1.4.4). The expression level of each receptor 
expressed by the selected cell lines (HOS, MG63, U2OS and MCF7) was evaluated by, fixing 
cells and antibody staining for both surface and intracellular receptor expression which was 
evaluated using flow cytometry (Section 2.8.2).  
Earlier findings indicated that the OS cell lines MG63 and U2OS respond with enhanced 
growth to all conditioned media apart from MCF7 media (Section 5.7). HOS only responded 
to MG63 and U2OS conditioned media. U2OS and MG63 conditioned media contained 
higher quantities of both cytokines compared to HOS conditioned media as determined by 
ELISA (Section 5.11). Therefore, it could be hypothesised that both U2OS and MG63 express 
higher levels of the growth factor receptor than HOS or MCF7, because they are able to 
respond to lower concentrations of the growth factor.   
The CXCR1 expression profile did not fit the expected receptor expression pattern with all 
OS cell lines having a similar profile (Figure 6.14) with mean receptor expression values 
between 158.1 to 277.1 (Table 6.1). For CXCR2 the highest expression was observed in 
MCF7 with a mean expression value of 39, whilst HOS and U2OS expressed the lowest levels 
of the receptor of 9.5 and 9.7 respectively (Table 6.1). Expression levels of CXCR2 receptor 
did not therefore correlate with the observed growth in response to conditioned media. 
CCR2 receptor expression did fit the hypothesized receptor expression with U2OS and 
MG63 containing the largest mean expression of the receptors with 196.8 and 83.1 
respectively (Table 6.1).  In addition, MCF7 contained significantly less CCR2 expression 
than U2OS, (Table 6.1). The flow cytometry histogram of U2OS demonstrates the large 
proportion of cells positive for CCR2 in this cell line, demonstrating the high number of cells 
expressing this receptor. 
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HOS 
MG63 
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MCF7 
Figure 6.14: Flow cytometry overlay analysis of CXCR1, CXCR2 and CCR2 expression from the cell lines HOS, MG63, U2OS and MCF7. Cells stained 
with primary and secondary antibodies for the markers (Section 2.8.2), for analysis stained cells normalised to 1 x 104 and dead cells and duplets (two 
cells passing through the laser at once) excluded. The control population of cells was stained with an isotype matched primary antibody and the same 
secondary antibody (red) as used for CXCR1 (green), CXCR2 (blue) and CCR2 (yellow) staining. The x axsis on graphs represents cell counts and y axis 
FL1 Log ranging from 100 - 104. 
A 
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Table 6.1: CXCR1, CXCR2 and CCR2 expression in the cell lines HOS, MG63, U2OS and 
MCF7. The values indicate the difference in mean fluoroesence between control 
populations (isotype matched primary antibody and the same secondary antibody used for 
analysis of CXCR1, CXCR2 and CCR2) and marker labelled population after removal of dead 
cells. Highlighted red indicates significant difference to expression in MCF7 (Significance 
Tukey’s post hoc analysis * < 0.01). 
 
Cell line CXCR1 expression  
± std dev 
CXCR2 expression 
± std dev 
CCR2 expression 
± std dev 
HOS 277.1 ± 196.2 9.5 ± 3.5 76.0 ± 54.8 
MG63 172.0 ± 75.6 13.1 ± 6.3 83.1 ± 27.3 
U2OS 295.5 ± 56.4 9.7 ± 6.8 196.8 ± 72.8* 
MCF7 151.8 ± 40.1 39.0 ± 21.2 32.3 ± 16.0 
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6.8 RNA inference of CCL-2 gene expression in U2OS cells 
In order to assess the role CCL-2 plays in OS proliferation CCL-2 gene expression was stably 
knocked down using RNA interference in the OS cell line U2OS. CCL-2 expression was 
suppressed using a retroviral based plasmid containing short hairpin RNA (shRNA) specific 
to CCL-2 (Section 2.6). To establish gene knockdown expression levels of CCL-2 were 
assessed using real time PCR, thermal melting curves of primers verified that the primers 
were binding to the same sequences within the cell lines (Appendix IV). The shRNA 
antisense sequences TTATAACAGCAGGTGACTGGG (knockdown 1) and 
TAAGGCATAATGTTTCACATC (knockdown 2), were found to reduce the presence of CCL-2 
mRNA in the CCL-2 knockdown cell lines compared to cells infected with a plasmid 
containing a shRNA sequence which has no specificity to any mammalian genes  (scrambled 
control).  
The sequence used in knockdown 2 was more effective than knockdown 1, which is evident 
because less CCL-2 mRNA is present in the knockdown 2 cells compared to knockdown 1 
(Figure 6.15). Conditioned media taken from the knockdown cells was tested using a CCL-2 
ELISA (Section 2.5.2) to confirm if CCL-2 had been knocked down at the protein level. 
Conditioned media (24 hour) of the knocked down cell lines was found to contain 82 % less 
CCL-2 for knockdown 1 and 96 % less  CCL-2 for knockdown 2 compared to the scrambled 
control cell line. U2OS wild-type cells (non-transduced) were found to contain a higher 
concentration of CCL-2 than scrambled control cells (Figure 6.15). The observed 
discrepancy of CCL-2 concentration between U2OS normal cells and empty vector control 
cells was not apparent in 72 hour conditioned media with both cell lines expressing 
approximately 22 ng/ml (Figure 6.17 and table 6.2). This finding confirms the CCL-2 mRNA 
levels observed in the cells lines correlate with CCL-2 expression at the protein level. 
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Figure 6.15: Relative mRNA expression of CCL-2 compared to 18S rRNA expression from 
U2OS empty vector cells and CCL-2 knockdown 1 and 2 cells. mRNA expression was 
calculated by subtracting ΔCt value of CCL-2 (target gene) from ΔCt of shRNA (calibrator 
gene) to produce ΔΔCt. Data presented as mean and standard deviation, all samples 
repeated in triplicate (n = 3). Statistical significance calculated using Tukey’s post hoc 
analysis (* = < 0.05, **= <0.01). 
 
 
Figure 6.16: Analysis of CCL-2 concentration of 24 hour conditioned media taken from 
normal U2OS cells along with U2OS CCL-2 knockdown lines. A CCL-2 ELISA was used to 
obtain concentrations, data presented as mean and standard deviation, all samples 
repeated in triplicate (n = 3). Statistical significance calculated using Tukey’s post hoc 
analysis (* = < 0.05, **= <0.01). 
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Figure 6.17: Analysis of CCL-2 concentration of 72 hour conditioned media taken from 
normal U2OS cells along with U2OS CCL-2 gene knockdown cell lines. A CCL-2 ELISA was 
used to obtain concentrations, data presented as mean and standard deviation, all samples 
repeated in triplicate (n = 3). Statistical significance calculated using Tukey’s post hoc 
analysis (**= <0.01). 
 
Table 6.2: Comparison of CCL-2 concentrations of conditioned media taken from U2OS 
cell, empty vector and knockdown 1 and 2 at 24 and 72 hours. CCL-2 concentrations 
(ng/ml) established using an ELISA, all samples tested in triplicate. Statistical significance 
calculated by comparing to scrambled control CCL-2 concentration using Tukey’s post hoc 
analysis (**p = <0.01). Data presented as mean values ± standard deviation (std dev). 
Conditioned media CCL-2 24 hr concentration 
(ng/ml) ± std dev 
CCL-2 72 hr concentration 
(ng/ml) ± std dev 
Normal U2OS 13.1 ± 0.23 ** 21.9 ± 0.24 
Scrambled control 8.9 ± 0.38  22.3 ± 0.94 
Knockdown 1 1.6 ± 0.01 ** 6 ± 0.16 ** 
Knockdown 2 0.4 ± 0.01 ** 1.7 ± 0.06 ** 
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6.9 Assessment of the U2OS CCL-2 knockdown cell lines proliferation rate 
To assess whether knockdown of CCL-2 effects the proliferation rate of U2OS cells, CCL-2 
knockdown cells were compared to U2OS empty vector control cells. Proliferation was 
assessed by seeding cells at 40 cells/96 well and growing for 8 days before staining with 
MTT and reading the absorbance at 530 nm (Section 2.4.3). The rate of growth of the 
scrambled control cells was found to be significantly faster than both U2OS CCL-2 
knockdown 1 and 2. Interestingly although knockdown 2 cells were found to express less 
CCL-2 than knockdown 1 (Table 6.2), this had no impact the overall growth rate of the two 
knockdown cell lines with both producing similar similar growth rates (Figure 6.18). 
Supplementing recombinant CCL-2 in to complete media had no impact upon the growth 
rates of either knockdown cell line, however, growth of both cell lines in 72 hour empty 
vector conditioned media restored the growth rates to that observed in empty vector cells 
(Figure 6.19). Interestingly, the 72 hour conditioned media from knockdown 1 cells 
restored growth to the same level as the scrambled control conditioned cells (Figure 
6.19.A), however, knockdown 2 cells grown in their own 72 hour conditioned media grew 
at a slower rate than empty vector conditioned cells (Figure 6.19.B). Knockdown 2 cells 
express less CCL-2 than knockdown 1 cells (Table 6.2), therefore, the reduced growth rate 
of knockdown 2 cells compared to scrambled control conditioned cells may be due to a 
lower concentration of CCL-2 in the conditioned media.  
Recombinant CCL-2 supplemented in to unconditioned media did not alter the growth rates 
of either knockdown cell line. To identify if a CCR2 signaling co-factor is required for the 
growth promoting effect, recombinant CCL-2 was added to 24 hour and 72 hour 
conditioned media collected from knockdown 2 cells. In both knockdown cell lines no 
increase in growth was observed when supplementing recombinant CCL-2 in to 72 hour 
conditioned media. However, the 24 hour conditioned media supplemented with CCL-2 
resulted in increased proliferation in knockdown 2 cells (Figure 6.20.B) but no change in 
growth was observed in the same conditions for knockdown 1 cells (Figure 6.19.A). This 
finding suggests that a co-factor may be required for the enhancement of growth in 
response to CCL-2, however, the increased proliferation observed at high recombinant CCL-
2 concentrations (100 ng/ml) did not restore growth to the same level as knockdown 2 72 
hour conditioned media which contains 1.7 ng/ml CCL-2.  Therefore, another growth factor 
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may also be responsible for the increased proliferation rates observed in response to U2OS 
conditioned media, as was indicated in the CCR2 antagonist growth experiments (Figure 
6.6). 
 
 
Figure 6.18: Analysis of U2OS empty vector control and CCL-2 knockdown cell lines 
growth rates. Cells grown seeded at a low density (40 cells/96 well) and grown for 8 day in 
1.25 µg/ml puromyicin and assessing growth by staining with 1 mg/ml MTT and measuring 
absorbance at 530 nm. Data presented as mean and standard error, all samples repeated 
in octruplicate in four separate experiments (n = 3 independent replicates). Statistical 
significance calculated using Tukey’s post hoc analysis comparing to scrambled control 
absorbance (**= <0.01). 
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(A) Knockdown 1 
 
(B) Knockdown 2  
 
Figure 6.19: Assessment U2OS CCL-2 knockdown cell lines growth response to CCL-2 (100 ng/ml) 
and conditioned media from scrambled control and CCL-2 knockdown cell lines. U2OS CCL-2 
knockdown 1 (A) and knockdown 2 (B) cell lines were seeded at low density (50 cells/96 well) and 
grown in the presence of CCL-2 (100 ng/ml), 72 hour conditioned media taken from the same cell 
knockdown cell line as was grown, 72 hour empty vector conditioned media. Empty vector cells 
were also included to identify for a growth rate comparison. Data presented as mean and standard 
error, all conditions repeated in octruplicate in 3 separate experiment (n = 3 independent 
replicates). Statistical significance calculated using Tukey’s post hoc analysis (* = < 0.05, ** = <0.01). 
Unconditioned and CCL-2 supplemented samples had a significantly lower absorbance than 
knockdown conditioned, scrambled control conditioned and scrambled control cells. 
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(A) Knockdown 1 
 
CCL-2 (100 ng/ml) - + - + - + 
24 hour 
knockdown 2 
conditioned 
- - + + - - 
72 hour 
knockdown 2 
conditioned 
- - - - + + 
 
(B) Knockdown 2 
 
CCL-2 (100 ng/ml) - + - + - + 
24 hour 
knockdown 2 
conditioned 
- - + + - - 
72 hour 
knockdown 2 
conditioned 
- - - - + + 
Figure 6.20: The growth effect of supplementing CCL-2 in to knockdown 2 conditioned media 
upon knockdown 1 and 2 cell lines. CCL-2 (100 ng/ml) was supplemented in to unconditioned 
media and conditioned media collected from knockdown 2 cells at 24 hours and 72 hours. U2OS 
CCL-2 knockdown 1 (A) and 2 (B) cell lines were used. Cells were seeded at 50 cells/96 well and 
grown for 8 days in standard cell culture conditions before staining with MTT. Data presented as 
mean and standard deviation, all conditions repeated in quadruplicate in 3 separate experiment (n 
= 3). Statistical significance calculated using an unpaired T-test (* = < 0.05), comparing the addition 
of CCL-2 in unconditioned, knockdown 1 and 2 conditioned media. 
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6.10 U2OS CCL-2 knockdown cell lines in low attachment conditions 
Growth of cancer cells within low attachment conditions has been found to replicate in vivo 
cancer growth (Courtenay, 1976). U2OS CCL-2 knockdown cell lines were grown within the 
soft agarose assay (Section 2.2.5) to assess whether CCL-2 expression effected colony 
formation in these conditions. The U2OS knockdown cell lines were grown in the absence 
and presence of recombinant CCL-2 (36.4 ng/ml). Cells grown in the presence of 
recombinant CCL-2 formed colonies which were in general larger in size and displayed a 
more oval appearance (Figure 6.21). An increased number of soft agarose colonies were 
formed by the scrambled control cells compared to the CCL-2 knockdown cell lines (Figure 
6.22), which suggests that the of expression CCL-2 may enhance proliferation in anchorage 
independent conditions. This finding is supported by supplementation of recombinant CCL-
2 (36.4 ng/ml) in to the soft agarose assay, which increased the number of colonies present 
in the scrambled control cells and knockdown 1 and 2 cells (Figure 6.23).  
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Figure 6.21: Comparison of soft agarose colonies formed by U2OS CCL-2 knockdown cell 
lines and empty vector control in the absence (unconditioned) and presence of CCL-2 at 
36.4 ng/ml. Cells seeded at a density of 1053 cells/cm2 and grown for 12 days under 
standard cell culture conditions Bar = 100 µM. 
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Figure 6.22: Assessment of colonies formed by U2OS CCL-2 knockdown cell lines and 
empty vector control in the soft agarose assay. Colonies ≥ 40 µM were counted, data 
presented as mean and standard deviation, all conditioned tested in triplicate. Statistical 
significance calculated using unpaired T-test (* = < 0.05).  
 
 
 
Figure 6.23: Assessment of colonies formed by U2OS CCL-2 knockdown cell lines and 
empty vector control in the soft agarose assay. Cell lines grown in the absence 
(unconditioned) or presence of CCL-2 (MCP-1) at 36.4 ng/ml. Colonies ≥ 40 µM were 
counted, data presented as mean and standard deviation, all conditioned tested in 
triplicate. Statistical significance calculated using unpaired T-test (* = < 0.05).  
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6.11 Identification of genes with altered expression in U2OS cells in response to CCL-2 
and U2OS conditioned media 
Illumina gene microarrays were used in order to identify genes with altered expression in 
response to CCL-2 and U2OS conditioned media. U2OS cells were exposed to CCL-2 at a 
concentration of 36.4 ng/ml or U2OS conditioned for 8 days before RNA was extracted and 
analysed using an Illumina gene microarray (Section 2.7). This gene microarray analyses the 
expression level of all genes within the human genome. Samples were tested in triplicate, 
however, due to one array from the unconditioned cells and another from U2OS 
conditioned cells failing Bioconductor quality controls these samples were removed from 
analysis (Appendix V).  Analysis of the remaining samples using Genespring (Agilent 
Technologies®) demonstrated that gene expression of unconditioned cells and CCL-2 
exposed cells was similar whereas U2OS conditioned cells gene expression was clearly 
altered compared to unconditioned cells (Figure 6.24 and 6.25).  
When comparing gene expression of CCL-2 treated cells to unconditioned cells, treated 
cells had a small number of genes (81) with an altered level of expression (Figure 6.25.A), 
whilst U2OS cells treated with conditioned media had a larger number of genes (857) with 
altered expression compared to the unconditioned cells (Figure 6.25.B). CCL-2 and U2OS 
conditioned cells shared 16 genes with altered expression (Figure 6.26). Annotation of 
these gene using NIH DAVID identified that these 16 genes were involved in transcription, 
producing a modified Fisher’s exact test (EASE) score of 0.032 (Table 6.3). An EASE score of 
< 0.05 is statistically significant (Huang et al., 2008), therefore, the assignment of these 
genes to transcription related processes is reliable. Annotation of genes with altered 
expression in CCL-2 compared to unconditioned cells, identified 14 genes with an EASE 
score of 0.0192 were associated with transcription regulation (Table 6.4). Annotation of 
genes with altered expression in response to U2OS conditioned media identified a number 
of different cellular functions. A highly significant EASE score of 3 x 10-4 was observed in 
genes associated with anti-apoptotic processes (Table 6.5) and also cancer signaling 
pathway associated genes (Table 6.6). Genes associated with cancer signaling were used to 
review published research to identify if any had been associated with CCL-2 signal 
transduction. Other genes which were found to be up-regulated in response to U2OS 
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conditioned media included genes involved with cell locomotion (Table 6.7), indicating that 
U2OS conditioned may enhance U2OS cell migration.  
 
 
 
Figure 6.24: Heatmap of genes expressed in U2OS cells in response to unconditioned 
(DMEM), CCL-2 (MCP-1) and U2OS conditioned media. U2OS cells were seeded at 36 
cells/cm2 and grown either in unconditioned media or media supplemented with 36.4 
ng/ml CCL-2 or U2OS 72 hour conditioned media for 7 days. Cell RNA was extracted and 
samples analysed using the genespring software to identify a 1.2 fold change in gene 
expression along with an unpaired T-test (p = <0.05) to establish statistical significance. 
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(A)  CCL-2 conditioned     (B) U2OS conditioned 
 
Figure 6.25: Volcoano plots of genes with altered expression in CCL-2 conditioned or 
U2OS conditioned cells compared to unconditioned cells. Genes with altered expression 
in CCL-2 (A) and U2OS conditioned cells (B), were analysed using genespring to identify a 
1.2  fold change in expression along with an unpaired T-test (p = <0.05) to establish 
statistical significance. 
 
 
Figure 6.26: Venn diagram of genes with altered expression compared to unconditioned 
cells in CCL-2 conditioned and U2OS conditioned cells. In CCL-2 (red) 65 gene were found 
to have been altered and 841 in U2OS conditioned cells (blue) compared to unconditioned 
cells. CCL-2 and U2OS conditioned cells shared 16 genes which had the same alterations in 
expression compared to unconditioned cells.  
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Table 6.3: Transcription genes with shared altered expression in U2OS cells in response 
to recombinant CCL-2 and U2OS conditioned media. Using NIH DAVID genes were 
associated with transcription producing an EASE score of 0.032.   
Gene Protein description Change in expression Fold change 
PRDM10 PR domain containing 10 Decreased 1.22 
SNORA25 TATA box binding 
protein 
Increased 1.22 
POLR3G Polymerase (RNA) III 
(DNA directed ) peptide 
Decreased 1.21 
TCEA2 Transcription elongation 
factor 
Decreased 1.34 
ZNF783 Zinc finger family 
member 
Increased 1.21 
 
 
Table 6.4: Transcription genes with altered expression in U2OS cells in response to 
recombinant CCL-2. Using NIH DAVID genes were associated with transcription producing 
an EASE score of 0.0192.  
Gene Protein description Change in expression Fold change 
SOX17 SRY (sex determining region 
Y)-box 17RGHomo sapiens 
Increased 1.22 
SNORA25 TATA box binding protein Increased 1.22 
HES1 hairy and enhancer of split 
1 
Increased 1.25 
MLL3 myeloid/lymphoid or 
mixed-lineage leukemia 
Increased 1.24 
ZNF783 Zinc finger family member Increased 1.21 
 
 
 
Table 6.5:  Apoptosis inhibiting genes with altered expression in U2OS cells in response 
to U2OS conditioned media. Using NIH DAVID genes were associated with apoptosis 
inhibition producing an EASE score of 3 x 10-4.  
Gene Protein description Change in expression Fold change 
TAX1BP1 ax1 (human T-cell 
leukemia virus type I) 
binding protein 
Increased 1.21 
BIRC3 baculoviral IAP repeat-
containing 
Increased 1.65 
CRYAB crystallin, alpha Increased 1.39 
FOXC1 forkhead box Increased 1.21 
GCLC glutamate-cysteine 
ligase, catalytic subunit 
Increased 1.49 
GSTP1 glutathione S-
transferase 
Increased 1.35 
Table 6.5 continued overleaf. 
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Table 6.5 
Gene Protein description Change in expression Fold change 
HSPBL2 heat shock 27kDa 
protein-like 2 
pseudogene; heat shock 
27kDa protein 
Increased 1.20 
NRG1 neuregulin Increased 1.20 
PIK3CA phosphoinositide-3-
kinase, catalytic, alpha 
polypeptide 
Increased 1.22 
RPS27 ribosomal protein S27a 
pseudogene 12; 
Increased 1.28 
SQSTM1 sequestosome Increased 1.63 
THBS1 thrombospondin Increased 1.45 
TNFAIP3 tumor necrosis factor, 
alpha-induced protein 3 
Increased 1.22 
UBB ubiquitin Increased 1.22 
 
 
 
Table 6.6:  Cancer signaling genes with altered expression in U2OS cells in response to 
U2OS conditioned media. Using NIH DAVID genes were associated with signaling in cancer 
cells producing an EASE score of 4.5 x 10 -5.  
Gene Protein description Change in expression Fold change 
BCL2L1 BCL2-like 1 Decreased 1.35 
TRAF1 TNF receptor-associated 
factor 1 
Increased 2.00 
ARNT2 aryl-hydrocarbon 
receptor nuclear 
translocator 2 
Increased 1.26 
AXIN2 axin 2 Increased 1.24 
BIRC2 baculoviral IAP repeat-
containing 2 
Increased 1.37 
BIRC3 baculoviral IAP repeat-
containing 3 
Increased 1.26 
BMP4 bone morphogenetic 
protein 4 
Decreased 1.64 
CDH1 cadherin 1, type 1, E-
cadherin 
Increased 1.28 
FGF1 fibroblast growth factor 
1 
Decreased 1.31 
FGFR3 fibroblast growth factor 
receptor 3 
Increased 1.25 
FN1 fibronectin 1 Increased 1.20 
FZD1 frizzled homolog 1 Increased 1.34 
FZD6 frizzled homolog 6 Increased 1.26 
GSTP glutathione S-
transferase pi 1 
Increased 1.35 
IKBKG inhibitor of kappa light 
polypeptide gene 
enhancer in B-cells, 
kinase gamma 
Increased 1.43 
Table 6.6 continued overleaf 
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Table 6.6 
Gene Protein description Change in expression Fold change 
ITGA3 integrin, alpha 3 
(antigen CD49C, alpha 3 
subunit of VLA-3 
receptor) 
Increased 1.48 
ITGA6 integrin, alpha 6 Decreased 1.30 
ITGAV integrin, alpha V 
(vitronectin receptor, 
alpha polypeptide, 
antigen CD51) 
Increased 1.27 
IL-8 Interleukin 8 Increased 1.99 
LAMA5 laminin, alpha 5 Decreased 2.05 
LAMB1 laminin, beta 1 Decreased 1.33 
LEF1 lymphoid enhancer-
binding factor 1 
Increased 1.27 
MMP-9 matrix metallopeptidase 
9 
Increased 1.35 
MAP2K2 mitogen-activated 
protein kinase kinase 2 
Increased 1.32 
PIK3CA phosphoinositide-3-
kinase, catalytic, alpha 
polypeptide 
Increased 1.22 
PDGFRB phosphoinositide-3-
kinase, catalytic, alpha 
polypeptide 
Increased 1.49 
PRKCA protein kinase C, alpha Increased 1.41 
AKT1 v-akt murine thymoma 
viral oncogene homolog 
Decreased 1.30 
AKT3 v-akt murine thymoma 
viral oncogene homolog 
3 (protein kinase B, 
gamma) 
Increased 1.24 
ETS1 v-ets erythroblastosis 
virus E26 oncogene 
homolog 1 
Increased 1.27 
FOS v-fos FBJ murine 
osteosarcoma viral 
oncogene 
Decreased 1.75 
VEGFC ascular endothelial 
growth factor C 
Increased 1.42 
Wnt5b 
 
Wingless-type MMTV 
integration site, 
member 5B 
Increased 1.33 
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Table 6.7: Locomotion genes with altered expression in U2OS cells in response to U2OS 
conditioned media. Using NIH DAVID genes were associated with cell locomotion 
producing an EASE score of 3.2 x 10-4. 
Gene Protein description Change in expression Fold change 
THY1 THY-1 cell surface 
antigen 
Decreased 1.23 
ADORA1 
 
Adenosine A1 receptor Decreased 1.24 
CXCL16 Chemokine (C-X-C 
motif) ligand 16 
Increased 1.44 
F2RL1 
 
Coagulation factor II 
(thrombin) receptor-like 
1 
Increased 1.24 
HDAC9 Histone deacetylase 9 Increased 1.27 
IL6ST 
 
Interleukin 6 signal 
transducer (gp130, 
oncostatin M receptor) 
Increased 1.21 
IL-8 Interleukin 8 Increased 1.57 
LAMA5 
 
Laminin, alpha 5 Decreased 2.06 
LAMB1 Laminin, beta 1 Decreased 1.33 
MMP9 
 
Matrix 
metallopeptidase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type 
IV collagenase) 
Increased 1.35 
PDGFRB Platelet-derived growth 
factor, receptor 
polypeptide 
Increased 1.49 
SERPINE2 Serpin peptidase, clade 
E (nexin plasminogen 
activator inhibitor), 
member 2 
Increased 1.61 
SLIT2 
 
slit homolog 2 
(Drosophila) 
 
Increased 1.31 
SPAG9 Sperm associated 
antigen 9 
Increased 1.21 
THBS1 
 
thrombospondin 1 Increased 1.45 
TPM1 Tropomyosin 1 (alpha) Increased 1.53 
AKT1 
 
v-akt murine thymoma 
viral oncogene homolog 
1 
Decreased 1.30 
VEGFC Vascular endothelial 
growth factor C 
Increased 1.42 
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6.12 Discussion 
 
In order to further elucidate the role that IL-8 and CCL-2 play in U2OS and HOS growth, 
receptor antagonists were used in the presence of growth enhancing conditioned media 
(MG63 and U2OS 72 hour conditioned media) to assess their impact upon proliferation. IL-
8 has been found to signal via two receptors CXCR1 and CXCR2 (Park et al., 2011b), 
therefore, antagonist antibodies for both receptors were supplemented in to conditioned 
and unconditioned media. An initial experiment at 200 ng/ml demonstrated that the 
antibodies had no effect upon growth in unconditioned or conditioned media. Treating the 
human breast cancer cell line SUM159 using the same CXCR1 inhibiting antibody as used 
within this study at 10 µg/ml reduced cell viability by 95 % (Ginestier et al., 2010). Due to 
this finding the concentration of CXCR1 was increased by 10 fold to 2 µg/ml, however, even 
at this increased concentration no effect on the growth rate of HOS or U2OS cells was 
observed. This suggests that IL-8 signalling is not involved with the enhanced proliferation 
in response to conditioned media.  
 
CCL-2 signals via the G-protein coupled receptor CCR2 (Deshmane et al., 2009) and 
therefore a specific CCR2 antagonist (RS 504393) was used which has a high affinity to 
selectively inhibiting CCL-2 binding to CCR2 (Mirzadegan et al., 2000, Cherney et al., 2008). 
RS 504393 when used at a concentration of 1 µM had no impact upon OS cell line 
proliferation, however increasing the concentration to 10 µM reduced the growth rate of 
both HOS and U2OS cells when grown in unconditioned and MG63 conditioned media. This 
finding suggests that HOS and U2OS cells both utilise CCR2 signalling for proliferation and 
MG63 conditioned media is reliant upon the presence of CCL-2 to enhance growth. The 
decreased growth observed in response to RS 504393 could be related to off target toxic 
effects, however, in the hamster ovary cell line (CHO) a RS 504393 concentration of 61 µM 
has been used and the cells are still able to migrate (Mirzadegan et al., 2000), therefore, 
the concentration of RS 504393 used within this study does not exceed in vitro published 
data. In addition U2OS conditioned growth enhancement was unaffected in both cell lines 
by RS 504393, suggesting that U2OS conditioned media contains additional growth factors, 
which compensates for the antagonism of CCR2.  
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In order to assess the growth enhancing potential of CCL-2, a commercially available 
recombinant CCL-2 was supplemented in to growth media. Findings show that recombinant 
CCL-2 did not increase the growth of either HOS or U2OS cells at 10 ng/ml. Increasing the 
concentration to 100 ng/ml did increase proliferation in U2OS and HOS cells. The increase 
in U2OS and HOS proliferation in response to 100 ng/ml CCL-2 was significantly less than 
the enhancement observed in response to U2OS 72 hour conditioned media. According to 
ELISA results this conditioned media contained 22 ng/ml CCL-2 which is less than the 100 
ng/ml of recombinant protein used. The reduced activity of recombinant protein could 
indicate; recombinant CCL-2 has less bio-activity than the native protein, another growth 
factor is present within growth enhancing conditioned media or a co-stimulatory factor is 
required for CCL-2 increased proliferation. Another level of complexity has also been 
identified in CCL-2 signalling. Normally CCR2 homodimers form post ligand interaction 
which allows signal transduction, however, heterodimers can also form between CCR2 and 
CCR5. These receptor heterodimers along with their ligands have been found to activate 
cellular response in HEK293 cells at 10 – 100 fold lower ligand thresholds than when a single 
cytokine is used (Mellado et al., 2001). RANTES signals via the CCR5 receptor (Wang et al., 
2012), RANTES was present in the conditioned media of all cell lines tested, therefore CCL-
2 and RANTES could be signalling via CCR2-CCR5 heterodimeric receptors to increase 
proliferation in OS cell lines. If a heterodimeric CCR2 is present within U2OS and HOS it 
could explain why a receptor antagonist for CCR2 inhibits proliferation but supplementing 
the recombinant protein has no effect. 
 
Soft agarose colony formation has been shown to be representative of in vivo cancer 
growth (Courtenay, 1976), and was used to identify if supplementing recombinant CCL-2 
and IL-8 enhanced U2OS and MG63 colony formation. IL-8 did not alter colony formation 
in either cell line, which suggests that IL-8 does not contribute to non-adherent colony 
formation in these OS cell lines. CCL-2 was found to enhance soft agarose colony formation 
in U2OS cells but not MG63, therefore CCL-2 may represent an important factor in tumour 
formation in vivo, however, a mouse model of OS growth is required for conclusive 
evidence. The inability of CCL-2 to increase MG63 soft agarose colony formation highlights 
the heterogeneity of the OS cell lines. ELISA evaluation of MG63 72 hour conditioned media 
demonstrated that it contained significantly greater amounts of CCL-2 than U2OS 
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conditioned media. Therefore, it could be possible that increased expression of CCL-2 from 
this cell line may help to compensate for the lack of CCL-2 in the unconditioned cells and 
enhance proliferation.  
 
Another assay which also selects cells able to grow in low attachment conditions is the 
spherical colony formation assay, however, this was originally utilised to select for multi-
potent stem cells (Reynolds et al., 1992), IL-8 supplementation in breast cancer cell lines 
has been demonstrated to enhance sarcosphere forming ability through increased putative 
CSC replication (Tsuyada et al., 2012, Ginestier et al., 2010). Due to MG63 being able to 
form secondary sarcospheres it was tested to identify if recombinant CCL-2 or IL-8 would 
enhance sarcosphere formation. Both IL-8 and CCL-2 did not increase MG63 sarcosphere 
formation suggesting that CCL-2 or IL-8 do not increase the presence of putative CSC in 
MG63.     
 
In order to assess whether the expression of IL-8 and CCL-2 receptors correlated with the 
observed sensitivity of the cell lines to growth enhancing conditioned media (MG63 and 
U2OS conditioned media). The cell lines HOS, MG63, U2OS and MCF7 were stained for 
receptor expression, cytokine receptors are frequently internalised in order to transduce a 
signal, in particular leukocyte CCR2 has been found to be rapidly internalised and a high 
rate of receptor recycling occurs (Volpe et al., 2012). Therefore intracellular expression of 
the receptors was tested to provide an accurate estimation of the receptors expressed by 
each cell line. CXCR1 was expressed to a high degree in the cell lines tested with no 
statistical difference in expression observed. For CXCR2 expression MCF7 was found to 
contain higher receptor CXCR2 expression than in the OS cell lines. Neither CXCR1 nor 
CXCR2 fitted the expected growth response to conditioned media, as U2OS and MG63 were 
found to be most responsive to the growth enhancement of the conditioned media, 
therefore, should have had a higher expression of a candidate growth receptor than HOS 
or MCF7. CCR2 however did fit this hypothesised expression pattern and MG63 and U2OS 
were found to express CCR2 at higher levels than HOS and MCF7. U2OS in particular was 
found to express the highest levels of CCR2, analysis of the flow cytometry histogram 
demonstrates that the receptor is expressed on almost all cells within this cell line. In 
prostate cancer enhanced CCR2 mRNA expression correlates with increased cell line 
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tumourigencity, which is also supported by analysis of clinical tissue samples, whereby an 
increase in CCR2 was associated with an increased Gleason score (Lu et al., 2007). It would 
be of interest to identify if CCR2 expression also correlated with OS progression and to 
identify if highly expressing CCR2 cells have enhanced tumourigenic properties. 
 
Short hairpin RNA (shRNA) is a method which has been found to inhibit gene expression, 
through viral transduction of plasmids into cells this allows stable integration of shRNA 
sequences in to the genome with high efficiency (Brummelkamp and Bernards, 2003). In 
order to assess the RNA gene interference of CCL-2 two CCL-2 antisense sequences 
TTATAACAGCAGGTGACTGGG (knockdown 1) and TAAGGCATAATGTTTCACATC (knockdown 
2) were transduced in to U2OS cells and found to reduce the presence of CCL-2 mRNA. 
Analysis of the presence of CCL-2 mRNA using real time PCR found that CCL-2 mRNA was 
significantly lower in both knockdown cell lines compared to a scrambled control vector. 
Knockdown 1 CCL-2 mRNA was present at a lower level than knockdown 2 cells, suggesting 
that knockdown 1 expresses more CCL-2 than knockdown 2. To confirm that CCL-2 protein 
expression reflects the CCL-2 mRNA levels, conditioned media from these genetically 
manipulated cells was analysed using a CCL-2 ELISA. The same pattern of CCL-2 mRNA 
expression observed in the knockdown cell lines and scrambled control cells was replicated 
in the CCL-2 concentrations in 24 hour and 72 hour conditioned media. This finding shows 
that the RNA interference has inhibited the expression of CCL-2 and this inhibition has 
increased efficiency in the knockdown 2 cell line. When comparing the scrambled control 
CCL-2 expression with the normal U2OS cells, at 72 hours both cell lines expressed 22 ng/ml 
of CCL-2, however, at 24 hours normal cells express statistically more CCL-2. This 
discrepancy is unexpected, however, cell density of conditioned media was not 
standardised and was collected after cells had reached confluency. Therefore, the higher 
expression of normal cells at 24 hours could be attributed to a higher cell density compared 
to the scrambled control cells.  
 
The proliferation of the knockdown cell lines was compared with the scrambled control 
cells to identify if decreasing CCL-2 expression effects U2OS growth. Findings show that 
both the knockdown 1 and 2 cells had a reduced proliferation rate compared to the control 
cells. However, although knockdown 2 cells expressed less CCL-2, this did not effect the 
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proliferation rate as both knockdown 1 and 2 produced the same amount of growth after 
8 days. Recombinant CCL-2 and conditioned media were assessed to identify if they could 
increase the proliferation of knockdown 1 and 2 cells, conditioned media from scrambled 
control cells was able to return the growth rate of the both knockdown cells to same 
proliferation rate as empty vector cells. This finding indicates that the CCL-2 present within 
the empty vector conditioned media is able to increase the growth rate, interestingly 
knockdown 1 conditioned media increased growth to the same level as the scrambled 
control conditioned media.  
 
The empty vector conditioned media contains 22 ng/ml of CCL-2 and knockdown 1 media 
contains 6 ng/ml CCL-2, this indicates that even though there is statistically a significant 
difference between the CCL-2 content of these conditioned media it has no impact upon 
growth. However, the lower concentration of 1.7 ng/ml found in 72 hour knockdown 2 
conditioned media did produce a lower growth enhancement than empty vector 72 hour 
conditioned cells. This suggests that the CCL-2 content of conditioned media may have an 
effect upon cell growth, however, recombinant CCL-2 at 100 ng/ml had no effect upon the 
growth of either knockdown cell line. It is possible that either the recombinant CCL-2 does 
not produce the same proliferative response as the native cytokine in the conditioned 
media or alternatively a CCR2 signalling co-factor may be required for CCL-2 signal 
transduction. In order to identify whether a co-signalling molecule is required, the effect of 
adding 100 ng/ml recombinant CCL-2 into 24 hour and 72 hour knockdown 2 conditioned 
media was tested using both knockdown cell lines. No increase in growth was observed 
when adding recombinant CCL-2 in to 72 hour conditioned media, however, the effect in 
response to 24 hour conditioned media were contrasting for each cell line. Knockdown 1 
had no growth enhancement, whereas knockdown 2 cells responded with increased 
growth in response to supplementing 100 ng/ml recombinant CCL-2 in to the conditioned 
media. The growth enhancement observed was not as high as occurred when cells were 
grown within 72 hour knockdown 2 conditioned media, therefore, supplementing 100 
ng/ml of recombinant CCL-2 does not have the same effect as the presence of 1.7 ng/ml 
native CCL-2. These findings complicate the role CCL-2 plays in growth enhancement and 
suggest that either the recombinant CCL-2 used does not have the same effect as the native 
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form of CCL-2 produced by U2OS or alternatively there is another growth factor which is 
required.  
 
The use of shRNA to inhibit CCL-2 expression could be causing off target effects which 
decrease growth, therefore producing misleading results indicating that CCL-2 is a OS 
growth factor. A scrambled control vector was used in this study, however, it is 
recommended that controls contain a sequence with a complimentary sequence except 
residues 2-7 or 2-8 from the 5’ end. This produces an shRNA which has a similar sequence 
but unable to inhibit gene expression, allowing the assessment of off target effects of the 
shRNA to be accurately assessed (Cullen, 2006). The gold standard to test RNAi specific 
gene inhibition is through the use of RNAi knockdown, followed by restoring gene function 
using an RNAi resistant gene for the same function. This procedure can be achieved by 
using a gene from a different species which carries out the same function to restore the 
organism to the original phenotype (Rusconi et al., 2005). In order to identify if CCL-2 
expression has been specifically inhibited in OS a functional complementary study would 
be required.     
 
CCL-2 was found to play a central role in promoting growth in the soft agarose colony 
formation assay for both knockdown cell lines. Both knockdown 1 and 2 were found to 
produce statistically less colonies than the scrambled control cell line. In addition 
supplementation of recombinant CCL-2 at a concentration reflecting that found in MG63 
72 hour conditioned media (36.4 ng/ml) enhanced the colony formation in both the 
scrambled control cell line and knockdown 1 and 2 cells. This demonstrates that 
recombinant CCL-2 does increase soft agarose colony formation, however, the inability to 
increase growth of the same cell lines in an adherent assay could be explained by the 
hierarchical nature of the cells which respond to CCL-2. Putative CSC in carcinomas which 
display EMT characteristics have been demonstrated to have an enhanced ability to form 
colonies in non-adherent in vitro conditions (Mani et al., 2008, Biddle et al., 2011), 
therefore, cells with similar EMT characteristics present in the U2OS knockdown and 
scrambled control cells lines may have enhanced sensitivity to CCL-2 than non-EMT cells.  
CCL-2 has been found to act as a chemoattractant for both prostate cancer and breast 
cancer cells, and is highly expressed by osteoblasts, therefore, has been hypothesised as a 
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mechanism by which these cancers commonly metastasise to the bone (Loberg et al., 2006, 
Molloy et al., 2009). Due to the high expression of CCL-2 from the OS cell lines it would 
appear contradictory to hypothesise that this is a chemoattractant for these metastatic OS 
cells, however, it may be a mechanism to increase the proliferation of OS EMT cells. The 
lungs are the primary site of OS secondary tumours (Jeffree et al., 1975), CCL-2 is expressed 
by the lungs and has been demonstrated to increase carcinoma lung metastasis through 
the recruitment of monocytes which promote tumour growth (Lu and Kang, 2009). It could 
therefore be hypothesised that CCL-2 may be an important protein in the establishment of 
secondary OS tumours through the recruitment of monocytes. 
 
Assessment of genes with altered expression in U2OS in response to recombinant CCL-2 
and U2OS conditioned media was achieved using a gene microarray. An increase in 
proliferation was observed by U2OS normal cells in response to recombinant CCL-2, 
therefore, U2OS normal cells were tested for their response to the cytokine and 
conditioned media. Due to a replicate from the unconditioned and U2OS conditioned 
microarray not meeting quality controls these samples were removed from analysis. 
Therefore, unconditioned and U2OS conditioned gene expression were tested in duplicate 
which will compromise the results and decrease the sensitivity of gene expression analysis. 
A total of 81 genes had altered expression in response to recombinant CCL-2 compared to 
unconditioned cells, U2OS conditioned media cells had a more dramatic change in gene 
expression with 857 genes displaying changes. In order to identify if genes with changed 
expression in response to CCL-2 were also present in response to U2OS conditioned media, 
the gene expression between the two conditions was compared, 16 genes had shared 
altered expression. Although 16 genes is a small sample size, annotation of these genes 
using NIH DAVID found that they were statistically enriched in transcription regulation, of 
the 16 genes 5 are involved in transcription regulation. This indicates that the increased 
proliferation observed in response to recombinant CCL-2 and U2OS conditioned media may 
be attributed to enhanced transcription. However, a limitation of NIH DAVID is that it does 
take in to account whether a gene has been up or down regulated, of these 5 genes only 2 
had increased expression. Therefore, the association of these genes with increased 
transcription is questionable.  
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In contrast to CCL-2, the 81 genes with changed expression in response to recombinant 
CCL-2 were also linked with transcription, however, 14 genes were identified all associated 
with transcription regulation and all had increased expression. FOXC1 and GSTP1 had 
increased expression in response to CCL-2 and loss of this gene in carcinoma cells decreased 
in vitro proliferation (Xu et al., 2012, Jin et al., 2012). Annotation of genes with altered 
expression in response to U2OS conditioned media identified a number of different cellular 
processes, including genes associated with inhibition of apoptosis, this indicates 
conditioned media may increase growth through suppression of cell death.  Inaddition 
U2OS conditioned media may enhance resistance to chemotherapeutic agents. GST1 which 
had increased expression in response to U2OS conditioned media has been associated with 
OS cis resistance in vitro and within clinical samples (Pasello et al., 2008). In OS IL-8 which 
was also increased in response to U2OS conditioned media has also been attributed to dox 
resistance (Rajkumar and Yamuna, 2008). Altered gene expression from U2OS conditioned 
media also identified an association with cell migration, indicating that the conditioning 
effect may also be promoting cell migration, however, further investigation will required 
to substantiate this hypothesis.  
 
The catalytic subunit of phosphoinositide-3-kinase (PIK3CA), was found up-regulated in 
response to U2OS conditioned media, and was associated with both anti-apoptotic and cell 
signalling processes. PI3K has been demonstrated as a signalling pathway utilised by CCR2 
in prostate cancer to increase proliferation (Loberg et al., 2006). Interestingly when CCR2 
forms a heterodimeric receptor complex with CCR5 and both receptors are activated by 
their respective ligands, this results in an increased and sustained activation of PI3K, 
compared to activation with CCL-2 alone (Mellado et al., 2001). Therefore, the 
enhancement in growth observed in response to U2OS conditioned media may be a 
consequence of intracellular signal transduction via PI3K and requires further investigation 
in OS proliferation.  
 
In conclusion, the growth enhancing properties of conditioned media from the cell lines 
MG63 and in particular U2OS has been established. The growth factors secreted from U2OS 
are able to enhance growth in not only alternative OS cell lines but sarcoma cell lines and 
MCF7 as well, indicating the presence of a common cancer growth factor. IL-8 and CCL-2 
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were identified as candidate growth factors in growth enhancing conditioned media, 
further testing of IL-8 and CCL-2 signal transduction demonstrated that CCR2 inhibition is 
required for growth and this finding was confirmed through CCL-2 RNA interference in 
U2OS. Supplementing recombinant CCL-2 to assess growth resulted in enhanced growth of 
normal U2OS and HOS or U2OS at high concentrations (100 ng/ml) but had no impact upon 
U2OS CCL-2 knockdown cell lines. A co-stimulatory factor did not appear to be required for 
CCL-2 growth enhancement, however, CCR2 and CCR5 heterodimers have been 
demonstrated to enhance CCR2 response to CCL-2 when in the presence of RANTES 
(Mellado et al., 2001), therefore, supplementing both cytokines may be necessary to 
increase proliferation. Within non-adherent conditions (soft agarose assay) did consistently 
increase proliferation of U2OS cells. This indicates that a subset of cells within U2OS cell 
line are able to grow within low attachment conditions are sensitive to growth 
enhancement in response to CCL-2. Analysis of altered gene expression in response to CCL-
2 suggests that the genes increase proliferation through up-regulation of transcription.
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7.1 General discussion 
 
This thesis is framed by three aims; to characterise putative CSC present in a panel of OS 
cell lines, identify if putative OS CSC contribute to chemotherapeutic drug resistance and 
to characterise OS signaling used to control growth.  
 
Defining populations of putative CSC within OS cell lines was achieved by screening OS cells 
for ALDH and CD117 expression, both markers have been previously identified as OS CSC 
markers in a small number of cell lines (Wang et al., 2011, Adhikari et al., 2010). Both 
proteins were found to be heterogeneously expressed in vitro (Section 3.2) with CD117 
expression ranging from a population of 0 % to 6.4 % and ALDH from 0.9 % to 60 % of cells. 
Cancer associated mutations have been demonstrated to enhance ALDH expression, loss 
of the tumour suppressor PTEN in mammary epithelial cells increased ALDH expression by 
2 fold (Dull et al., 1998). OS tumours are characterised by a host of genetic abnormalties 
(Hansen, 2002), therefore the acquisition of these mutations during OS progression may 
result in the observed variations in ALDH expression between the cell lines. The OS cell lines 
tested are all able to recapitulate the colony hierarchies at low cell density (Section 3.5), 
however, the highly expressing ALDH cell lines (>10 % ALDH expression) contained ALDH 
positive cells within all the colony hierarchies not just the holoclones which are thought to 
originate from and contain CSC (Section 3.6). Therefore, if OS holoclones represent 
populations of OS CSC, as has been observed in carcinoma (Li et al., 2008), this makes ALDH 
an unsuitable CSC marker in these cell lines with an ALDH population greater than 10 % 
(143B, G292 and HOS). In contrast cell lines with lower ALDH expression (<10 % of cells) 
(MG63, SaOS-2 and MCF7) contained ALDH positive cells only within the holoclones, which 
indicates it has potential to function as a CSC marker in these cell lines, although further 
research is required to confirm the location of OS CSC within the colony hierarchies. This 
research will be aided by the use of multiple CSC markers for definitive identification of 
CSC, as has been utilised with the use of CD117 and stro-1 expression in the identification 
of OS CSC (Adhikari et al., 2010).  
 
As part of the putative CSC characterisation cell lines were screened for epithelial and 
mesenchymal markers to evaluate the cellular origin of these cell lines. Results indicate 
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that all OS cell lines display a mesenchymal phenotype, this was evident from low e-cad 
expression (< 0.22 %) and high vimentin expression (> 90 %) (Section 3.3). These findings 
are suggestive of a mesenchymal cell origin of OS, which has been previously hypothesised 
(Tang et al., 2008), however, further conclusive evidence linking MSC to OS is required. One 
recent study demonstrated that human xenotransplanted MSC cells lacking Rb and P53 
could form OS tumours when grown upon calcified ceramic scaffolds in a murine model 
(Rubio et al., 2014). P53 and Rb are common OS mutations but still present in only 62 % of 
OS tumours (Miller et al., 1996), therefore the finding by Rubio et al (2014) linking MSC to 
OS may not be representative of all OS tumours. CD44 is another protein highly expressed 
by MSC cells (Lee et al., 2004) and also OS cell lines, however, cells expressing CD44 and 
the epithelial marker e-cad had an enhanced primary sarcosphere forming ability (Section 
3.7). A putative CSC population has been identified based upon a similar expression profile 
of CD44/e-cad in head and neck carcinoma cells in vitro (Biddle et al., 2011), therefore, it 
will be of interest to test OS cells expressing CD44+/e-cad+ to analyse their CSC properties 
by FACS sorting and comparison of their sarcosphere forming ability. 
 
To identify if putative OS CSC (based on ALDH expression) display enhanced chemo-
resistance the effect of inhibiting ALDH activity was analysed using the ALDH inhibitor 
DEAB. OS ALDH expressing cells were previously shown to have an enhanced resistance to 
chemotherapeutics (Honoki et al., 2010), however, in Chapter 4 ALDH was found to 
comprise a chemo-resistant population in MG63 cells in response to MTX, U2OS cells in 
response to cisplatin and HOS cells in response to doxorubicin (Section 4.10). This finding 
indicates that ALDH expressing cells in different OS cell lines display resistance to opposing 
chemotherapeutics. If ALDH expressing cells do comprise a CSC population then the ability 
to successfully target them may require tailoring chemotherapeutic treatments strategies 
to individual patients. 
 
Cell density dictates the in vitro population sizes of OS cells expressing ALDH, higher cell 
densities were observed to reduce ALDH expression (Section 4.7). In vivo conditions have 
been demonstrated to reduce the ALDH compared to in vitro culture conditions of the OS 
cell line OS99-1 (Wang et al., 2011), therefore, this reduction in ALDH expression could be 
attributed to an increase in cell density. Sarcospheres which has been shown to select for 
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the growth of OS cells with enhanced tumourigenicity (Rainusso et al., 2011), were found 
to contain more abundant ALDH expression in sarcospheres larger in size, which suggests 
that ALDH expressing cells may be driving growth in low attachment conditions (Section 
3.8.1). CD117 expression was found to become reduced upon culture at low density 
(Section 3.6.2), therefore, CD117 may be increased in expression as cell density increases. 
These findings indicate a potential cell communication network, which controls CSC marker 
expression within a tumour and further elucidation of this network may help in the 
advancement of our understanding of OS progression.  
 
In order to elucidate the paracrine growth factors utilised by OS conditioned media from a 
panel of sarcoma cell lines and MCF7 was tested. All the OS and sarcoma cell lines tested 
except for the Ki-ras transformed OS cell line 143B and its parental cell line HOS, secreted 
a paracrine factor which was found to enhance growth. The conditioned media from the 
cell line U2OS was found to also increase the growth of a fibrosarcoma cell line and breast 
carcinoma cell line (MFC7), suggesting the cytokine growth enhancement pathway may be 
common in both carcinomas and sarcomas. Alternatively, the paracrine growth factor may 
be an artifact of the cancer cells adaptation to in vitro conditions, which is common in cell 
lines derived from different cancer types.  
 
The growth enhancement observed in the OS cell line U2OS in response to OS conditioned 
media increased growth by enhancing the presence of holoclone forming cells, indicating 
that an OS paracrine factor may enhance the CSC population. A similar observation has 
been observed in breast cancer in response to IL-8 (Singh et al., 2013), however analysis of 
IL-8 signaling in OS demonstrated it was not involved with OS proliferation. In order to 
identify candidate OS growth factors, the cytokines present in conditioned media of 
selected OS cell lines (HOS, U2OS and MG63) and MCF7 was anlaysed. The cytokines MIF, 
IL-5, IL-23, serpinE1 and RANTES were expressed by all four cell lines (Section 5.9). These 
cytokines have been associated with tumour progression either through mediating 
inflammation or promoting cell survival. Cytokines which have been found to mediate 
inflammatory responses include MIF, which promotes tumour formation through the 
suppression of immune response to cancer cells (Teng et al., 2010). IL-23 suppresses 
natural killer cell responses to cancer cells (Teng et al., 2010), and IL-5  and RANTES recruit 
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eosinophils during immune responses (Dubucquoi et al., 1994, Kameyoshi et al., 1992). 
SerpinE1 is important in tissue repair and has an anti-apoptotic role in fibrosarcoma and 
breast cancer cell lines (Fang et al., 2012). 
 
CCL-2 was identified as a candidate growth factor and CCR2 antagonism (Section 6.2) and 
CCL-2 gene RNAi resulted in decreased proliferation of OS cell lines (Section 6.8). 
Supplementation of complete media with recombinant CCL-2 increased the growth rate of 
U2OS and HOS cells (Section 6.3) when used at a high concentration (100 ng/ml). The 
increase in proliferation in response to 100 ng/ml recombinant CCL-2 was lower than the 
increase in growth observed in response to U2OS 72 hour conditioned media (which 
according to ELISA results contained 22 ng/ml CCL-2). An explanation for this finding may 
be due to CCR2 heterodimers formed with CCR5, which can lead to intracellular signal 
transduction when both receptors are activated by their ligands CCL-2 and RANTES 
(Mellado et al., 2001, Sohy et al., 2009). Mellado et al (2001), identified that the 
heterodimeric receptor was able to enhance signal transduction by 10 – 100 fold compared 
to the monomeric CCR2 receptor via increased and sustained activation of 
phosphoinositide 3-kinase (PI3K). Therefore in order to increase proliferation in response 
to recombinant CCL-2 recombinant RANTES may also be required.  Analysis of genes in 
U2OS cells with altered expression in response to U2OS conditioned media identified that 
PI3K catalytic gene (PIK3CA) was increased but not in response to recombinant CCL-2 
(Section 6.10). Therefore, RANTES which is present in U2OS conditioned media (Section 
5.10) may be enhancing proliferation when also in the presence of CCL-2, through PI3K 
signal transduction (Figure 7.1).  
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Figure 7.1: Proposed signal transduction of homodimeric CCR2 and heterodimeric CCR2 
and CCR5. Based on Mellado et al (2001) findings CCR2 when bound to CCL-2 
homodimerises and intracellular signal is proposed to activate JAK2, which leads to a 
moderate increase in PI3K and STAT3 activation and proliferation. Heterodimeric CCR2 and 
CCR5 which form after the binding to CCR2 to CCL-2 and CCR5 to RANTES are able to 
transduce intracellular signaling at 10 – 100 fold lower concentrations than the 
homodimeric receptor complex. Upon activation of the heterodimeric receptor complex 
signal is transduced via JAK1 and 2 which lead to an increased sustained activation of PI3K, 
which then activate both STAT3 and 5 and lead to increased proliferation. 
 
 
CCL-2 was found to play a central role in colony formation in low attachment conditions 
(soft agarose colony formation), the presence of recombinant CCL-2 was shown to increase 
colony formation (Section 6.4) and knock-down of CCL-2 by RNAi was shown to decrease 
colony formation in U2OS cells (Section 6.8). In vitro carcinoma cells which demonstrate 
EMT characteristics have been shown to have enhanced ability to form colonies in low 
attachment conditions (Biddle et al., 2011, Mani et al., 2008). Cells present within the OS 
cell lines which have a mesenchymal phenotype may therefore have an enhanced 
sensitivity to CCL-2 possibly through the up-regulation of CCR2, which may also have a 
chemotactic role. In prostate cancer CCL-2 expression is associated with cancer progression 
(Izumi et al., 2013) and has been shown to attract breast and prostate cancer cells to the 
bone (Loberg et al., 2006, Molloy et al., 2009). CCL-2 has been shown to attract the breast 
cancer cell line MDA-MB-231 to lungs in a mouse model due to CCL-2 expression from both 
the target organ and the cancer cells via recruitment of inflammatory monocytes (Qian et 
al., 2011). These CCR2 expressing monocytes have been proposed to aid pulmonary breast 
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metastasis by facilitating cancer colonisation (Lu and Kang, 2009). The primary site of OS 
metastasis is the lungs (Jeffree et al., 1975), therefore, CCL-2 expression from the lungs and 
OS cells may be attributing to its  migration to the this organ and may provide a mechanism 
for reducing OS metastasis.   
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7.2 Conclusions 
To conclude the findings within this thesis, the following novel observations have been 
made: 
 The putative OS CSC markers ALDH and CD117 are heterogeneously expressed 
within 7 OS cell lines.  
 The OS cell lines express mesenchymal markers vimentin and lack the epithelial 
marker e-cadherin. 
 ALDH expression in the MG63 and MCF7 is decreased in response to increased cell 
density. 
 The cell lines Cal72, G292, MG63, U2OS, SaOS-2, HT1080 and SKLNS1 were all found 
to secrete a factor which enhanced growth. 
 Growth factors secreted by U2OS cells increase OS, sarcoma and MCF7 cell line 
proliferation. 
 Cytokines secreted by OS cell lines are associated with inflammation. 
 Cell line CCL-2 expression (measured by commercial ELISA) correlated with OS and 
MCF7 growth enhancement observed in response to conditioned media.  
  CCR2 receptor antagonism and CCL-2 RNA interference decrease U2OS 
proliferation. 
 Genes with altered expression in response to recombinant CCL-2 are associated 
with transcription. 
 Genes with increased expression following exposure to U2OS conditioned media 
were associated with cancer signaling pathways and cell migration. 
 
To summarise, the data presented in this thesis characterised OS cells expressing putative 
CSC markers (ALDH and CD117) in a panel of 7 OS cell lines and MCF7. OS cell lines have 
been observed to secrete a paracrine growth factor, decreased proliferation has been 
observed in response to CCR2 antagonism and reduced CCL-2 expression. Genes associated 
with altered expression in response to CCL-2 signaling are associated with transcription, 
and U2OS conditioned media was found to express genes associated with cancer cell 
signaling pathways and cell locomotion.  
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7.3 Future work 
In summary, future directions of this study could focus on the following aspects: 
 Analysis of clonogencity and sarcosphere forming ability of OS cells expressing 
CD44+/e-cad-. Flow assisted cell sorting (FACS) can be used to isolate OS cell line 
cells which express the phenotypes CD44+/e-cad-, CD44+/e-cad+, CD44-/e-cad+ and 
CD44-/e-cad-. These four populations of cell can then be seeded at low density to 
assess clonogenicity through colony formation along with sarcosphere forming 
efficiency. This would confirm if CD44+/e-cad- cells have enhanced colony forming 
capabilities in both these assays.   
 Cell sorting of OS ALDH expressing cells to identify if these cells have an enhanced 
chemotherapy resistance. ALDH expressing cells can be isolated using FACS and 
tested for resistance to cisplatin, doxorubicin and methotrexate by identifying the 
LD50 concentrations for each drug.  
 Improving CCL-2 knockdown through the use of an appropriate CCL-2 shRNA 
control, which utlises functional complementation to identify the effect of this upon 
OS proliferation. The murine chemokine MCP-5 shares 66 % sequence homology 
with human CCL-2 and carries out the chemotraction of leukocytes (Sarafi et al., 
1997). OS cell lines transfected with murine MCP-5 can then have human CCL-2 
expression reduced through RNAi. The expression of murine MCP-5 can be assessed 
to identify if CCL-2 RNAi has specific CCL-2 gene knockdown. 
 CCR2 shRNA inhibition to identify the effect upon OS proliferation. To analyse the 
impact of reducing CCR2 expression upon OS cell lines, lentiviral shRNA particles 
can be generated and used to inhibit CCR2 expression. The growth of these CCR2 
RNAi cell lines growth can then be assessed, along with the response of these cell 
lines to recombinant CCL-2 and conditioned media.  
 Analysis of MG63 CCL-2 shRNA inhibition and effect upon cell proliferation. The 
impact of CCL-2 expression in the cell MG63 which highly expresses CCL-2 can 
assessed through RNAi gene knockdown. Upon confirmation of CCL-2 gene 
knockdown the cells can be tested for proliferation rates and compared to the 
scrambled control cell line. 
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 Analyse effect of recombinant CCL-2 upon calcium influx in order to assess bio-
activity in an alternative CCL-2 signal transduced pathway. To confirm the bio-
activity of recombinant CCL-2, HEK293 cells transfected with CCR2 have been shown 
to respond to CCL-2 with an influx of intracellular calcium (Sarafi et al., 1997). Using 
the same system recombinant CCL-2 can be utilised upon HEK293 cells to assess the 
ability to recombinant CCL-2 to signal via CCR2.   
 Assess the chemo active capabilities of CCL-2 on OS cell lines. In prostate cancer 
CCL-2 has been shown to act as a chemokine (Loberg et al., 2006), OS cells can be 
assessed for their ability to migrate towards CCL-2 using a transwell assay. 
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Appendix 
 
I. Control images of confocal microscopy staining 
To assess whether antibodies and reagents used to assess putative CSC marker expression 
(ALDH, CD117 and CD44) using confocal microscopy. Isotype control antibodies which had 
affinity only to murine proteins were also matched according to fluorescent label were 
tested to assess non-specific binding.  Control antibodies were used at the same 
concentration as CSC marker antibodies (Section 2.8). For ALDH which is analysed using the 
BODIPY® aminoacetaldehyde, which is converted to a fluorescent molecule by ALDH, has 
been inhibited by the ALDH inhibitor DEAB. For all ALDH and CD44 isotype control images 
no non-specific binding can be observed for 143B when stained adherently (Figure I.A) or 
when grown under sarcosphere conditions (Figure I.B). No 
 
  
   (A)      ` (B) 
Figure I: Negative control confocal microscopy images of ALDH and CD44 co-stained 
images. (A) and (B) are representative images of 143B cells stained the ALDH (FITC) 
inhibitor DEAB and a CD44 isotype control and fluorescent label (PE) matched antibody  
when adherent (A) or grown under sarcosphere conditions (B). FITC fluorescence (green) 
can be observed in the top left panel, PE (red) in top right panel, bottom left indicates To-
pro-3 fluoresence (blue) and an overlay in the bottom right panel.   
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Figure II: Negative control confocal microscopy image of CD117 and CD44 co-stained 
image. Image is representative 143B cells stained the CD117 (FITC) and CD44 (PE) isotype 
control and fluorescent label matched antibody. FITC fluorescence (green) can be observed 
in the top left panel, PE (red) in top right panel, bottom left indicates To-pro-3 fluoresence 
(blue) and an overlay in the bottom right. (C) 143B representative image of adherent cells. 
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II. Calibration curves to determine CCL-2 and IL-8 concentrations 
To determine the concentration of IL-8 and CCL-2 in conditioned media (Section  
2.5.2) a commercial ELISA kit (BioLegend) was used. For each experiment a calibration 
curve was constructed using a concentration of 0 – 500 pg/ml for CCL-2 and 0 – 1000 
pg/ml for IL-8, each standard concentration was tested in triplicate. Absorbance 
readings at 570 nm were subtracted from 450 nm, and ploted as absorbance readings 
minus the blank absorbance (0 ng/ml) (Figure III). R2 values varied from 0.98 – 0.99.      
 
A      B 
 
Figure III: Calibration curves of CCL-2 and IL-8 concentration. CCL-2 (A) and IL-8 (B) 
standards were prepared in triplicate (Section 2.5.2). Concentration  of standards for CCL-
2 was 0 – 500 pg/ml and IL-8 was 0 – 1000 pg/ml. Absorbance reading at 570 were 
subtracted from 450 nm readings and average blank reading were subtracted from 
standards. Average values were plotted and an excel power trendline was used to assess 
linearity. 
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III. Real time PCR 18s rRNA and CCL-2 primer efficiencies 
In order to assess the amplification efficiencies of the target gene (CCL-2) and 
endogenous reference gene (18s rRNA), both primers were tested using  U2OS DNA 
concentrations of 0.16  – 100 ng/ml (Figure II). The amplification efficiencies of both 
primers was assessed using the by using the gradient of each primer DNA 
concentration curve, to calculate primer efficiency (E). An E value of 2 represents 100 
% efficiency, CCL-2 primer produced an E value of 2.33 and 18s rRNA produced an E 
value of 2.11 (Table IV). 
   
 
 
Figure IV: Real time PCR primer efficiencies. 18s rRNA and CCL-2 primers were used to 
assess DNA amplification for U2OS DNA concentrations at 0.16 – 100 ng/ml, ΔCt values 
were calculated, each primer was tested in triplicate for each DNA concentration.  Data 
presented as mean and standard deviation.   
 
Table I: Primer efficiencies (E) for 18s rRNA and CCL-2. 
Primer E value 
18s rRNA 2.33 
CCL-2 2.11 
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IV. Real time PCR melt curve 
To assess the specificity of primers used for real time PCR (Section 2.7.3) CCL-2 gene 
expression analysis of U2OS CCL-2 RNAi cell lines, the temperature required to 
dissociate primer from the template strand was assessed. All cell lines were tested in 
triplicate, for the 18s rRNA primers melting temperatures varied from 76.5 – 76.7 ºC 
(Figure V and table II) and CCL-2 primer melting concentration varied from 85.3 – 85.5 
ºC (Figure VI and table III). The due to the low concentration of CCL-2 present within 
knockdown 2 cell lines a melting temperature was not recoreded because the peak was 
below the threshold. However, a small peak is visible for this cell line at 85.3 – 85.5 ºC 
(Figure IV). All control samples which contained no DNA all did not produce a melting 
peak within the threshold.  
 
 
 
Figure V: Melting curves of 18s rRNA primers. U2OS cell knockdown cell lines were 
tested in triplicate using 100 ng of template DNA and 1 µM of forward and reverse 
primers  
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Table II: Melting temperatures of 18s rRNA primers tested with U2OS CCL-2 knockdown 
cell lines reverse transcribed RNA.  
Colour Name Temperature (ºC) 
 Neagtive control  
 Empty vec sample 1 76.5 
 Empty vec sample 2 76.5 
 Empty vec sample 3 76.7 
 Knockdown (1) sample 1 76.5 
 Knockdown (1)  sample 2 76.5 
 Knockdown (1) sample 3 76.5 
 Knockdown (2) sample 1 76.5 
 Knockdown (2)  sample 2 76.5 
 Knockdown (2) sample 3 76.5 
 
 
 
Figure VI: Melting curves of CCL-2 primers. U2OS cell knockdown cell lines were tested in 
triplicate using 100 ng of template DNA and 1 µM of forward and reverse primers  
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Table III: Melting temperatures of CCL-2 primers tested with U2OS CCL-2 knockdown 
cell lines reverse transcribed RNA.  
Colour Name Temperature (ºC) 
 CCL-2 negative control  
 Empty vec CCL-2 sample 1 85.5 
 Empty vec CCL-2 sample 2 85.3 
 Empty vec CCL-2 sample 3 85.5 
 Knockdown (1)  sample 1 85.5 
 Knockdown (1) sample 2 85.5 
 Knockdown (1) sample 3 85.3 
 Knockdown (2) sample 1 Below threshold 
 Knockdown (2) sample 2 Below threshold 
 Knockdown (2) sample3 Below threshold 
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V. Quality control of microarray data 
In order to assess the suitability of all samples analysed using the affymetrix microarray 
(Section 2.7.4), samples were assessed using the R analysis package in the Bioconductor 
program. The software identified one of unconditioned sample (DMEM) and one of the 
U2OS conditioned samples did not have the same expression profiles as the other two 
samples tested in the same conditions. This was apparent when samples were analysed 
using a box plot of the fluorescence intensity (Figure VII), which is confirmed by the multi-
dimensional plot (Figure VIII). Due to both these samples not conforming the expression 
observed in the other samples from the same conditions they were removed from 
analysis. 
 
Figure VII: Box plot of samples tested in using the affymetrix gene microarray. Sample 1 
(unconditioned) and sample 9 (U2OS conditioned media) do not correspond with the 
same box plot as the other samples. 
 
 
Figure VIII: Multi-dimensional plot of genes expressed by microarray samples. One 
sample from U2OS and another from DMEM do not have the same expression profile as 
the other samples so were removed from analysis.
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